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Summary 
Campylobacter concisus is a fastidious hydrogen-requiring, Gram-negative, curved rod. This 
bacterium can be frequently isolated from the oral cavity of healthy individuals; however, the 
first isolation of C. concisus was in 1981 from a gum infection and it was then suggested to 
be a potential cause of gastroenteritis in children and immunocompromised adults. More 
recently, C. concisus has been associated with inflammatory bowel diseases (IBD) in 
children. However, some studies could not report a significant difference in the prevalence of 
C. concisus between IBD patients and healthy controls.  
The potential pathogenic role of C. concisus in enteric infections is still not well investigated. 
Additionally, it has not been confirmed yet whether C. concisus is an opportunistic pathogen 
or if a certain group/genomospecies can cause human infections. Moreover, the virulence of 
C. concisus isolates from the oral cavity of healthy individuals and intestinal isolates has not 
been intensely investigated.  
C. concisus has been grouped to two different genomospecies (A and B) on the basis of 
DNA-DNA hybridisation studies and PCR amplification of 23S rDNA. This study 
investigated the molecular diversity of potential pathogenic groups of C. concisus using two 
molecular techniques: PCR-denaturing gradient gel electrophoresis (PCR-DGGE) (to amplify 
and analyse 16S rDNA), and a conventional PCR (to amplify several putative virulence genes 
including cjaC, cjaA, dnaJ and zot). These techniques were applied to C. concisus faecal and 
oral isolates. DGGE grouped C. concisus isolates into two new distinct groups. The putative 
virulence genes, cjaC, cjaA and dnaJ, were detected in the majority of C. concisus isolates, 
but there were DNA sequence variations, which could have led to PCR amplification failure 
in some C. concisus isolates. It was found that the location of cjaC in the genome of 
genomospecies A was different from its location in the genome of genomospecies B. Another 
xxii 
 
virulence gene (zot) encodes a tight junction toxin, could be only amplified from a few 
isolates. 
An invasion assay was used to investigate the virulence of C. concisus using the human 
intestinal cell line INT407. Two C. concisus isolates from the oral cavity of healthy 
volunteers were identified as invasive isolates, while all tested faecal isolates from patients 
with diarrhoea were found to be non-invasive. Oral isolates obtained from healthy volunteers 
have not been previously reported to be more invasive than clinical intestinal isolates. 
Furthermore, C. concisus isolates possessing zot were unable to show significant invasion 
capability. In addition, semi-quantitative SYBR green assays were developed to evaluate the 
expression of the putative virulence genes (cjaC, cjaA, dnaJ and zot) in C. concisus grown on 
Columbia agar with the addition of horse blood (HBA), on Columbia agar (CA) only, 
maintained in tissue culture medium with or without INT407 cells. The expression of cjaC 
and cjaA was slightly enhanced when the bacterial cells were grown on CA compared with 
HBA. However, dnaJ expression was significantly reduced in bacterial cells sustained in the 
tissue culture medium only when compared with those maintained with INT407 cells 
growing in a similar tissue culture medium. 
Another aspect of this study was to investigate the prevalence and possible association of 
particular C. concisus genomospecies in adults with IBD. A total of 350 intestinal biopsies (at 
least seven intestinal biopsies from each participant) were collected from 51 participants 
(IBD and control participants) attending the Gastroenterology Clinic at the Austin Hospital in 
Melbourne, Australia. Also from each participant, a gum and faecal samples were collected at 
the time of the biopsy collection. The presence of C. concisus was investigated by 
conventional culture and molecular techniques in all collected specimens. To detect the 
prevalence of C. concisus genomospecies B and zot directly from the clinical samples, new 
nested PCR techniques were developed. The direct detection of genomospecies A DNA in the 
xxiii 
 
clinical samples was not included, as in the start of this study the whole genome of 
genomospecies A has not been published. 
Overall, the prevalence of C. concisus DNA was significantly higher in biopsies of IBD 
patients (59.5%) than in biopsies of control participants (21.4%). Moreover, C. concisus was 
isolated for the first time from duodenal and ascending colonic biopsies. The prevalence of 
genomospecies B was significantly higher in IBD patients than in control participants using 
the nested PCR to detect this genomospecies in intestinal biopsies, faeces and gum samples. 
Among the C. concisus isolates cultured from gum samples, the prevalence of genomospecies 
B was also significantly higher in IBD patients than in control participants, while 
genomospecies A was more predominant in control participants. These findings suggested 
that genomospecies B might be associated with IBD. Furthermore, zot was not detected in 
most of the clinical isolates and there was no significant difference in its prevalence between 
IBD patients and control participants. 
Collectively, the main results of this research project reinforced the extreme genetic diversity 
of C. concisus and more specifically between genomospecies A and B, on the basis of the 
putative virulence genes. In addition, it was shown that C. concisus invasive strains can exist 
in the oral cavity of healthy individuals. Gene expression assays for cjaC, cjaA and dnaJ 
were successfully developed in this study for the first time and it was shown that dnaJ was 
possibly involved in cellular invasion since its expression significantly reduced after 
exposure to tissue culture medium without INT407 cells. Furthermore, new PCR techniques 
were developed to detect genomospecies B and zot directly from clinical samples. The results 
suggested an association of C. concisus, in particular genomospecies B, with adults with IBD 
while no association of zot was recognised in the same group.  
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Chapter 1 : General introduction 
1.1 Campylobacter species 
Members of the Campylobacter genus are Gram-negative, curved or spiral rod shaped 
bacteria. Currently, they have been assigned to at least 25 species (Man 2011; Murray et al. 
2009). Most of the members are motile with a polar flagellum at one end or two flagella 
located at each end (Man et al. 2010a; Vandamme et al. 2005). All Campylobacter spp. are 
extremely fastidious in utilising nutrients and require strictly anaerobic or microaerophilic 
conditions for growth. Campylobacter spp. normally colonise the gastrointestinal tract of 
mammals, reptiles, shellfish and birds (Debruyne et al. 2009; Inglis et al. 2006; Rossi et al. 
2009; Tu et al. 2005). 
 
1.1.1 Campylobacter species as pathogens 
In recent decades, campylobacters have been considered as major causes of human 
gastroenteritis across the world (Altekruse et al. 1999; Tauxe 2001). The most common 
clinical features of enteric infections caused by campylobacters are watery or bloody 
diarrhoea, abdominal pain, fever, headache, anorexia and asthenia. These features can evolve 
after an incubation period of 2-3 days. In about 0.1% of cases, bacteraemia occurs (Skirrow et 
al. 1993), following translocation of the bacterial cells from the intestinal epithelial cells to 
the bloodstream. Immune deficient patients infected with Campylobacter spp. are more likely 
than patients with normal immunity, to develop systemic infections that require longer 
periods of hospitalisation (Sorvillo et al. 1991). The most common species to be related to 
systemic campylobacteriosis in humans is C. fetus (Blaser 1998), which could be related to its 
resistance to human serum factors (Kirk et al. 2015). Other species reported to be involved in 
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bacteraemia in humans include C. insulaenigrae, C. upsaliensis and C. lari (Chua et al. 2007; 
Lastovica 2006; Tauxe et al. 1985).  
C. jejuni is a common cause of acute gastroenteritis in humans. Four million people including 
adults and children develop gastroenteritis due to C. jejuni each year worldwide (Allos 2001; 
Blaser et al. 1983; Leach 1997; Tauxe et al. 1987). Moreover, progression to serious diseases 
like reactive arthritis or Guillain-Barre syndrome can follow in a small number of patients 
who have acute infection (Altekruse et al. 1999). C. coli is the next most important 
Campylobacter spp. to cause gastroenteritis in humans, causing 4-18% of gastroenteritis 
cases caused by campylobacters (Friedman et al. 2004; Leach 1997; Valenza et al. 2010). In 
the last two decades, studies have shown the emergence of other Campylobacter spp. as 
potential causes of human enteric infection. These include C. concisus, C. curvus, C. gracilis, 
C. lari and C. upsaliensis (Maher et al. 2003; On 2001). Several recently discovered species 
(C. helveticus, C. mucosalis and C. showae) have not been recognised as pathogens, but more 
information is required on their possible pathogenic role (Man 2011). Recently, C. concisus, 
C. hominis, C. showae and C. ureolyticus were detected in intestinal biopsy specimens of 
children with Crohn’s disease (CD) (Zhang et al. (2009), and C. concisus, C. showae, C. 
gracilis, C. rectus and C. ureolyticus were detected in faecal samples of children newly 
diagnosed with CD (Man et al. 2010b). Remarkably, C. concisus was the most predominant 
Campylobacter spp. in the intestine of children with CD (Man et al. 2010b; Zhang et al. 
2009). Furthermore, C. concisus and C. rectus have been suggested to be associated with 
human periodontitis (Macuch et al. 2000; Tanner et al. 1981). 
In animals, Campylobacter spp. including C. jejuni, C. coli and C. hyointestinalis are known 
to cause enteric infections in cattle and pigs, while C. fetus has been reported to be associated 
with abortion in sheep (Nachamkin et al. 2008). 
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Recent improvements in molecular techniques have led to an increase in the detection rates of 
these fastidious organisms from the human gastrointestinal tract and consequently more data 
has become available. Our understanding needs to be improved further on such fastidious 
bacteria based on developing the laboratory techniques to detect these species (in particular 
from the gastrointestinal tract), investigating their growth requirements and assessing their 
putative virulence factors. 
 
1.2 Campylobacter concisus 
C. concisus is a microaerophilic fastidious hydrogen-requiring, Gram-negative curved rod 
(Figure 1.1) that is normally found in the human oral cavity. It is motile with a single polar 
flagellum (Figure 1.2) (Paster et al. 1986). The cells are 0.5-1 µm in width and 2-6 µm in 
length (Figure 1.2) (Zhang et al. 2014). C. concisus is a small non-pigmenting asaccharolytic 
bacterium (Tanner et al. 1981) that grows slowly and requires enriched media. The G:C 
content of C. concisus DNA was found to be low (34-38%) (Tanner et al. 1981). 
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Figure  1.1: A Gram stained smear of Campylobacter concisus cells from 5 day old 
culture plate. The smear shows the short curved (blue arrow) and long curved (black arrow) 
cells. The magnification is 1000x (Istivan 2005). 
 
 
Figure  1.2: Campylobacter concisus cells under the electron microscope. The image 
shows the cells have a single polar flagellum (Ismail et al. 2012).  
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1.3 Association of Campylobacter concisus with human diseases 
C. concisus has been isolated and detected by molecular means in clinical samples obtained 
from patients with different medical conditions; it has been detected in oral infections 
(Kamma et al. 2001; Socransky et al. 1998; Tanner et al. 1981), gastroenteritis (Istivan 2005; 
Istivan et al. 2004; On 2001), intestinal specimens of patients with IBD (Hansen et al. 2013; 
Mahendran et al. 2011; Man et al. 2010b; Mukhopadhya et al. 2011; Zhang et al. 2009), and 
abscesses (de Vries et al. 2008; Johnson et al. 1987). It has been reported that the prevalence 
of C. concisus has been underestimated in clinical samples because suitable detection 
methods in clinical microbiology laboratories are limited, unlike the situation for C. jejuni 
and C. coli (Vandenberg et al. 2006). A better understanding of the relationship between C. 
concisus and human infections is required because its association with human diseases is still 
unclear. 
 
1.3.1 Gastroenteritis 
C. concisus is a common coloniser in the human oral cavity and has been isolated from 
several sites including teeth, gum and saliva. Thus, the oral cavity could be the main source 
of C. concisus to the gastrointestinal tract, as around 1-1.5 L of saliva is produced every day 
and passed to the gastrointestinal tract (Humphrey et al. 2001). However, several studies have 
found that the isolation rate of C. concisus from faeces was much lower than from saliva 
samples of healthy individuals (Man et al. 2010b; Zhang et al. 2010). These findings could be 
explained as the gastrointestinal tract may not be a suitable environment for C. concisus to 
colonise. 
The initial isolation of C. concisus from the gastrointestinal tract was by Vandamme et al. 
(1989) using a standard culture technique and it was suggested to be associated with 
diarrhoea after being isolated from patients with persistent diarrhoea. Using the same 
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technique, C. concisus was subsequently isolated from faecal samples of 2.5-3% and <1.5% 
in children and adults with diarrhoea, respectively (Engberg et al. 2000; Istivan 2005; 
Lastovica 2009; Lastovica et al. 2000; Lauwers 1991; Lindblom et al. 1995). Using the 
filtration technique, the isolation rate increased to 6% and to 2.8% from faecal samples of 
patients with gastroenteritis and from healthy individuals respectively (Aabenhus et al. 2002; 
Engberg et al. 2000; Musmanno et al. 1998; Nielsen et al. 2013b; Van Etterijck et al. 1996). 
However, none of these studies have shown significant differences in C. concisus isolation 
rate between patients and healthy controls (Engberg et al. 2000; Nielsen et al. 2011a; Van 
Etterijck et al. 1996). Collado et al. (2013) used the filtration technique and failed to isolate 
C. concisus from either patients with gastroenteritis or healthy controls; however, this 
difference could be due to the use of smaller pore size filter 0.45-µm instead of the standard 
0.65 µm filter (Collado et al. 2013). 
Generally, molecular methods detected higher rates of C. concisus than culture methods due 
to possible its fastidious nature. Inglis et al. (2011) used two nested PCRs to amplify C. 
concisus DNA from faecal samples of patients with diarrhoea and healthy controls; the first 
PCR targeted the 23S rDNA gene, while the second PCR targeted the cpn60 region. 
Curiously, the detection rate of C. concisus was significantly higher in healthy controls (57%) 
than in the patients (31%) (Inglis et al. 2011). The study concluded that the bacterium could 
be non-pathogenic. However, Collado et al. (2013) reported contradicting findings and the 
prevalence of C. concisus DNA in faeces of patients with gastroenteritis was higher than 
healthy controls. 
The variations in the prevalence of C. concisus between the studies could be due to many 
factors such as a low bacterial load, age differences and sensitivity of different detection 
techniques (Newell 2005). Since, C. concisus has been detected in faeces of healthy controls, 
there remains uncertainty on the role of this bacterium as a pathogen in human gastroenteritis 
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(Engberg et al. 2000; Istivan 2005; Lastovica 2009; Lawson et al. 1998; Vandamme et al. 
1989). 
 
1.3.2 Infections of the oral cavity 
The initial isolation of C. concisus from the oral cavity was from patients with gum disease. 
Three isolates were obtained from patients with gingivitis and another three were obtained 
from patients with periodontitis (Tanner et al. 1981; Tanner et al. 1987). The authors 
suggested that C. concisus might have a pathogenic role in oral cavity infections. Further 
evidence that C. concisus may be associated with periodontitis came from a study that 
detected higher numbers of C. concisus attached to teeth than other sites of the oral cavity of 
patients with periodontitis (Haffajee et al. 1984). C. concisus was also present in a higher 
numbers at bleeding sites of patients with progressive periodontitis lesions as compared to 
non-bleeding sites (Kamma et al. 2000a, 2000b; Kamma et al. 1994; Nakou et al. 1998). 
Others found higher levels of C. concisus antibodies in patients with periodontitis than in 
healthy controls (Ebersole et al. 1985; Taubman et al. 1992). Also supporting an association 
of C. concisus with periodontitis was the findings that C. concisus isolation rates were 
significantly higher when gingival crevicular fluid of patients was positive for aspartate 
aminotransferase (AST) compared to patients negative for AST in gingival crevicular fluid 
(Kamma et al. 2001). AST is normally confined to the host cell, but during cell damage or in 
cell death it is released into the extracellular space (Schmidt et al. 1985). The increase of the 
AST activity in gingival crevicular fluid is strongly associated with periodontal diseases 
(Chambers et al. 1991). C. concisus was also found to be more prevalent in the oral cavities 
of patients with gingivitis than in healthy individuals (Macuch et al. 2000; Moore et al. 
1987). 
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In summary, several studies have reported the possible association of C. concisus with oral 
infections, but its association with these infections is still not well understood. To clarify 
links with the disease, studies should focus on the pathogenic role of specific C. concisus 
isolates from patients rather than the isolation rate from the oral cavity. It is unclear whether 
the presence of C. concisus in the site of the infection in the oral cavity is due to its 
involvement in the infections or secondary colonisation of an infected site. 
 
1.3.3 Detection of C. concisus at other sites 
The first isolation of C. concisus from a site other than the oral cavity or lower intestinal tract 
was from a diabetic foot ulcer (Johnson et al. 1987). Following that, Cox et al. (2003) 
detected C. concisus RNA in synovial fluid of patients with reactive and post infectious 
arthritis. Remarkably, the investigators could not detect the common Campylobacter spp. that 
have been reported to be related to reactive arthritis such as C. jejuni and C. coli (Cox et al. 
2003). 
In oesophageal biopsies collected from patients with Barrett’s oesophagus (BO), the most 
prevalent Campylobacter spp. detected using PCR were C. concisus and C. rectus, while 
these species could not be detected in healthy controls. Hence, it was suggested that these 
campylobacters in BO patients may play a significant role in initiation, maintenance or 
exacerbation of the disease and progression to induce adenocarcinoma formation (Macfarlane 
et al. 2007). Furthermore, in oesophageal bacterial biofilms, Blackett et al. (2013) used the 
culture technique to show that C. concisus was the most predominant species and was present 
in a higher proportion in BO patients (42.2%) than in healthy controls (12.8%). However, it is 
not clear whether C. concisus was present in BO samples as one of the normal microbiota or 
it had a special role to play in the disease. 
9 
 
In gastric fluid samples collected by gastroscopy from patient with gastritis, C. concisus was 
found to be the highest transcriptionally active bacterium in the stomach. However, the study 
did not include healthy controls (von Rosenvinge et al. 2013). Thus, it is not clear whether 
the source of RNA in the gastric fluid was from the bacterial colonisation in the stomach or in 
the oral cavity. 
Furthermore, C. concisus was isolated as part of the poly-microbial flora (Staphylococcus 
aureus, Klebsiella pneumoniae, Stenotrophomonas maltophilia, Prevotella spp. and 
Peptostreptococcus anaerobius) in a brain abscess in a 65 year old man who had a post-
craniotomy for a maxillary sinus carcinoma (de Vries et al. 2008). The source of infection it 
seemed to be from the oral cavity. 
In summary, C. concisus has been isolated from several unusual locations of the human body 
other than the oral cavity or the lower intestinal tract. However, in all of these sites, C. 
concisus was detected in combination with other commensals which has made it difficult to 
confirm its role in the infections rather than being a contaminant due to its colonisation in the 
oral cavity. Consequently, C. concisus, if involved in these types of human infections, could 
be part of the poly-bacterial flora rather than causing an individual infection. 
 
1.3.4 Immune deficiency diseases 
A few studies investigated the prevalence of C. concisus in different sites of 
immunocompromised patients. A large study that included 11550 faecal samples from 
different patient groups found 70% of subjects that had C. concisus were 
immunocompromised (Aabenhus et al. 2002). Moreover there was a significantly higher 
prevalence of C. concisus in sub-gingival biofilms of HIV patients with detectable plasma 
viral load than in a control group of HIV patients with undetectable plasma viral load (Pereira 
et al. 2014). The higher association of C. concisus with these patients could be due to the 
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immune deficiency state, rather than microorganism characteristics as C. concisus isolates 
obtained from faeces and intestinal biopsies were susceptible to normal human serum in vitro, 
suggesting that normal human serum is protective (Kirk et al. 2015). 
1.4 Inflammatory bowel diseases (IBD) in humans 
IBD generally refers to two major chronic incurable diseases; Crohn’s disease (CD) and 
ulcerative colitis (UC). Clinically, IBDs are usually chronic, idiopathic relapsing ailments 
that can occur at any site of the gastrointestinal tract (Podolsky 2002). The onsets of CD and 
UC can occur at all ages; however, CD is more likely to present during early adulthood while 
UC is more likely to present in late adulthood. CD is characterised by transmural 
inflammatory lesions that can spread via the mucosa into underlying serosa, while in UC the 
inflammation commonly occurs in the colon and rectum with ongoing inflammation in the 
sub mucosa (Colletti 2004; Podolsky 2002). 
Histopathologically, CD lesions consist of tight granulomas formed by giant cells, 
macrophages, and epithelioid cells, while in UC the number of polymorphonuclear cells in 
the lamina propria and the intestinal crypts are elevated leading to abscess formation (Colletti 
2004). The main distinguishable diagnosis between IBD and acute self-limited 
gastrointestinal tract mucosal infections is based on whether the infiltration of inflammatory 
cells in intestinal crypts are branching; whether the layer of intestinal epithelial cell change is 
acute or chronic; and whether granulomas are present. Also, the symptoms of IBD typically 
consist of acute episodes each lasting for several weeks (Colletti 2004; Hanauer 2006). 
Over the past two decades, the number of IBD patients requiring hospitalisation has 
significantly increased, resulting in increased financial burden for that health services 
(Sonnenberg 2010). A study conducted in Greater Geelong, Victoria found the annual 
incidence rates of IBD in Australia was one of the highest in the world (Wilson et al. 2010). 
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It has been suggested that IBD depends on the involvement of several factors including the 
environment, genetic background, immune system and intestinal commensals (Fiocchi 1998; 
Podolsky 2002; Sartor 2008). In particular, several bacterial species were suggested to be 
associated with CD including Helicobacter spp., Bacteroides spp., Mycobacterium avium 
subspecies paratuberculosis and Campylobacter spp. (Bohr et al. 2004; Man et al. 2008; 
Zhang et al. 2006; Zhang et al. 2009). It was suggested that the overlying bacteria at the 
intestinal mucosa may cause initial damage to mucosal cells, facilitating penetration of other 
organisms through the mucosal layer, and triggering inflammatory markers of the host cell 
(O'Rourke et al. 2001). 
 
1.5 Association of C. concisus with IBD 
A few studies have investigated a possible association of C. concisus with IBD, based on the 
detection of C. concisus in intestinal biopsy, faecal, and saliva samples of patients (Tables 1.1 
and 1.2). 
 
1.5.1 Detection of C. concisus in the intestinal biopsies of patients with IBD 
The detection rate of C. concisus DNA in intestinal biopsies varied widely between studies in 
IBD patients (33%-69%) and in healthy controls (2%-38%) (Tables 1.1 and 1.2). Initially, 
Zhang et al. (2009) found the prevalence of C. concisus DNA in colonic biopsies of children 
newly diagnosed with CD was significantly higher when compared with a healthy control 
group. The authors suggested that C. concisus may play a major role in the development of 
CD in young children (Zhang et al. 2009). A strain isolated from the intestinal biopsy of a 
CD patient was later named C. concisus UNSWCD (Kaakoush et al. 2012). 
 
 
12 
 
 
 
 
Table  1.1: The percentage of C. concisus detection in clinical specimens collected from 
patients with IBD and control participants, (adopted from Kaakoush et al. (2012)). 
Disease Recruits Specimens 
source 
PCR 
type 
Primer set Patients 
(%) 
Controls 
(%) 
Study 
IBD Children Intestinal 
biopsy 
One-step Not stated 58.3 42.3 Hansen et al. 
(2011)  
IBD Adults Intestinal 
biopsy 
Nested C418/C1228 
Concisus 
68.0* 36.0 Mahendran et al. 
(2011) 
IBD Children Intestinal 
biopsy 
One-step C418/C1228 38.6 38.1 Hansen et al. 
(2013) 
IBD Adults Faeces One-step 16S rDNA 21 9.0 Tankovic et al. 
(2009)  
 
IBD: inflammatory bowel disease. 
CD: Crohn’s disease. 
UC: ulcerative colitis. 
*: there was a significant difference between the patients and controls. 
C418/C1228 & Concisus primer sets: targeting 16S rDNA. 
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Table  1.2: The prevalence of C. concisus in CD and UC patients, and control 
participants, (adopted from Kaakoush et al. (2012)). 
Disease Recruits Specimens 
source 
PCR type Primer set Patients 
(%) 
Controls 
(%) 
Study 
CD Children Intestinal 
biopsy 
One-step C418/C1228 53.0* 2.0 Zhang et al. (2009) 
CD Children Intestinal 
biopsy 
One-step Not stated 66.7 42.3 Hansen et al. (2011)  
CD Adults Intestinal 
biopsy 
Nested C418/C1228 
Concisus 
67.0 36.0 Mahendran et al. 
(2011) 
CD Children Intestinal 
biopsy 
One-step C418/C1228 44.8 38.1 Hansen et al. (2013) 
UC Children Intestinal 
biopsy 
One-step Not stated 37.5  42.3 Hansen et al. (2011)  
UC Adults Intestinal 
biopsy 
Nested C418/C1228 
Concisus 
33.3* 10.8 Mukhopadhya et al. 
(2011) 
UC Adults Intestinal 
biopsy 
Nested C418/C1228 
Concisus 
69.0* 36.0 Mahendran et al. 
(2011) 
UC Children Intestinal 
biopsy 
One-step C418/C1228 30.8 38.1 Hansen et al. (2013) 
CD Children Faeces Nested C418/C1228 
Concisus 
65.0* 35.0 Man et al. (2010b) 
CD Children 
& Adults 
Saliva Nested C418/C1228 
Concisus 
100.0 97.0 Zhang et al. (2010) 
 
IBD: inflammatory bowel disease. 
CD: Crohn’s disease 
UC: ulcerative colitis 
*: there was a significant difference between the patients and controls. 
C418/C1228 & Concisus primer sets: targeting 16S rDNA. 
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In a later study on adults with CD and UC, C. concisus DNA was detected by nested PCR in 
biopsy samples collected from four intestinal anatomic sites (ileum, caecum, descending 
colon and rectum), while bacterial isolation was only preformed on a caecal biopsy 
(Mahendran et al. 2011). The prevalence of C. concisus was found significantly higher in 
biopsies of patients with UC than in controls, but unlike the study in children with CD 
(Zhang et al (2009), there was no significant difference in the prevalence of C. concisus 
between CD patients and healthy controls. The authors stressed that the possible involvement 
of C. concisus in UC and CD requires confirmation with more investigations to be 
undertaken. Mukhopadhya et al. (2011) reported a significantly higher C. concisus DNA 
prevalence in colonic biopsies of adults with UC than in controls, using similar nested primer 
sets, although the precise colonic anatomic site was not stated. In contrast, other studies failed 
to show significant differences between patients with IBD and healthy controls in the 
detection rate of C. concisus DNA in colonic biopsies (Hansen et al. 2013; Hansen et al. 
2011). The conclusion of these studies was that C. concisus was not strongly associated with 
IBD. 
 
1.5.2 Detection of C. concisus in faecal samples of patients with IBD 
Man et al. (2010b) found the prevalence of C. concisus DNA in faecal specimens of children 
newly diagnosed CD was significantly higher than in non-IBD patients and healthy controls 
using nested PCR (Table 1.2). This study suggested that there was a role of C. concisus in 
paediatric CD; nonetheless, the mechanisms of how C. concisus contributed and initiated CD 
were unclear. The study strengthened the suggestion previously made by Zhang et al (2009) 
on the role of C. concisus in IBD; however, Tankovic et al. (2009) could not show the 
statistical significant difference in the prevalence of C. concisus DNA in faecal samples 
between IBD patients and a control group (Table 1.1). 
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1.5.3 Detection of C. concisus in the oral cavity of patients with IBD 
A single study performed by Zhang et al. (2010) investigated the prevalence of C. concisus in 
human saliva collected from IBD patients and healthy controls. C. concisus was isolated from 
85% in patients with CD, 100% in UC and 75% in healthy controls. The detection rate of C. 
concisus by PCR was 100% in IBD (CD and UC) and 97% of healthy controls (Table 1.2). 
There were no significant differences in prevalence of C. concisus between the patients and 
healthy controls, or between males and females in the prevalence of C. concisus (Zhang et al. 
2010). 
 
1.5.4 Human immune responses against C. concisus in IBD 
Little is known about specific immune response against C. concisus. Recently, 37 
immunoreactive proteins of C. concisus strain UNSWCD were identified by Western blotting 
analysis in sera collected from patients with CD. Only three of these (flagellin B, ATP 
synthase F1 alpha subunit, and outer membrane protein 18) were recognised by the sera of all 
patients studied. Six of the immunoreactive proteins were associated with host cell adhesion 
(Kovach et al. 2011). Moreover, it was found that the level of C. concisus specific 
immunoglobulin G (IgG) in patients with CD was significantly higher than in healthy 
controls (Zhang et al. 2009).Thus, it was suggested that C. concisus is able to pass the 
intestinal mucosa to initiate an immune response (Kovach et al. 2011). However, C. concisus 
could also pass through the epithelial cells of the oral cavity and its antigens might be 
exposed to the immune system. Hence, investigations of whether the human immune 
response was generated from intestinal or from oral C. concisus colonisation are required. 
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1.5.5 Summary of IBD studies 
Several studies using PCR reported a significantly higher rate of detection of C. concisus in 
the intestinal biopsies of IBD patients than in healthy controls; however, other studies failed 
to detect such a difference. This difference could be due different techniques and some 
studies used one-step PCR, while the other studies used a nested PCR approach. Nested PCR 
is more sensitive than the one-step PCR and indeed most of the studies using nested PCR 
showed a significant difference in detection of C. concisus in IBD patients compared with 
controls (Tables 1.1 and 1.2). The use of different primer sets could also affect the detection 
rate, due to the variations in DNA sequences within C. concisus strains. Finally, if more 
intestinal anatomic sample sites are used, this may increase the detection rate. 
In contrast, the rate of isolation of C. concisus in patients with IBD has been <11% and C. 
concisus has not been isolated from healthy controls to date. Thus, all statistical analysis 
methods were based on PCR detection results. The isolation rate has remained constant over 
time, which could be due to colonisation in the intestinal tract in very small numbers, or the 
bacterium may exist in a viable but non-culturable form. It is also possible that C. concisus in 
the intestinal tract of IBD patients is derived from the mouth flora, and the number of 
bacterial cells colonising the intestinal tract increases due to pre-existing inflammation. 
All the studies that detected C. concisus in intestinal biopsies were collected at one anatomic 
site of the colon in children, with the exception of a single study that recruited adults 
(Mahendran et al. 2011) that included four anatomic sites of the colon. Thus information is 
lacking on the presence of C. concisus in all intestinal anatomic sites. Moreover, there is no 
information with respect to C. concisus groups associated with IBD. Furthermore, it is 
unclear whether the intestinal strains are similar to the strains that colonise the mouth of the 
same person at the same time. Serological studies could improve our understanding of the 
bacterial involvement in IBD, in particular quantifying immunoglobulin M (IgM) by enzyme-
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linked immunosorbent assay (ELISA) instead of IgG (as in past studies) in serum of patients 
with C. concisus isolated from biopsies, as this approach might strengthen the association of 
C. concisus with IBD, and determine whether the C. concisus antibodies were produced as 
result of the bacterial load in the oral cavity or from gut infections. 
 
1.6 Colonisation of the oral cavity of healthy individuals with C. concisus 
C. concisus is found significantly higher in numbers on the surface of permanent than 
deciduous teeth in healthy children with mixed dentition (Kamma et al. 2000a). Furthermore, 
it was isolated more frequently from molars than incisors in healthy children with primary 
dentition (Kamma et al. 2000a). Isolation of C. concisus from faeces of healthy individuals 
was very low compared with the oral cavity (Cornelius et al. 2012; Engberg et al. 2000; 
Nielsen et al. 2013a), suggesting that the intestinal tract is not a primary site of carriage. 
Interestingly, smokers were found to have a higher colonisation number of C. concisus than 
non-smokers in their oral cavity (Kamma et al. 1997; Kamma et al. 1999), which is possibly 
due to the potential risks of smoking associated with progression of gum diseases. 
 
1.7 C. concisus in animals and in animal source foods 
Several campylobacters have been detected in samples from mammals and birds but C. 
concisus has not been reported as a normal coloniser in any healthy animals (Chaban et al. 
2010; Vandamme et al. 2005). C. concisus was detected in saliva of a 2 year old cat with gum 
infection, while the bacterium could not be detected in healthy dogs (Petersen et al. 2007). 
Moreover, C. concisus was detected in faeces of diarrheic dogs, while again none of the 
healthy dogs were positive for C. concisus (Chaban et al. 2009; Chaban et al. 2010). To date 
only a single study has detected C. concisus in faecal samples collected from broiler chickens 
with a proportion of 6.4%. This study suggested that chickens could be a reservoir for C. 
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concisus (Kaakoush et al. 2014). However, the study did not attempt to isolate C. concisus by 
culture to determine whether the chickens had viable bacterial cells in the gut. 
Furthermore, using culture technique, C. concisus was isolated from retail fresh meat of 
chickens, beef and pork in low percentages (<10%) (Lynch et al. 2011; Scanlon et al. 2013) 
and also from raw cow’s milk (Serraino et al. 2013). These examples of detection of C. 
concisus in animals, retail fresh meat or milk may have resulted from cross-contamination 
from humans as the very limited studies available have failed to detect C. concisus 
colonisation in healthy animals. 
Although C. concisus was detected in humans and animals, no studies have sought its 
detection in plants that are a source of food for humans such as fruit and vegetables. These 
studies are required because plants might be a reservoir of C. concisus with the potential to 
transmit to the human gastrointestinal route. Therefore, it is likely that from the collective 
information of these studies, the human oral cavity is the primary reservoir of C. concisus as 
it commonly found there in healthy individuals. 
 
1.8 Laboratory diagnosis, isolation and detection of C. concisus in clinical 
specimens 
Since C. concisus is usually present in mixed culture with other organisms, including 
commensals, techniques using filtration and molecular techniques are more reliable than 
standard culture. 
 
1.8.1 Cultivation and incubation conditions of C. concisus 
C. concisus is routinely cultivated on Columbia agar base or blood agar base supplemented 
with 5-6% defibrinated horse blood (HBA) in a mixture of gases consisting of 7% H2, 7% 
CO2, 7% O2 and ~79% N2 in an anaerobic jar at 37 °C (Istivan et al. 2010; Istivan et al. 2004; 
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Lee et al. 2014). Microaerophilic growth conditions can also be generated by evacuating an 
anaerobic jar to -7 bar and then adding gas with a mixture of 10% H2, 10% CO2 and ~80% N2 
(Istivan et al. 2010; Lee et al. 2014). C. concisus appears on HBA as colonies measuring 1-2 
mm in diameter, round, entire, semi translucent and grey in colour (Istivan 2005). 
 
1.8.2 The isolation of C. concisus from clinical samples 
There is no a standard technique for C. concisus isolation from faeces, saliva or tissue. 
However, the most common technique used for C. concisus isolation from faeces is the ‘Cape 
Town protocol’, which involves filtration of samples onto enriched media such as HBA 
without antibiotics (Engberg et al. 2000; Lastovica et al. 2000). The faecal sample is initially 
suspended in liquid medium or phosphate buffered saline (PBS) at 1:2 to 1:10; then, 4-5 
drops are placed on a cellulose acetate filter (pores size 0.65 µm) positioned on HBA. The 
suspension is soaked in the filter for approximately 10 min. The filter was then discarded and 
the plate was incubated for 3-5 days (Istivan et al. 2010). 
Tissue samples such as intestinal biopsies are spread on HBA containing 10 mg/ml of each 
trimethoprim and vancomycin prior to incubation under suitable growth conditions for C. 
concisus (Mahendran et al. 2011; Zhang et al. 2009). Alternatively, a two-step enrichment-
filtration method can be used (Kaakoush et al. 2011b) as follows: in step 1, the biopsy is 
incubated in enrichment broth containing 3 ml of Ham’s F-12 medium with foetal bovine 
serum (5% FBS) and 10 µg/ml of vancomycin; then, incubated under C. concisus growth 
conditions for 48 h. Step 2 consists of filtration of 200 µl from the growth mixture obtained 
from step 1 onto HBA containing 10 µg/ml of vancomycin; then, incubation under C. 
concisus growth conditions for 2-4 days (Kaakoush et al. 2011b). 
Isolation of C. concisus from saliva was achieved by streaking 6 µl of saliva on HBA 
containing 10 µg/ml vancomycin and incubation under suitable growth condition for 3 days. 
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Then the mixed bacterial growth was filtered using cellulose acetate filter (pores size 0.65 
µm) on a fresh HBA plate and incubated for 2 days (Zhang et al. 2010). However, this 
method might not reflect the original C. concisus load in saliva because C. concisus may 
grow during both incubation periods. Commensals that are resistant to vancomycin could also 
compete and reduce the growth of C. concisus. 
Although most previous studies have used the cellulose acetate filter (pore size 0.65 µm), 
Nielsen et al. (2013b) recently reported that an alternative polycarbonate filter (pore size 0.60 
µm) led to a significantly greater isolation rate for C. concisus from faecal samples (Nielsen 
et al. 2013b). 
 
1.8.3 Detection and confirmation of C. concisus by molecular methods 
For a bacterium of fastidious nature and slow in growth like C. concisus, molecular 
techniques can improve detection and identification in clinical samples. However, genetic 
variations should be considered in these detection methods otherwise some strains might be 
missed. 
 
1.8.3.1 Direct detection of C. concisus DNA in clinical samples 
The presence of C. concisus DNA was investigated directly in faeces, intestinal biopsy and 
saliva samples (Huq et al. 2014; Zhang et al. 2010; Zhang et al. 2009). Initially a primer set 
(C412F and C1288R) designed by Linton et al. (1996) to amplify the 16S rDNA gene (816 
bp), was used as one step PCR to detect C. concisus from colonic biopsies (Zhang et al. 
2009). Then, to identify C. concisus, the PCR product was sequenced and aligned to 
published sequences (Zhang et al. 2009). Following that, Man et al. (2010b) developed a 
specific nested PCR to detect C. concisus in faecal specimens also targeting the 16S rDNA 
gene. In the first step PCR, the primer set used was C412F and C1288R while in the second 
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step PCR a new primer set (ConcisusF and ConcisusR) was designed to specifically amplify 
560 bp of C. concisus 16S rDNA gene. This nested PCR has been used for C. concisus DNA 
detection in other human clinical specimens including intestinal biopsies and saliva 
(Mahendran et al. 2011; Man et al. 2010b; Mukhopadhya et al. 2011; Zhang et al. 2010). 
Recently, Huq et al. (2014) developed a multiplex PCR (m-PCR) to detect C. concisus and 
other members of Campylobacter in faecal samples, based on the size of PCR product. 
However, as C. concisus is present in very low numbers in intestinal samples, using the 
nested PCR could be more sensitive than m-PCR. 
 
1.8.3.2 Molecular confirmation of C. concisus isolates 
The first specific PCR used for C. concisus identification was developed by Bastyns et al. 
(1995) using the primer set MUC1 (a forward primer) and CON1/CON2 (reverse primers), 
which amplified the 23S rDNA region from all tested C. concisus isolates. Another primer set 
(Pcisus5-F and Pcisus6-R) to amplifies gyrB was developed by Matsheka et al. (2001). It was 
initially used to amplify DNA fragments (344 bp) obtained from a C. concisus genomic 
library and later shown to specifically amplify C. concisus (Huq et al. 2014; Istivan 2005; 
Matsheka et al. 2001). 
 
1.9 Diversity of C. concisus strains 
There is no standard classification method to fully address the diversity of C. concisus. The 
unavailability of standard typing methods has led to limitations in our understanding of the 
transmission, natural habitat and virulence of C. concisus (Lastovica 2006). Typing of C. 
concisus could determine whether isolates obtained from diarrhoeic patients differ from those 
colonising healthy individuals (Aabenhus et al. 2005a; Engberg et al. 2005; Macuch et al. 
2000; Newell 2005). 
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1.9.1 Typing by protein profiling technique 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of protein extracts 
has been applied successfully to distinguish C. concisus from other small oral bacteria with 
very similar characteristics to C. concisus, such as C. mucosalis, other species of Gram-
negative rods, as well as non-pigmenting and asaccharolytic bacteria (Penner 1988; Tanner 
1986). Other studies have used SDS-PAGE analysis of protein patterns to identify clusters 
within C. concisus; and the strains were classified into 2-5 clusters (Engberg et al. 2005; 
Istivan et al. 2004). Therefore, the protein profiling technique could be discriminative for C. 
concisus isolates, but the discriminative power might be improved if combined with another 
typing technique such as genotyping. It should also be noted that protein profiles of C. 
concisus isolates from IBD patients and healthy controls were indistinguishable in one study 
(Ismail et al. 2012). 
 
1.9.2 Genomic typing by PCR and other techniques 
There is no documented standard technique for genotyping C. concisus isolates. The first 
genetic method to type C. concisus was DNA-DNA hybridization (Vandamme et al. 1989). 
The genetic diversity was later confirmed by analysis of 100 C. concisus isolates using 
randomly amplified polymorphic DNA (RAPD) (Matsheka et al. 2006; Van Etterijck et al. 
1996). Another approach used to type C. concisus was amplification of 23S rDNA (section 
1.8.3.2; Bastyns et al. (1995)) using the specific primer set MUC1 and CON1 or MUC1 and 
CON2 (Aabenhus et al. 2005a; Istivan et al. 2004). In this system, isolates amplified by 
MUC1 and CON1 were assigned to genomospecies A, while those amplified by MUC1 and 
CON2 were designated genomospecies B (Aabenhus et al. 2005a; Istivan 2005; Istivan et al. 
2004; Kalischuk et al. 2011). It was noted that there are six base pairs difference between the 
binding site of primers CON1 and CON2 on the genomes of these two genomospecies. 
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Through this study, genomospecies A and B will be used to refer the two genomospecies (A 
and B) generated by amplifying 23S rDNA using MUC1 and CON1/CON2. 
Multilocus sequence typing (MLST) was also applied to 70 oral and intestinal C. concisus 
isolates from eight patients with IBD and six healthy controls (Figure 1.3) (Ismail et al. 
2013). Subsequently, the neighbour-joining tree divided these isolates into 26 types 
(including C. concisus 13826) and two main groups (Figure 1.3). Most isolates (87.5%) in 
cluster 1 were from IBD patients compared with only 28.6% in cluster 2 (P <0.05). It was 
also found that all of the invasive C. concisus isolates were localised in cluster 1 (Ismail et al. 
2013). Two main groups were also demonstrated by MLST using a different set of 
housekeeping genes (aspA, atpA, glnA, gltA, glyA, ilvD, and pgm), applied to 60 C. concisus 
faecal isolates (Miller et al. 2012). However in both of these studies, it was not clear whether 
the two main groups correlated with genomospecies A and B. 
Pulsed field gel electrophoresis (PFGE) also indicated the diversity of C. concisus isolates 
and assigned them into two main groups according to the source of the isolates (faeces and 
the oral cavity), (Matsheka et al. 2002). In addition, C. concisus faecal isolates were allocated 
into four groups using the amplified fragment length polymorphism analysis technique 
(AFLP) (Aabenhus et al. 2005a; Kalischuk et al. 2011). Groups 1 (22 isolates) and 2 (32 
isolates) matched with C. concisus genomospecies A and B (based on 23S rDNA PCR), 
while groups 3 (one isolate) and 4 (five isolates) were considered as additional 
genomospecies as they could not be amplified by 23S rDNA PCR (Aabenhus et al. 2005a). 
Group 2 isolates were found to be significantly more predominant in immunocompetent 
patients, in patients with chronic diarrhoea, bloody diarrhoea or with fever than group 1 
isolates. Group 3 isolate was from an immunocompetent patient, while group 4 isolates were 
from immunodeficient patients with organ transplants or haematological malignancies 
(Aabenhus et al. 2005a). 
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Figure  1.3: MLST analysis targeting six housekeeping genes (asd, aspA, atpA, glnA, pgi 
and tkt) of 60 C. concisus isolates from oral and enteric samples. The gene sequences 
were analysed by neighbour-joining tree. Red: C. concisus isolates from patients with IBD. 
Blue: C. concisus isolates from healthy individuals. The two main groups are depicted in 
roman numerals. This Figure was adapted from Ismail et al. (2012). 
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1.9.3 Typing by denaturing gradient gel electrophoresis (DGGE) 
The PCR-DGGE technique was initially used to evaluate the microbial diversity in complex 
environments (Petersen et al. 2007). In environmental microbiology applications, universal 
primers are designed to target the 16S rDNA gene for the detection of mixed bacterial 
communities and differentiation of bacterial species (Petersen et al. 2007). The PCR product 
is separated by polyacrylamide gel electrophoresis based on the use of different melting 
temperatures and its mobility in gradient denaturation of formamide and urea (Fischer et al. 
1983). A study conducted on DNA extracted from human saliva using PCR-DGGE to detect 
Epsilobacteria (Campylobacters, Helicobacters and Arcobacters and related bacteria) found 
the three reference strains of C. concisus fell into two different DGGE profile groups 
(Petersen et al. 2007). However, Cornelius et al. (2012) found C. concisus isolates assigned 
into only one DGGE profile group. The authors suggested that PCR-DGGE can be a useful 
tool to be used for a direct detection of Epsilobacteria. The application of DGGE to 21 C. 
jejuni isolates and one C. coli isolate using primer sets targeting the flagellin gene identified 
nine different groups (Najdenski et al. 2008). 
 
1.9.4 Full genome sequencing of C. concisus 
At the commencement of this study, C. concisus 13826 (also known C. concisus BAA-1457) 
was the only the strain to be completely sequenced (Table 1.3) (Fouts et al. 2007). Following 
that, other C. concisus strains were sequenced and are available in the NCBI data-base site as 
whole-genome shotgun contigs (WGS) (Deshpande et al. 2011; Deshpande et al. 2013) 
(Table 1.3). The sequencing of C. concisus revealed that some genes might not exist in all C. 
concisus strains. Consequently intensive genetic studies based on sequence comparisons 
would improve our understanding on the bacterial virulence and epidemiology. 
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Table  1.3: C. concisus strains that have been sequenced (whole-genome). 
 
C. concisus 
strains 
Sample 
type 
Disease Age NCBI 
accession 
Genome 
size (Mbp) 
Year of 
sequencing 
13826 Faeces Acute 
gastroenteritis 
- CP000792.1 2.05 Fouts et al. 
(2007) 
UNSWCD Intestinal 
biopsy 
Crohn’s disease Child AENQ00000000 1.81 Deshpande 
et al. 
(2011) 
UNSW1 Intestinal 
biopsy 
Chronic 
gastroenteritis 
Child ANNF00000000 1.94 Deshpande 
et al. 
(2013) 
UNSW2 Intestinal 
biopsy 
Crohn’s disease Child ANNJ00000000 2.01 Deshpande 
et al. 
(2013) 
UNSW3 Intestinal 
biopsy 
Crohn’s disease Child ANNE00000000 1.91 Deshpande 
et al. 
(2013) 
UNSWCS Faeces Acute 
gastroenteritis 
Child ANNG00000000 2.11 Deshpande 
et al. 
(2013) 
ATCC 
51561 
Faeces None Adult ANNH00000000 1.99 Deshpande 
et al. 
(2013) 
ATCC 
51562 
Faeces Acute 
gastroenteritis 
Child ANNI00000000 1.84 Deshpande 
et al. 
(2013) 
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In summary, these studies show that C. concisus is genetically a diverse species, but the 
extent of the differences between strains remains largely unknown. There appear to be two 
main genomospecies (A and B), as demonstrated by PCR of 23S rDNA; however, these two 
genomospecies may not directly correspond to the two groups defined by PFGE, MLST and 
RAPD. These techniques, together with AFLP and whole genome sequencing demonstrate 
the diversity of C. concisus. Therefore, it is possible that certain groups could be more likely 
to be associated with clinical disease than others. From the reviewed studies, C. concisus 
strains should be assigned to at least two main groups in order to start generating a standard 
genetic profiling scheme for C. concisus. 
 
1.10 Virulence factors in C. concisus 
The number of studies investigating the potential pathogenic role of C. concisus has increased 
in the past three years possibly due to suggestions that C. concisus might have a potential 
association with IBD. Several putative virulence factors have been investigated including the 
capability for invasion of intestinal cell lines, haemolysin production and several other 
virulence mechanisms. 
 
1.10.1 Invasion of C. concisus into host cells 
The ability of C. concisus to invade and adhere to HEp-2 cells was investigated by Russell et 
al. (1998). Four faecal C. concisus isolates were 4-100-fold more invasive under these 
conditions than C. jejuni or C. coli. However C. concisus isolates differ in their ability to 
adhere to and invade human intestinal cell lines (Caco2 & LS174T), possibly due to the 
possession of a plasmid harbouring virulence factors (Kaakoush et al. 2011b; Kalischuk et al. 
2011; Man et al. 2010a; Nielsen et al. 2011b). Importantly, the capability of C. concisus 
isolates from biopsies of children with chronic intestinal diseases to invade host cells was 
28 
 
significantly higher (500-fold) than for isolates from children with acute intestinal diseases or 
healthy controls (Kaakoush et al. 2011b). Moreover, Ismail et al. (2012) found that half of 
the patients with IBD were colonised by strains capable of invading intestinal cells (Caco2) in 
their oral cavities, while none of the strains isolated from the healthy controls were invasive. 
In contrast, Kalischuk et al. (2011) and Nielsen et al. (2011b) did not observe any differences 
in invasion, adherence or translocation of T84 and HT-29/B6 cells between C. concisus 
faecal isolates from patients with diarrhoea and healthy controls. These differences between 
studies could relate to the different cell lines used, the source of isolates or to the groups of 
isolates. Future adhesion and invasion studies using C. concisus groups may lead to finding a 
certain pathogenic group or subgroup or could indicate whether C. concisus is an 
opportunistic pathogen. 
Furthermore, C. concisus isolates can stimulate pro-inflammatory cytokines of host cells in 
vitro (Kaakoush et al. 2011b; Kalischuk et al. 2011; Man et al. 2010a; Nielsen et al. 2011b). 
This stimulation depended on whether C. concisus isolates were invasive or adherent, for 
example, all adhesive/invasive isolates, unlike adhesive/non-invasive isolates up-regulated 
IL12 and induced interferon-γ during the infection of the host cells. The authors suggested 
that the in vitro response had significant similarities to the immune response observed in the 
mucosa of CD patients (Kaakoush et al. 2011b). Recently, Burgos-Portugal et al. (2014) 
reported that inhibition of autophagy increased up to 2-4 fold as the numbers of C. concisus 
in host cells (Caco-2) increased, leading to a significant reduction in C. concisus clearance. 
They concluded that C. concisus could manipulate the host cell autophagy process to enhance 
its survival (Burgos-Portugal et al. 2014). 
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1.10.1.1 Mechanism of C. concisus adherence and invasion 
Based on scanning electron microscopy images, the initial contact between C. concisus and 
the host cells appears to be with the flagellum. The adherence mechanism was suggested to 
be an interaction between C. concisus cells and intestinal mucosal cells with the possibility of 
biofilm formation (Kaakoush et al. 2011b) as C. concisus ATCC 33237 is able to aggregate 
and grow within biofilms (Gunther et al. 2009). Following attachment, the bacterial cells 
penetrate the epithelial cell membrane. This process is mediated by secretion of a fibronectin 
binding protein at the host cell outer membrane (Man et al. 2010a), as shown in Figure 1.4. 
This mechanism was suggested to be similar to C. jejuni invasion (Kaakoush et al. 2011b). 
 
1.10.2 Presence of putative virulence genes in C. concisus 
Only limited studies have investigated C. concisus virulence genes. As whole genome 
sequencing has shown that C. concisus strains are genetically heterogeneous and differ in the 
number of genes they possess, studying putative virulence genes could improve our 
understanding of any role in virulence and in the taxonomy of this species. The following 
genes will be investigated in this study as they have been reported to be putative virulence 
factors in other pathogenic Campylobacter spp.: cjaC, cjaA, dnaJ and zot. In C. jejuni, the 
cjaC and cjaA genes encode immunodominant proteins and may have a role in the bacterial 
virulence status (Laniewski et al. 2014; Muller et al. 2005; Wyszynska et al. 2004). The cjaA 
gene also involved in increasing bacterial resistance to β-lactam antibiotics (Mansell et al. 
2013). The dnaJ is a stress gene and it is one of virulence-associated genes in C. jejuni (Bui 
et al. 2012; Konkel et al. 1998). The zot gene encodes zonula occludens toxin and it has been 
used by several pathogenic bacteria (Fasano et al. 1995). 
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Figure  1.4: Adherence and invasion of C. concisus UNSWCD. A) The initial contact and 
attachment of C. concisus into the host cell (Caco-2) by interaction of the bacterial polar 
flagellum and the microvillus tip (triangles). B) The bacterial flagellum folds around the 
microvillus (triangle). C) C. concisus induces and performs a membrane ruffling-like effect 
(*). D) Half of the C. concisus cell appears to penetrate and internalise the membrane of the 
host cell, causing a membrane surface protrusion, and half of its flagellum appears outside the 
host cell. The host cell appears to be infected by more than one bacterial cell as the host cell 
displays irregularities and a rough textured membrane on the cell due to protrusions induced 
during the bacterial invasion (arrows). These images were adapted from Man et al. (2010a). 
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1.10.2.1 The cjaC and cjaA genes 
The cjaC (trap-type mannitol/chloroaromatic compound or C. jejuni antigen C) and cjaA 
genes (C. jejuni antigen A) encode secreted proteins, which are amongst the ABC 
components of outer membrane proteins (Pawelec et al. 1998; Wyszynska et al. 2004). The 
ABC system is a complex of several components that are implicated in the cell membrane 
transport system to control solute movements throughout biological membranes of cells. The 
ABC export systems have been found in all microorganisms that have been studied (Pawelec 
et al. 1998; Saier 1994; Tam et al. 1993). Approximately 100 systems have been determined 
to date (Fath et al. 1993; Higgins 1995; Tam et al. 1993). In Gram-negative bacteria, ABC 
transporting systems consist of soluble proteins generally found in the periplasm; whereas in 
Gram-positive bacteria, these proteins are present on the external surface of the cell 
membrane as anchored lipoproteins. 
The cellular location of the CjaC and CjaA proteins depends on the hosts. These proteins are 
present in the periplasmic space in E. coli, while they are found in the inner membrane as 
anchored proteins in C. jejuni and C. coli (Wyszynska et al. 2007; Wyszynska et al. 2008). In 
campylobacters, the CjaC and CjaA proteins may be responsible for histidine and cysteine 
up-take, respectively (Muller et al. 2005; Wyszynska et al. 2004; Wyszynska et al. 2007). 
They might be vital for campylobacters, which are asaccharolytic microorganisms that use 
amino acids as an alternative carbon source (Wyszynska et al. 2007). Although bioinformatic 
predictions for C. concisus UNSWCD showed that the CjaC and CjaA could be secreted 
proteins (Kaakoush et al. 2010), the cellular location and function of the corresponding genes 
has not been investigated. The CjaC and CjaA proteins in C. concisus are predicted to have a 
similar function as the corresponding genes in C. jejuni (Kaakoush et al. 2010). 
Furthermore in other campylobacters, the CjaC and CjaA proteins are highly immunogenic 
surface proteins and are likely to play a substantial role in bacterial virulence (Muller et al. 
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2005; Wyszynska et al. 2004). The product of a cloned cjaC gene of C. jejuni 72Dz/92 was 
highly immunogenic in rabbits (Pawelec et al. 1998) and was also suggested as a good 
vaccine candidate in chickens (Skirrow 1992). Moreover, the CjaA protein from C. jejuni was 
effective as a vaccine against different Campylobacter species (Clark et al. 2012; Wyszynska 
et al. 2004). In C. concisus, the CjaC and CjaA proteins were reported to show 
immunoreactivity against CD patients’ sera (Kovach et al. 2011). 
 
1.10.2.2 The dnaJ gene 
The dnaJ gene encodes a stress protein, which belongs to Hsp-40 (heat shock protein 40 KD); 
a family of molecular chaperones that are produced by many bacterial species (Konkel et al. 
1998). DnaJ is considered to be among virulence-associated genes (Li et al. 2008) that may 
play a significant role in C. jejuni colonisation in chickens (Konkel et al. 1998) since mutant 
dnaJ strains grow slowly at 46°C and fail to colonise newly hatched Leghorn chickens 
(Konkel et al. 1998). In C. concisus, dnaJ has not been investigated but could be involved in 
colonising different areas of the human body such as the oral cavity, intestinal tract and 
faeces. 
 
1.10.2.3 The zot gene 
The ZoT protein, a tight junction toxin encoded by the zot gene that is expressed by virulent 
bacteria such as Neisseria meningitides and Vibrio cholera (Fasano et al. 1995). Recently, a 
related toxin has been detected in C. concisus (Kaakoush et al. 2010), C. ureolyticus 
(Bullman et al. 2013), but not in other Campylobacter spp. (Kaakoush et al. 2010). 
Alignment of the translated protein sequence from C. concisus 13826 to similar proteins from 
N. meningitidis and V. cholerae showed four conserved domains suggesting that these could 
be linked to the ZoT toxin activity (Figure 1.5) (Kaakoush et al. 2010). C. concisus strains 
may have acquired the gene from these other pathogens by gene transfer (Kaakoush et al. 
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2010; Zhang et al. 2014). The gene transfer may occur by a specific species of a prophage 
containing the zot gene as the majority of Campylobacter spp. do not possess the gene. The 
function of ZoT is to enhance tissue permeability (Fasano et al. 1995) as its interaction with 
receptors on host cells results in intracellular signalling activation, which ultimately 
disassembles the intercellular tight junctions (Di Pierro et al. 2001). Therefore, it may play a 
role in C. concisus virulence (Kaakoush et al. 2010; Uzzau et al. 2000). In C. concisus, 
polymorphic forms of zot in which valine at position 270 is substituted with other amino 
acids may be linked to patients with active IBD (Mahendran et al. 2013). 
 
1.10.3 Other putative toxins produced by C. concisus 
Several toxins have been reported to be produced by C. concisus isolates. Initially, C. 
concisus isolates from children with gastroenteritis were shown to lyse human and animal 
erythrocytes (Istivan et al. 1998; Kalischuk et al. 2011). Extracted outer cell membrane 
proteins of C. concisus of both genomospecies A and B possess haemolytic phospholipase A2 
activity, that caused stable vacuolating and cytolytic effects on ovarian cells of Chinese 
hamster (CHO) in tissue culture, providing strong suggestive evidence that C. concisus 
possess virulence mechanisms (Istivan et al. 2004; Istivan et al. 2008). Recently, cytotoxic 
activity by oral and faecal isolates of C. concisus to intestinal cell lines (HT-29/B6 and T84) 
was demonstrated by showing the release of high levels of lactate dehydrogenase (LDH) and 
induction of apoptotic DNA fragmentation (Kalischuk et al. 2011; Nielsen et al. 2011b). 
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Figure  1.5: Alignment of ZoT toxin sequences from the genomes of C. concisus 13826, V. 
cholerae 86015 and N. meningitidis MC58. The sequences in boxes refer to the highly 
conserved domains (this Figure was adapted from Kaakoush et al (2010)). 
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1.11 C. concisus and biofilm formation 
C. concisus isolates obtained from faeces (of gastroenteritis patients and a healthy control), 
colonic biopsies (of CD patients) and the oral cavity (of a patients with periodontitis) were 
able to form biofilms on all tested surfaces (stainless steel, glass and polystyrene plastic) with 
no significant differences in biofilms formation between these isolates (Figure 1.6) (Gunther 
et al. 2009; Lavrencic et al. 2012). The biofilms formed by C. concisus were described to 
have higher consistency compared to other 16 tested Campylobacter spp. (Gunther et al. 
2009). 
These studies demonstrated another possible virulence factor of C. concisus. The bacterium 
could produce biofilm in the human gut leading to long term residence in a protected 
environment in the intestinal tract. It is most likely that biofilms help bacteria to survive in 
the gut by protection from the immune response of the host cell and antibacterial agents 
(Donlan 2002). 
 
1.12 Motility of C. concisus  
Motility can facilitate bacterial virulence since highly motile bacterial cells are able to swim 
through the protective barrier of the intestinal mucosa, allowing direct contact with host cells 
(Haiko et al. 2013). Intestinal C. concisus isolates display two distinct types of motility 
(Lavrencic et al. 2012) and attracted by several chemicals including formate and mucin 
(Kaakoush et al. 2011b; Paster et al. 1986). However, the authors did not correlate the two 
types of motility to the genetic diversity of C. concisus isolates (Lavrencic et al. 2012). 
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Figure  1.6: Scanning electron images for C. concisus (ATCC 33237) forming biofilms on 
glass. These images were adapted from Gunther et al. (2009). 
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1.13 C. concisus and antimicrobial susceptibility 
The effects of antimicrobial agents on C. concisus are still not well studied, possibly due to 
the lack of standard validated techniques for use in the diagnostic laboratory. The disc 
diffusion method could be unsuitable for these slow growing bacteria (Istivan et al. 2010). 
Moreover, it is unclear which medium is most useful for antibiotic susceptibly testing. As 
most studies have used HBA to grow C. concisus, incorporating the antimicrobial agents into 
HBA would seem logical. 
In most of the reviewed studies, C. concisus was found to be susceptible to the majority of 
antimicrobial agents including erythromycin, ciprofloxacin, tetracycline, ampicillin, 
clindamycin, azithromycin, gentamicin, chloramphenicol, cephalothin and ceftriaxone 
(Aabenhus et al. 2005b; Pruckler et al. 2002; Vandenberg et al. 2006), while it was mainly 
resistant to nalidixic acid, rifampin, vancomycin and bacitracin (Aabenhus et al. 2005a; 
Istivan 2005; Pruckler et al. 2002; Tanner et al. 1981). Remarkably, Moore et al. (2006) 
studied the change in the resistance state of 457 C. concisus isolates obtained between 1998-
2006, against several antimicrobial agents and it was found that resistance increased by 22% 
for nalidixic acid, 16.9% for erythromycin, 11.1% for ciprofloxacin and 0% for ceftriaxone. 
 
1.13.1 Treatment of C. concisus infections with antimicrobial agents 
Most campylobacter infections are self-limited and treatment with antimicrobial agents is 
usually not required, particularly for gastroenteritis. The role of treatment with antimicrobial 
agents for other infections possibly by C. concisus is still not well addressed (Fitzgerald et al. 
2008); however, infections in immunocompromised, elderly and immune deficient patients 
should be treated with antimicrobial agents (Hess et al. 2012; Zhang et al. 2009). 
Antimicrobial agents that are effective against infections due to other campylobacters can be 
effective for the treatment of C. concisus, in particular the antibiotics that inhibit RNA 
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synthesis, for example rifaximin (Guslandi et al. 2009). Erythromycin was suggested to be 
the antibiotic of first choice to treat intestinal campylobacteriosis caused by C. concisus 
(Vandenberg et al. 2006). Other suitable antimicrobial agents are ciprofloxacin, ampicillin 
and ceftriaxone. 
 
In summary, the main reservoir of C. concisus is the human oral cavity. The organism is 
fastidious and its taxonomy is not well established. It is clear from several studies that the 
species is highly diverse, with some strains having the role of colonisers and others as 
possible pathogens. C. concisus has been isolated from cases of periodontitis/gingivitis, 
gastroenteritis and recently from intestinal biopsies of patients with IBD, but the role of C. 
concisus as causative agents for these infections is still unclear. Putative virulence factors 
include invasiveness, toxin production, haemolysin activity, and the ability to grow as 
biofilms. Most of the reviewed studies have urged intensive work to expand our knowledge 
of this organism in order to obtain clear views on its role in common diseases including 
gastroenteritis, infections of the oral cavity infections and IBD. 
 
1.14 Project aims 
This study investigated the role and prevalence of C. concisus as a possible pathogen in 
patients with enteric diseases by achieving these objectives: 
 
Objective 1: Type a collection of C. concisus isolates from carriage and disease states 
by DGGE, presence and variation of virulence genes (cjaC, cjaC, dnaJ and zot), and 
bioinformatics analysis in order to confirm the diversity of the species and detect the 
association of particular types with disease status. 
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Objective 2: Investigate the capability of C. concisus oral and faecal isolates to 
invade intestinal epithelial cell line (INT407) and examine the expression of the 
possible virulence genes (cjaC, cjaC, dnaJ and zot) to evaluate the virulence state of 
the isolates obtained from different sites. 
 
Objective 3: Detect the prevalence of C. concisus in clinical samples (intestinal 
biopsies, faeces and gum swabs) collected from patients with IBD and control 
participants by culture and molecular techniques. 
 
Objective 4: Develop nested PCRs to detect the possible involvement of 
genomospecies B and zot in IBD patients. 
 
Objective 5: Use SDS-PAGE analysis to evaluate the similarity between C. concisus 
isolates obtained from different sites (intestine and mouth) of the same patient in 
order to investigate a possible association of C. concisus in patients with IBD. 
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Chapter 2 : General materials and methods 
2.1 General procedures 
Chemicals used in this study were analytical and molecular grade reagents unless otherwise 
stated. The solutions used were prepared in deionised water (dH2O) filtered by a Millipore 
Milli-Q® water system (Liquipure) except where otherwise itemised, and stored at room 
temperature except where otherwise mentioned. Small volumes of the solutions were 
dispensed with micropipettes of Finnpipette (Pathtech Pty Ltd., Australia) using the range of 
the following volumes: 200 µl - 1 ml, 20 µl - 200 µl, 5 µl - 50 µl, 0.5 µl - 10 µl and 0.1 µl - 2 
µl. All reusable plasticware and glassware was washed and cleaned by Pyroneg detergent, 
then rinsed in tap water and finally with dH2O. Sterilisation of glassware, autoclavable 
consumables (micropipette tips, 1.5 ml tubes, toothpicks and PCR tubes), media, used 
bacterial solutions like dH2O and PBS was autoclaved at 121°C for 20 min unless otherwise 
indicated. 
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2.2 General materials and equipment 
2.2.1. General materials 
Reagent Supplier 
Acetic acid                                                                  Sigma-Aldrich Pty. Ltd., Australia 
Acetone                                                                       Sigma-Aldrich Pty. Ltd., Australia 
Acrylamide, 40% (W/V) solution                               Astral Scientific Pty. Ltd, Australia  
Agarose (DNA grade)                                                 Bioline, Australia 
Albumin, bovine serum                                            Sigma-Aldrich Pty. Ltd., Australia 
Ammonium acetate                                                     Ajax Chemicals Ltd, Australia  
Ammonium chloride                                                   BDH Chemicals, Australia  
Ammonium hydroxide                                               Sigma-Aldrich Pty. Ltd., Australia 
Ammonium persulfate                                               Bio-Rad Laboratories, Australia 
Ammonium sulphate                                                 Sigma-Aldrich Pty. Ltd., Australia 
Bacteriological tryptone                                           Cell BioSciences, Australia 
Brain-Heart infusion broth                                       Oxoid, Australia 
Brilliant Blue G (for Coomassie blue)                   Sigma-Aldrich Pty. Ltd., Australia 
Bromo-phenol blue                                                   Sigma-Aldrich Pty. Ltd., Australia 
CampyGen Sachet (Gas Pack)                                 Oxoid, Australia 
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Columbia agar base                                                Cell BioSciences, Australia 
Columbia Broth                                                       Cell BioSciences, Australia 
Coomassie brilliant blue  Coomassie Brilliant Blue R-250 
Brilliant blue G                             Sigma-Aldrich Pty. Ltd., Australia 
Copper sulphate                                                      Merck, Australia 
Dimethylsulphoxide (DMSO)                                Merck, Australia 
Dulbecco's Modified Eagle's Medium 
(DMEM) 
Life technologies, Australia 
Ethanol                                                                    Merck, Australia 
Ethidium bromide                                                   Sigma-Aldrich Pty. Ltd., Australia 
EDTA (Ethylene diamine tetra acetic acid)          Merck, Australia 
Fetal bovine serum (FBS) Bovogen serumBiologicals, Australia  
Ficoll-400 Reagent                                                 Merck, Australia 
Folin-Ciocalteau reagent                                          Sigma-Aldrich Pty. Ltd., Australia 
Formaldehyde                                                        Merck, Australia 
Formamide  Merck, Australia 
Gentamicin sulfate                                                   Sigma-Aldrich Pty., Ltd, Australia  
Glycerol                                                                   Merck, Australia 
Glycine                                                                     BDH Chemicals, Australia  
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Ham’s F-12 Life technologies, Australia 
HEPES buffer (1M) (N-2-hydroxyethyl 
piperazine-N-2-ethane sulfonic acid)                                                
Thermofisher, Australia  
Horse Blood (Defibrinated)                                    Oxoid, Australia  
Hydrochloric acid (32%)                                                  Merck, Australia  
Hydrogen peroxide (30 %) BDH Chemicals, Australia 
Lambda DNA (50 µg) Biolabs, Australia  
Immersion oil (Gurr) BDH Chemicals, Australia 
Isolate II Genomic DNA kit Bioline, Australia 
Isolate RNA Mini kit  Bioline, Australia 
Isolate II PCR and Gel Kit                              Bioline, Australia 
Isopropanol                                                           Merck, Australia 
Lysozyme                                                               Astral Scientific Pty. Ltd, Australia 
Magnesium chloride (Hexahydrate)                         BDH Chemicals, Australia 
Magnesium Sulfate                                                   BDH Chemicals, Australia 
β-Mercaptoethanol                                                  Sigma-Aldrich Pty. Ltd., Australia  
Methanol                                                                BDH Chemicals, Australia  
Microaerophilic gas mixture                                   Linde Gas, Australia  
MyTaq DNA Polymerase                                     Bioline, Australia 
Orange G                                                           Merck, Australia 
ParaFilm tape                                                           InterPath, Australia 
Petri dish                                                            VWR international, Australia  
Phosphate buffer saline (PBS) tablets                Astral Scientific Pty. Ltd, Australia 
Potassium chloride                                             BDH Chemicals, Australia  
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Protein Prestained standards marker       Bio-Rad, Australia 
PstI (100 U/µL). Biolabs, Australia 
SensiFASTTM SYBR No-ROX’ kit Biolabs, Australia 
Skim milk                                                           Coles, Australia 
Sodium acetate                                                    BDH Chemicals, Australia  
Sodium bicarbonate                                          Cytosystems Pty Ltd, Australia 
Sodium Carbonate                                              Merck, Australia 
Sodium chloride                                                 Merck, Australia  
Sodium dodecyl sulfate (SDS)                           Merck, Australia 
Sodium hydroxide                                              Merck, Australia  
Sodium Potassium Tartrate                                Merck, Australia 
Sulphuric acid                                                    BDH Chemicals, Australia  
TEMED 
(N,N,N’,N’tetramethylethylenediamine)    
Bio-Rad, Australia 
Tetro cDNA Synthesis kit Bioline, Australia 
Tissue culture flask (25 cm2, 75 cm2)                               VWR, Australia 
Tris-HCl                                                             Merck, Australia  
Triton-X-100                                                      Sigma-Aldrich Pty., Ltd, Australia  
Trypan blue                                                        Sigma-Aldrich Pty., Ltd, Australia 
Trypsin – EDTA                                                 Life Technology, Australia  
Tryptone                                                             Cell BioSciences, Australia  
Turbo DNA-freeTM kit Ambion, Life technologies, Australia 
Ultrapure water Bioline, Australia 
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UltraPure Tris-base                                            Sigma-Aldrich Pty. Ltd., Australia 
Urea BDH Chemicals, Australia 
Wizard Genomic DNA Purification Kit           Promega, Australia 
Yeast extract                                                      Cell BioSciences, Australia 
 
2.2.2. General equipment 
Equipment                                                                     Supplier  
Anaerobic jars: 2.5 L, 3.5 L and 10 L  Oxoid, Australia, Don Whitely, 
Australia 
Analytical balance Sartorius GMBH, Australia 
Balance (0.1-500 g)  U-Lab, Australia 
Bench top centrifuge Eppendorf, Australia 
Biological Safety Cabinet Class II  LAF Technologies, Australia  
Cell counting chamber                                                        Life Technology, Australia 
Cell Counter                                                                       Life technology. Australia 
Cellulose Acetate Filter (0.65 µm)                                        Sartorius GMBH, Australia 
Centrifuge tubes: 
- 1.5 ml Eppendorf centrifuge tube. 
- 10 ml centrifuge tube 
- 15 ml centrifuge tube 
- 50 ml centrifuge tube 
 
VWR, Australia 
VWR, Australia 
VWR, Australia 
VWR, Australia 
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Copan Eswab Copan Diagnostics, Inc, USA 
Cover slips                                                                  Mediglass, Australia  
Cryovials (1.8 ml) Mcfarlane Medical, Australia 
Cuvette                                                                        Eppendorf, Australia. 
DNA Thermocycler (for PCR)                                     G-Storm, England  
Electrophoresis Power Supply 
(A) PowerPac Basic  
 
Bio-Rad, Australia 
Electrophoresis Units: 
    (1) DNA: 
- Mini Gel 
- Midi Gel 
    (2) Protein: 
- Mini Protein II gel system 
 
 
Bio-Rad, Australia 
Bio-Rad, Australia 
 
Bio-Rad, Australia 
Filters: syringe Filters (0.22 µm) Sarstedt, Germany 
GELDOC system                                                                 Bio-Rad, USA 
Tissue culture (5% CO2) incubator Forma Scientific, USA 
Loops: normal plastic & L-shape                                          Interpath, Australia 
Microscopes: 
- Light microscope 
- Inverted Optical ix71 
 
Olympus optical, Japan 
Olympus optical, Japan 
pH meter                                                                            Metrohm, Swiss 
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Plate (24 and 96 wells)                                               VWR, Australia 
Rotor-Gene Q (Real-Time PCR)                                      Qiagen, Australia 
Centrifuges: 
- Microcentrifuge  
- High-Speed centrifuge 
 
Zentrifugen, Germany 
Thermofisher, Australia 
Scanner (SDS-PAGE imaging)                                        Canon, Australia 
Shaker (with incubation service)                                     Bioline Global, Australia 
Slides                                                                               LivingStone, Australia 
Spectrophotometer (OD600)                                       Eppendorf, Australia 
SpectroStar Omega Reader (ELISA reader for 
Protein Concentration)                                          
BMG-LabTech, Australia 
Syringe (1 ml, 5 ml, 10 ml, 20 ml, 50 ml)                          LivingStone International, Australia   
Syringe needle (18G)                                     Terumo Pty, Ltd., Australia 
Tips (Sterile filtered 10 µl, 20 µl, 100 µl, 200 µl 
and 1000 µl) 
VWR, Australia 
Tips (10 µl, 200 µl and 1000 µl)                                                VWR, Australia 
Vortex mixer                                                              Ratek Instruments, Australia 
Water Bath                                                                       Ratek Instruments, Australia 
Weight Trays  Mirella Research, Australia 
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2.3 Bacteriological media 
2.3.1 Brucella broth 
Brucella broth powder (2% w/v) was dissolved in dH2O and then sterilised by autoclaving 
under standard conditions (121°C for 15 min under 1.05 kg/cm2 pressure). 
 
2.3.2 Brain heart infusion broth 
Brain heart infusion broth powder (3.7% w/v) was dissolved in dH2O and sterilised by 
autoclaving under standard conditions. It was then cooled down until approximately 55°C 
and aliquoted into 50 ml plastic tubes prior to storing at 4-8°C. 
 
2.3.3 Columbia broth 
Columbia broth base powder (3.5% w/v) was dissolved in dH2O and sterilised by autoclaving 
under standard conditions. It was cooled until approximately 27°C (room temperature) and 
aliquoted into 50 ml plastic tubes prior to storing at 4-8°C. 
 
2.3.4 Columbia agar (CA) 
Columbia agar base (Acumedia, USA) powder (4.1% w/v) was dissolved in dH2O and 
sterilised by autoclaving using standard conditions. Then, it was cooled until approximately 
55°C. Following that, around 25 ml of the medium were poured into 90 mm sterile Petri 
dishes. The plates were left to solidify at room temperature for two hours prior to storage at 
4-8°C. 
 
2.3.5 Horse blood agar (HBA) 
Columbia agar base powder (4.1% w/v) was dissolved in dH2O and sterilised by autoclaving 
using standard conditions. Then, it was cooled down until approximately 55°C. Defibrinated 
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horse blood (5% v/v) (Oxoid, Australia) was added to the medium, mixed thoroughly and 
approximately 25 ml of the mixture was poured into 90 mm sterile Petri dishes. The plates 
were left to solidify at room temperature for 2 h. The plates were stored at 4-8°C. 
 
2.4 Bacterial isolates and growth conditions 
2.4.1 Bacterial isolates 
A total of thirty-three C. concisus isolates and three Campylobacter reference strains were 
recruited in this study. C. concisus isolates were obtained from two sources. The first source 
was a collection of 15 C. concisus isolates and two C. concisus reference strains from RMIT 
University bacterial stock collection as listed in Table 2.1. In this collection, the isolates were 
obtained from children who suffered from slight to severe bloody diarrhoea attending the 
Royal Children's Hospital (RCH), Victoria, Australia (Istivan et al. 2004). The second was a 
collection of 16 oral isolates obtained from healthy volunteers (adults and children at RMIT 
University, Melbourne, Australia) (Table 2.1). In this study the ethics approval for the second 
collection was made and granted by RMIT University Human Research Ethics Committee 
(HREC) (Ethics no. 57/13). 
The oral isolates obtained for this study and were identified as described by Tanner et al. 
(1981) and Vandamme et al. (2005). The isolation of C. concisus was performed by 
collecting gum swabs from the participants. Suspected colonies grown on HBA were 
identified by morphological characterisation as mentioned in section 2.4.3 to confirm the 
identity of C. concisus isolates in Table 2.1. 
 
 
 
50 
 
Table  2.1: C. concisus isolates and Campylobacter reference strains used in this study. 
Strain no Source of the 
strain 
Clinical 
manifestation 
Age and 
sex 
classification Isolate collected 
location 
RCH3 Faeces 3 days diarrhoea & vomiting 1 y, male C. concisus (A) RCH, Australia 
RCH4 Faeces 5 days diarrhoea & vomiting 1 y, female C. concisus (A) RCH, Australia 
RCH5 Faeces 5 days diarrhoea 5 m, female C. concisus (A) RCH, Australia 
RCH6 Faeces 3 days diarrhoea 2 y, male C. concisus (B) RCH, Australia 
RCH7 Faeces 7 days gastroenteritis & vomiting 16 m, male C. concisus (A) RCH, Australia 
RCH9 Faeces 7 days diarrhoea & fever 2 y, male C. concisus (A) RCH, Australia 
RCH11 Faeces 4 days diarrhoea 2 y, male C. concisus (B) RCH, Australia 
RCH12 Faeces 20 days diarrhoea 30 m, male C. concisus (A) RCH, Australia 
RCH15 Faeces 9 days gastroenteritis & vomiting 5 m, female C. concisus (A) RCH, Australia 
RCH19 Faeces 5 days gastroenteritis & vomiting 2 y, female C. concisus (A) RCH, Australia 
RCH20 Faeces 14 days gastroenteritis & vomiting 10 m, female C. concisus (A) RCH, Australia 
RCH23 Faeces gastroenteritis < 15 y,  C. concisus (A) RCH, Australia 
RCH24 Faeces gastroenteritis < 15 y C. concisus (A) RCH, Australia 
RCH25 Faeces gastroenteritis < 15 y C. concisus (A) RCH, Australia 
RCH26 Faeces gastroenteritis < 15 y C. concisus (A) RCH, Australia 
O1 Oral swab healthy 41 y, male C. concisus (A) RMIT, Australia 
O2 Oral swab healthy 41 y, male C. concisus (A) RMIT, Australia 
O3 Oral swab healthy 41 y, male C. concisus (A) RMIT, Australia 
O4 Oral swab healthy 35 y, male C. concisus (A) RMIT, Australia 
O5 Oral swab healthy 35 y, male C. concisus (A) RMIT, Australia 
O6 Oral swab healthy 35 y, male C. concisus (A) RMIT, Australia 
O7 Oral swab healthy 60 y, male C. concisus (A) RMIT, Australia 
O8 Oral swab healthy 3 y, female C. concisus (B) RMIT, Australia 
O9 Oral swab healthy 3 y, female C. concisus (A) RMIT, Australia 
O10 Oral swab healthy 27 y,  female C. concisus (A) RMIT, Australia 
O11 Oral swab healthy 27 y, female C. concisus (B) RMIT, Australia 
O12 Oral swab healthy 5 y, male C. concisus (A) RMIT, Australia 
O13 Oral swab healthy 5 y, male C. concisus (B) RMIT, Australia 
O14 Oral swab healthy 27 y, male C. concisus (A) RMIT, Australia 
O16 Oral swab healthy 5 y, male C. concisus (B) RMIT, Australia 
O17 Oral swab healthy 5 y, male C. concisus (A) RMIT, Australia 
O2 Oral swab healthy 41 y, male C. concisus (A) RMIT, Australia 
O3 Oral swab healthy 41 y, male C. concisus (A) RMIT, Australia 
O4 Oral swab healthy 35 y, male C. concisus (A) RMIT, Australia 
O5 Oral swab healthy 35 y, male C. concisus (A) RMIT, Australia 
O6 Oral swab healthy 35 y, male C. concisus (A) RMIT, Australia 
O7 Oral swab healthy 60 y, male C. concisus (A) RMIT, Australia 
O8 Oral swab healthy 3 y, female C. concisus (B) RMIT, Australia 
O9 Oral swab healthy 3 y, female C. concisus (A) RMIT, Australia 
O10 Oral swab healthy 27 y,  female C. concisus (A) RMIT, Australia 
O11 Oral swab healthy 27 y, female C. concisus (B) RMIT, Australia 
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O12 Oral swab healthy 5 y, male C. concisus (A) RMIT, Australia 
O13 Oral swab healthy 5 y, male C. concisus (B) RMIT, Australia 
O14 Oral swab healthy 27 y, male C. concisus (A) RMIT, Australia 
O16 Oral swab healthy 5 y, male C. concisus (B) RMIT, Australia 
O17 Oral swab healthy 5 y, male C. concisus (A) RMIT, Australia 
ATCC 51561T Faeces healthy 24y, female C. concisus (B) CCUG 20034 
ATCC 51562T Faeces diarrhoea 7m, male C. concisus (A) CCUG 20700 
81116 Human faeces - - C, jejuni UK, 1983 
ATCC 43264T pig - - C. mucosalis CCUG 10771 
NCTC 11366T Pig - - C. coli Belgium, 1980 
 
ATCC 51561 and ATCC 51562: C. concisus reference strains. ATCC 43264: C. mucosalis reference strain. 
81116: C. jejuni strain. NCTC 11366: C. coli reference strain. RCH: C. concisus isolates were collected 
previously from The Royal Children's Hospital, Victoria, Australia. O: the oral C. concisus isolates were 
obtained in this study. Y: years. m: months 
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2.4.2 Bacterial growth conditions 
C. concisus was cultivated on HBA plates unless otherwise specified. The plates were 
incubated at 37ºC for 2-4 days under microaerobic conditions with a gas mixture consisting 
of 6% O2, 8% CO2, 6-7% H2, and 80% N2. All bacterial isolates used in this study were 
obtained from cultures no older than 2-3 passages. 
 
2.4.3 Identification of C. concisus 
The identification of C. concisus was initially by morphological characterisation of bacterial 
colonies. Suspected C. concisus colonies at 48 h that were small in size (0.5-1.0 mm in 
diameter), grey in colour, round in shape and convex with entire edge, were subjected to 
Gram-stain, oxidase test, catalase test, ability to grow in microaerobic conditions (section 
2.4.2) on HBA, and then confirmed by molecular techniques. 
 
2.4.4 Bacterial storage 
Bacterial strains were grown on HBA plates for 2-4 days. The bacterial growth was harvested 
from the plate using a plastic loop and suspended in a cryovial containing ~1 ml tryptone 
skim milk. The bacterial suspension was stored at -80°C. 
The preparation of tryptone skim milk was as following: Tris-HCl (157.6 mg) was dissolved 
in dH2O (100 ml) to give a final concentration of 10 mM. Skim milk (10 % w/v) and tryptone 
(1 % w/v) were dissolved in the prepared solution with a final adjustment of pH at 7.5 using 
NaOH. The solution was gently mixed and each 10 ml aliquot was dispensed into a small 
glass container. The containers were then autoclaved at 109°C for 30 min before the 
containers were stored at 4-8°C. 
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2.5 Genomic bacterial DNA techniques 
2.5.1 DNA extraction 
Bacterial growth from an entire HBA plate (2-4 days old) was collected and suspended in 1 
ml PBS. The suspension was centrifuged at 14000 x g. The bacterial pellet was washed with 
1 ml PBS twice and centrifuged again under the same conditions. After the second 
centrifugation the bacterial pellet was used for the DNA extraction. The DNA extraction was 
performed as recommended by the manufacturer (Wizard® Genomic DNA Purification Kit, 
Promega, USA). Purified bacterial genomic DNA obtained from each bacterial isolate was 
stored at -20°C. 
 
2.5.2 Rapid DNA extraction 
Bacterial colonies (2-3) were suspended in 100 µl of sterile dH2O in a 1.5 ml microcentrifuge 
tube. The suspension was boiled in a block heater at 100°C for 5 min; following that it was 
incubated on ice for 5 min. The boiled bacterial suspension was centrifuged at 14000 x g for 
3 min. The supernatant was used as DNA template for PCR reactions.  
 
2.5.3 Determination of DNA concentration 
Extracted bacterial genomic dsDNA was diluted in sterilised dH2O. The DNA was diluted 
~30 times and then was measured by a spectrophotometer or a NanoDrop 2000 at absorbance 
of 260 nm and 280 nm. The obtained concentration was adjusted to the required 
concentration for each experiment. 
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2.6 Oligonucleotides (primers) 
2.6.1 Primers design 
The Clone Manager 7 software (Scientific & Educational Software, USA) was used for 
designing the primers following its default standard criteria (GC: 50-60%, Tm: 55-80°C, 3' 
dimers: < 3 matches 3'end, dimers-any: < 7 adj homol bases, GC clamp: > 1 G or C at 3' end, 
stability: > 1.2 kcals 5'vs3', repeats: < 3 dinuc repeats, hairpins Annealing: 55°C and length: 
18-30 bp). The NCBI data-base site was used to find C. concisus 13826 genome sequence 
and to test the specificity of the primer sets. Most primers sets were designed according to C. 
concisus 13826 genome sequence unless otherwise mentioned. This sequence was the only 
one available in public databases at the commencement of the study. 
 
2.6.2 Primer sets used in this study 
The primers designed and used in all chapters of this study are described in Table 2.2. 
 
2.7 PCR amplification conditions 
A total reaction volume of 25 µl contained 10 pmol of each primer set (GeneWorks), 20 ng 
bacterial DNA, 0.7 U of Taq polymerase. ‘MyTaqTM’ DNA Polymerase mixture (Bioline, 
Australia) was used as the PCR reaction solution. 
Thermal cycling conditions for the targeted DNA, unless otherwise indicated, were: 2 min at 
95°C, then thirty cycles of 30 seconds at 94°C, 30 seconds at 54°C and 2 min at 72°C, 
followed final extension of 7 min at 72°C with the exception of the extension temperature for 
primer set VI was 68°C and the annealing temperature for DnaJT and CjaAT primer sets was 
58°C and extension time was 1 min. 
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Table  2.2: The sequence and targeted DNA regions of primer sets used in this study. 
Primer sets Primer sequence (5ˋ to 3ˋ) Target region on 
the genomic 
DNA 
Produc
t size 
(bp) 
Reference Usage of 
primers  
in chapters  
MUC1 
CON1 
CON2 
F-ATGAGTAGCGATAATTGGG 
R-CAGTATCGGCAATTCGCT 
R-GACAGTATCAAGGATTTACG 
23S rDNA 
23S rDNA 
23S rDNA 
 
306 
308 
Bastyns et al. 
(1995) 
 
3 & 5 
Pcisus5-F 
Pcisus6-R 
F-AGCAGCATCTATATCACGTT 
R-CCCGTTTGATAGGCGATAG 
Gyrase B 
 
344 Matsheka et al. 
(2001) 
3 & 5 
Primer set (I) F-TGGATACTCGGCCTTCATCTTG 
R-ATCTCTTGGCCTAGCAGCTC 
CCC13826_0963 
 
800 This study 
This study 
3 & 5 
Primer set 
(II) 
F-GCCAAGCGCCATGTCATAAG 
R-TGAATTTGGCGGCGGCAAAG 
CCC13826_0963 
 
300 This study 
This study 
3, 4 & 5 
Primer set 
(III) 
F-GAGATCGTTGAGTCTCAAAG 
R-TATATCAAGCGGTCTTAGC 
cjaC & shikimate 
5-dehydrogenase 
330 Istivan 
(Unpublished 
data) 
3 
Primer set 
(IV) 
F-CTATCTATAATAGCCACCAGTA 
R-GTTGAGTCTCAAAGAGCTTTC 
cjaC & shikimate 
5-dehydrogenase 
270 Istivan 
(Unpublished 
data) 
3 
Primer set 
(V) 
F-TCCTTCTCCAGCTTCTCATC 
R-AGGCCGAGTATCCAGACATC 
CCC13826_0962 
& 
CCC13826_0963 
330 This study 
This study 
3 
Primer set 
(VI) 
F-CTCTTGCAGTAGTAACCTTAG 
R-AAGCGGCTGCTGCTGAAGTG 
CCC13826_0962 
& 
CCC13826_0963 
600 This study 
This study 
3 
CjaA 
 
F-TAGAGTTTGCCGCCTTCGAC 
R-ATGTGGCTAAGCAAGGTTGG 
CCC13826_0664 
& 
CCC13826_0663 
1200 This study 3 
CjaAT F-GGCGTTATCATGCGCTAGAG 
R-GCTGACAAGGTCGATATCAC 
CCC13826_0664 299 This study 3 & 4 
DnaJ 
 
F- TCTCGTCGGTGCTTGACTTG 
R- AAACGCTGGTGACAAAGAGG 
CCC13826_0965 900 This study 3 
DnaJT 
 
F-CGTAAAGATCGCCTTGAACG 
R-GCCTTGCCCAACATGTAACG 
CCC13826_0965 304 This study 3 & 4 
ZoT F-TGCAAACCCTTTGTGATGAA 
R-CATGAGCCAGCTCAATCAAC 
CCC13826_2276 355 Kalischuk et al. 
(2011) 
3, 4 & 5 
518Rª 
341F-GC 
907R 
R-ATTACCGCGGCTGCTGG 
F-CCTACGGGAGGCAGCAG 
R-CCGTCAATTCMTTTGAGTTT 
 
CCC13826_2336 
170 
 
562 
Muyzer et al. 
(1993) Muyzer 
et al. (1998) 
3 
C412-F F-GGATGACACTTTTCGGAGC 16S rDNA 816 Linton et al. 5 
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C1288-R R- CATTGTAGCACGTGTGTC 16S rDNA (1996) 
HipO-F 
HipO-R 
F-GACTTCGTGCAGATATGGATGCTT 
R-GCTATAACTATCCGAAGAAGCCATC 
A 
Hippuricase of 
C. jejuni 
500 Persson et al. 
(2005) 
5 
CC18F 
CC519R 
F-GGTATGATTTCTACAAAGCGAG 
R-ATAAAAGACTATCGTCGCGTG 
Aspartokinase of 
C. coli 
416 Linton et al. 
(1997) 
5 
Concisus-F 
Concisus-R 
F-CTTGTGAAATCCTATGGCTTA 
R-CTCATTAGAGTGCTCAGCC 
16S rDNA 
16S rDNA 
560 Man et al. 
(2010b) 
5 
ZoT 
ZotA2-R 
F-TGCAAACCCTTTGTGATGAA 
R-TCGGTCCTCCACGATCTG 
CCC13826_2276 1055 Mahendran et 
al. (2013) 
5 
ZotB-F 
ZotB-R 
F-TTGAGCTGGCTCATGCTTAG 
R-GTCTAAGCGTCAGACAAATAGAG 
CCC13826_2276 
CCC13826_2276 
300 This study 
 
5 
ª: Muyzer primer set 1 (341F-GC and 518R and). Muyzer primer set 2 (341F-GC and 907R). 
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2.8 Preparation of DNA samples for sequencing 
DNA purification from agarose gels and PCR reactions for sequencing DNA was by Isolate II 
PCR and Gel kit (Bioline, Australia) as recommended by the manufacturer. The sequencing 
was performed by Australian Genome Research Facility (AGRF). The DNA amount was 
adjusted according to AGRF instructions based on the DNA length. The DNA was made up 
to a volume of 11 µl in Nuclease-Free Water (Qiagen, Australia) and to this was added 1 µl 
of either forward or reverse primer. The mixture of the DNA and primer (12 µl) was sent to 
AGRF by post (it took approximately 16-22 h to be received by AGRF). 
 
2.9 Gel electrophoresis techniques 
2.9.1 Loading buffer (11x) 
The loading buffer was made by dissolving Tris-HCl (50 mM) in sterilised dH2O at pH 8.0. 
Then this solution was added EDTA (10 mM), ficol-400 (10% v/v), SDS (1% w/v), Orange G 
dye (0.5% w/v) and glycerol (50% v/v). A volume of 1.0 ml was aliquoted into 1.5 ml tubes 
and stored at room temperature. 
2.9.2 λ DNA (PstI) marker 
The λ DNA marker was a mixture of 900 µl sterile dH2O, 90 µl buffer H (10X), 108 µl λ 
DNA (50 µg) and 18 µl PstI (100 U/µl). The mixture was then incubated overnight at 37°C. 
The mixture was added to 90 µl of loading dye prior to use. The whole mixture was aliquoted 
into 200 µl volumes in 1.5 mm tubes and stored in -20°C. 
 
2.9.3 TAE Buffer (50x) 
The TAE buffer was prepared by dissolving a mixture of glacial acetic acid (5.17% w/v), 
EDTA (1.86% w/v) and Tris-base (24.2% w/v) in dH2O and then diluted to 1x before use. 
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2.9.4 Preparation of agarose gel and DNA electrophoresis 
Agarose powder (1.5% w/v) was dissolved into 1x TAE buffer and boiled until completely 
dissolved. Two gel sizes were used: mini-gels (50 ml) of 1x TAE and midi-gels (100 ml). The 
boiled agarose was allowed to cool on a shaker to reach approximately 55°C. It was then 
decanted into a casting tray and allowed to solidify for 30 min when it was ready for use. 
A volume of 11x loading dye was added to 10 volumes of each DNA sample and mixed well. 
The mixture of DNA sample with loading dye (12 µl) was loaded into the prepared gel well. 
Electrophoresis was then performed at voltages of 100-120 V using a power supply unit for 
the required time period. The DNA gel was stained in ethidium bromide solution at a 
concentration of 1 mg/ml for 15 min. The DNA gel was destained by washing in a stream of 
tap water. The gel was visualised by a UV transilluminator to detect DNA bands, and 
photographed by the Gel-Doc System. 
 
2.10 Denaturing gradient gel electrophoresis (DGGE) technique 
2.10.1 Acrylamide denaturant (100%) 
Every time a gel was run, a fresh mixture was prepared consisting of 40 ml acrylamide/bis-
acrylamide (40%) 37.5:1, 84 g urea, 80 ml formamide (100%), 2 ml TAE (50x) made up to 
200 ml in dH2O. The catalysts, TEMED (100 µl) and ammonium persulfate (APS) (2 ml of a 
10% solution) were then added to the mixture to polymerise acrylamide cross-linkage and 
form a solid gel. 
 
2.10.2 TAE stock (50x) 
TAE stock was prepared by mixing 242 g tris-base, 57.1 ml glacial acetic acid, 100 ml EDTA 
(0.5 M) and made up to 1 L with dH2O. 
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2.10.3 DGGE solutions 
1- Acrylamide/bis-acrylamide (6%) 
Chemicals Denaturant (0%) Denaturant 
(70%)  
Acrylamide/bis-acrylamide 
40%, 37.5:1 
15 ml 15 ml 
Formamide - 28 ml 
Urea - 29.4 g 
TAE (50x) 2 ml 2 ml 
dH2O Up to 100 ml Up to 100 ml 
 
 
 
2- Acrylamide/ bis-acrylamide (12%) 
Chemicals Denaturant (0%) Denaturant (70%)  
Acrylamide/bis-acrylamide 
40%, 37.5:1  
30 ml 30 ml 
Formamide - 28 ml 
Urea - 29.4 g 
TAE (50x) 2 ml 2 mL 
dH2O up to 100 ml Up to 100 ml 
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2.10.4 Preparation of staining solution 
    Solutions Chemicals quantity 
Fixing Solution I 
 
50 ml ethanol (100%) was mixed with 2.5 ml glacial acetic 
acid and 447.5 ml dH2O. 
Silver nitrate (prepared 
fresh) 
0.2 g silver nitrate was dissolved in 200 ml dH2O. 
Developing solution 
(prepared fresh) 
0.02 g sodium borohydride and 3 g sodium hydroxide were 
dissolved in 200 ml dH2O containing 0.8 ml formaldehyde.  
Fixing Solution II 3.75 g sodium carbonate was dissolved in 500 ml dH2O. 
Preservative solution A mixture of 125 ml ethanol (100%), 50 ml glycerol and 325 
ml dH2O. 
 
2.10.5 DGGE PCR conditions and solutions 
The DGGE PCR was performed in a 50 µl PCR reaction and PCR thermal cycling 
environments were as previously described (Muyzer et al. 1993; Muyzer et al. 1998). For 
Muyzer primer set 1 (341F-GC & 518R), the reaction started with five min at 94 ºC then four 
cycles of 30 seconds at 95°C, 30 seconds at 55°C and 1 min at 72°C, followed by 25 cycles 
of 30 seconds at 92°C, 30 seconds at 55°C and 1 min at 72°C. Finally the reaction was 
terminated with 10 min at 72°C. For Muyzer primer set 2 (341F-GC & 907R), the PCR 
conditions were 94°C for 5 min, followed by 20 cycles of 94°C for 1 min, 65°C to 55°C for 1 
min (touchdown -0.5°C/cycle), and 72°C for 3 min, followed by 15 cycles of 94°C for 1 min, 
55°C for 1 min and 72°C for 3 min, followed by final extension of 7 min at 72°C. The PCR 
results were analysed by DGGE. 
 
61 
 
2.10.6 DGGE 
DGGE analysis was performed by loading 15 µl of PCR product into 6% and 12% (w/v) 
polyacrylamide gels that were prepared as a denaturing gradient from 45%-65% (each 100% 
denaturant was comprised of 40% formamide and 7 M urea). Electrophoresis was performed 
in 1x TAE buffer at 60 V for 18 h at 60°C. The gel was then stained with silver nitrate and 
fixed for 2 h in 200 ml solution I. After that, the gel was incubated in a 200 ml the silver 
nitrate solution for 20 min. The DGGE gel was then developed in 200 ml of a solution 
containing 3 g sodium hydroxide, 0.8 ml formaldehyde and 0.02 g sodium borohydride for 30 
min and then incubated in another fixing solution II for 10 min. The staining was finalised by 
soaking the gel in 200 ml the preservative solution for 10 min. The DGGE gel was visualised 
with EPSON Expression scanner 1600 V.2.65 E software 2.9. 
 
2.11 Tissue culture techniques 
All tissue culture work was performed in a class II biological safety cabinet to reduce 
contamination risks. Media and solutions were stored in reusable containers. Glassware was 
cleaned using Pyroneg detergent, washed at least twice with dH2O and finally immersed in 
dH2O overnight. The containers were then autoclaved and used to store tissue culture 
solutions. The sterile containers were re-autoclaved with unsterilised solutions before use in 
tissue culture. 
 
2.11.1 Dulbecco's Modified Eagle Medium (DMEM) 
The modified Dulbecco's Eagle Medium (DMEM) was made by adding 10 ml of HEPES (N-
2-hydroxyethylpiperazine-N-2-ethane sulfonic acid) buffer to a bottle containing 500 ml 
DMEM. The DMEM with HEPES was aliquoted into 50 ml conical tubes (45 ml of 
DMEM/tube) and stored at 4°C. Before use, the medium was supplemented with filtered 
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heat-inactivated FBS (10% v/v) in the conical tube (DMEM/FBS). This medium was used for 
the growth of the INT407 cell line. 
 
2.11.2 Triton X-100 (detergent) 0.3% 
A working solution of triton X-100 (0.3% v/v) was made by dilution in sterile PBS. The 
solution was sterilised by filtration using a small size filter (0.22 µm) and stored at 4°C. 
 
2.11.3 Tissue culture growth environments 
A frozen stock of INT407 cells in liquid nitrogen was resuscitated by thawing and inoculating 
into a flask containing DMEM/FBS. INT407 cells were incubated in a CO2 incubator at 37°C. 
INT407 cells were allowed to grow to become confluent (80-95%). The growth was then split 
into a new flask for use in the experiment or collected for a new stock. INT407 cells were 
passaged no more than 10 times before they were discarded prior to a new stock being 
cultured. 
 
2.11.4 Seeding and maintaining the intestinal cell line (INT407) 
For seeding INT407 cells in new flasks, the old medium was discarded and the cells were 
washed with PBS twice. Then the cells were dissociated by adding trypsin-EDTA (1 ml for 
25 2C flasks or 3 ml for 75 2C flasks) and incubated at 37°C for 10 min. The dissociated cells 
were transferred to a centrifuge tube. The cells were washed twice in DMEM without FBS to 
remove the trypsin-EDTA solution. After each wash, the cells were resuspended in 5 ml 
DMEM and centrifuged at 1000 x g for 3 min. The supernatant was discarded at each of 
washing. After the last washing, the pellet of cells was resuspended in the appropriate amount 
of DMEM/FBS. The cells were counted and used for either seeding or making stocks. 
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The stocks of INT407 cells were made in cryovials from the cleaned resuspended cells in 
DMEM/FBS with 10% dimethyl sulfoxide (DMSO), as a cryoprotectant. The cryovials were 
first stored at -80°C for 48 h and then transported and stored in liquid nitrogen. 
Cell counts were determined by Countess® Automated Cell Counter (Invitrogen, Australia) 
following the manufacturer’s instructions. The following is a brief outline of the procedure 
using resuspended cells. The first step was to mix 10 µl of resuspended cells with an equal 
amount of 0.4% trypan blue stain. Then, from the mixture, 10 µl was loaded into a counting 
chamber. The count obtained for the total number of viable cells was used to obtain the 
desired experimental cell concentration. Dilutions were prepared based on calculations made 
by the cell counter. 
 
2.11.5 Invasion and adhesion assays 
The capability of C. concisus isolates to adhere to and invade INT407 cells in vitro was 
investigated according to the method previously described by Elsinghorst (1994) and then 
modified by Chang (2002), RMIT University with some modifications. In brief, the 
preparation of INT407 cells was as follows: INT407 cells were seeded in large flasks (75 
cm2) and allowed to reach a semi-confluent monolayer in 2-3 days. The cells were harvested 
from the flask, counted and the cell viability was determined by staining with trypan blue. 
The viability of cells used in these assays was >95%. 
The INT407 cells were seeded in a 24 well microtiter plate at 105 cells per well. The plates 
were incubated for 12-16 h to allow the cells to attach. On the day of the assays, the old 
medium was discarded and the cells were washed three times with PBS. After washing, 400 
ml of fresh DMEM/FBS were added to each well before adding the bacterial cells. 
Bacterial cells were prepared by selecting 5-7 colonies from 48 h old bacterial growth on 
HBA and suspending in Columbia broth. The OD600 value for the bacterial suspension was 
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adjusted to 0.1, which is equivalent to 108 CFU. Then 100 µl from this bacterial suspension 
were inoculated into each well containing 105 INT407 cells to obtain multiplicity of infection 
(MOI) at ~100. The plates were centrifuged at 160 x g for 5 min to enhance the bacterial 
contacts with INT407 cells. The inoculated plates were incubated for 6 h at 37°C under C. 
concisus growth conditions (section 2.4.2) to allow the bacteria to adhere to and invade 
INT407 cells. 
The adhesion assay was performed by washing the plates three times with PBS after 6 h 
incubation to remove the non-adhering/non-invading bacterial cells. To release the adherent 
and intracellular bacterial cells, INT407 cells were lysed by adding 200 µl of 0.3% triton-X-
100 in each well. Plates were incubated in 5% CO2 at 37°C for 15 min. The cell lysate was 
diluted by adding 800 µl PBS. To retrieve the viable bacterial cell number, the CFU was 
determined and the percentage of adhered cells was calculated by the following equation: 
Adhesion	% =
	no. of	bacterial	cells	retrieved/ml
	no. of	bacterial	cells	initially	used/ml	
× 	100 
Invasion was determined by the gentamicin protection assay as follows: plates were washed 
three times with PBS to remove the non-adhering/non-invading bacterial cells. Then 1 ml of 
DMEM/FBS containing 400 µg/ml gentamicin was added to each well and the plates were 
incubated in 5% CO2 at 37°C for 90 min to kill bacterial cells that had not invaded; since 
gentamicin is bactericidal. After gentamicin treatment, the plates were washed three times 
with PBS to remove gentamicin. The INT407 cells were lysed by 0.3% triton-X-100 to 
release the invaded bacterial cells. To ensure the bacterial cells were susceptible to the 
gentamicin concentration used, DMEM/FBS containing 400 µg/ml gentamicin was added to 
wells containing bacterial cells in DMEM/FBS without INT407 cells. Finally, to retrieve the 
bacterial viable cell number, the CFU was determined and the percentage of invaded cells 
was calculated by the following equation: 
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Invasion	% =
no. of	bacterial	cells	retrieved	from	gentamicin − treated	cells/ml
no. of	bacterial	cells	initially	used/ml	
× 	100 
To evaluate the invasiveness of C. concisus isolates, the invasive index was calculated by 
dividing the number of internalised C. concisus cells by the number of adherent C. concisus 
cells multiplied by 100 (Larson et al. 2008).  
invasive	index	value =
	No. of	invaded	bacteria	(%)	
No. of	adherent	bacteria	(%)
× 100 
 
2.12 Gene expression studies 
2.12.1 RNA techniques 
All RNA experiments were performed in a class II biological safety cabinet to avoid any 
environmental contaminants such as RNases. Reusable items like glass bottles were treated 
with diethylpyrocarbonate (DEPC) before autoclaving to eliminate any chance of 
contamination with nucleases. All solutions used for RNA methods, were prepared in RNase-
free water. The prepared solutions were stored in DEPC-washed containers or in plastic 
sterilised RNase-free containers. All disposable plastic ware used during RNA techniques 
was sterile and RNase-free. Pipettes were sterilised before use and tips were sterilised RNase-
free filter. Glassware and plastic ware was sterilised prior to each experiment using UV for 
20 min. 
 
2.12.2 TE buffer 
TE buffer was prepared by dissolving EDTA (1 mM) and Tris-base (10 mM) in RNase-free 
water. The pH was then adjusted to 8 and the buffer was sterilised using a 0.22 µm filter. 
 
66 
 
2.12.3 RNA extraction 
The RNA extraction was performed by the ‘Isolate RNA Mini’ kit (Bioline, Australia) 
following the instructions provided by the manufacturer. 
Extracted RNA of each isolate was treated with DNase to remove any residual genomic DNA 
using the ‘Turbo DNA-freeTM’ kit (Ambion) following the instructions of the manufacturer 
with the exception of the incubation at 37°C was for 60 min instead of 30 min to degrade 
residual genomic DNA. 
 
2.12.4 cDNA synthesis 
cDNA synthesis was performed with the same amount of RNA (1 µg) for each strain. The 
cDNA was synthesised using the ‘Tetro cDNA Synthesis’ kit (Bioline, Australia) as 
recommended by the manufacturer with the exception of the incubation at 45°C for 55 min 
instead of 30 °C min. 
 
2.12.5 RT-PCR conditions 
Semi-quantitative SYBR green real time PCR was performed using the ‘SensiFASTTM SYBR 
No-ROX’ kit (Bioline, Australia) in the Qiagen Rotagene (Qiagen). A total mixture of 12 µl 
reaction contained of 6 µl of 2X SensiFAST SYBR No-ROX Mix, 5 pmol of each primer set 
(GeneWorks) and 5 µl template (1 ng of cDNA) with the exception of primer set I, 2.5 pmol 
was used instead of 5. 
Thermal cycling conditions were in accordance with the manufacturer’s instructions with 
some modifications as follows: 5 min at 95ºC for hot start Taq DNA polymerase activation, 
forty cycles of 15 sec at 95°C, 15 sec at 55°C and 60 sec at 72°C. 
The melting curves were generated by ramping the temperature from 45-95°C in two steps as 
follows: 
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- Step1 (pre-melting), the temperature ramp rate was one degree every 90 sec. 
- Step 2 (melting point) the temperature ramp rate was one degree every 5 sec. 
Primer efficiency was determined, and relative gene expression, normalised to the 
housekeeping gene, was determined using the method described by Pfaffl (2001). 
 
2.13 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
2.13.1 Lowry assay reagents 
The preparation of Lowry assay reagents was as described by Markwell et al. (1978) 
summarised by the following steps: 
I. Reagent A: sodium carbonate
 
(2% w/v), sodium hydroxide (0.4% w/v), sodium 
potassium tartrate (0.16% w/v) and SDS (1% w/v) were dissolved in dH2O. 
II. Reagent B: Copper sulphate (4% w/v) was dissolved in dH2O. 
III. Reagent C: A mixture of reagent A (50 ml) and reagent B 0.5 ml. This solution was 
freshly prepared before use. 
IV. Reagent D: Folin-ciocalteu reagent was diluted (1:1) in dH2O. 
 
2.13.2 SDS sample buffer (5x) solution (for loading the protein into gels) 
The SDS sample buffer (5x) solution was a mixture of glycerol (25% v/v), bromophenol blue 
(0.1% w/v), SDS (2% w/v) and β-mercaptoethanol (14.4 mM v/v) in a solution of Tris-HCl 
(60 mM) at pH 6.8. The storage of this solution was at -20°C. 
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2.13.3 SDS-PAGE running buffer (10x) 
The SDS-PAGE running buffer (10x) was prepared by dissolving tris-base (3% w/v), glycine 
(14.4% w/v) and sodium dodecyl sulfate (SDS) (1% w/v) in dH2O. The pH of the mixture 
was adjusted to 8.3 and it was diluted to 1x before use. 
 
2.13.4 Coomassie brilliant blue stain preparation 
The Coomassie brilliant blue stain was made by mixing Coomassie brilliant blue (0.05% w/v) 
in methanol (40% v/v), glacial acetic acid (10% v/v) and dH2O (50% v/v). 
 
2.13.5 Cell lysate buffer 
The cell lysate buffer was prepared by dissolving 2 g of SDS (2% w/v), 15 ml of glycerol 
(15% v/v) and 35 mg of 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (Pefabloc® 
SC) (2mM) in 85 ml of Tris-HCL (0.1M) at pH 6.8. 
 
2.13.6 De-staining solution 
The de-staining solution was made by papering a mixture of glacial acetic acid (10% v/v) and 
methanol (40% v/v) in dH2O. 
 
2.13.7 Whole cell lysate preparation 
C. concisus isolates were grown on HBA plates for 48 h. The entire bacterial growth on a 
HBA plate was harvested and suspended in 1 ml of 10 mM Tris-HCL. The suspension was 
centrifuged at 14,000 x g for 2 min. The supernatant was discarded and the pellet was 
resuspended in 1 ml of 10 mM Tris-HCL. The suspension was then precipitated by 
centrifugation at 14,000 x g for 2 min. To lyse the bacterial cells, the supernatant was 
discarded and 500 µl of cell lysate buffer was added to the pellet. The mixture (cell pellet and 
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lysate buffer) was incubated at 100°C for 3-5 min (without boiling the lysate). The mixture 
was then centrifuged at 14,000 x g for 5 min and the supernatant (containing the whole cell 
lysate) was transferred to a clean tube and stored at -20°C. 
 
2.13.8 Protein estimation for whole cell lysate 
The protein concentration of whole cell lysates was determined by the modified Lowry 
method as described by Markwell et al. (1978) using a spectrophotometer. A standard curve 
was constructed by performing several dilutions from standard albumin as follows: 0, 10, 20, 
30, 40, 50, 70 and 100 µl of protein standard (1 mg/ml) and completed with sterile dH2O to 
make a final volume of 200 µl. For bacterial lysate, 10 µl was added to 190 µl of dH2O to 
make the same final volume of 200 µl. The blank was 10 µl of cell lysate buffer (without 
bacterial cells) added to 190 µl of dH2O. 
Reagent C (600 µl) was added to all tubes and the mixtures were incubated at room 
temperature for 20 min. Reagent D (60 µl) was then added, mixed and the mixture incubated 
at room temperature for 30 min. From each tube, 200 µl was aliquoted (in triplicate) into a 96 
plate and the absorbance was measured by a spectrophotometer at 600 nm (OD600). From the 
absorbance values, the standard curve was plotted using Microsoft Excel and the protein 
concentration of the samples was calculated by the equation obtained from the standard 
curve. 
 
2.13.9 Preparation of the protein sample for gel electrophoresis 
Protein samples were prepared as described by Laemmli (1970). Bacterial whole cell lysate 
protein was adjusted to a concentration of 10 µg/µl by diluting the lysate in sterile dH2O. 
Then, 10 µl was mixed with 5 µl of 5x-SDS sample buffer solution. The mixture was 
denatured at 95°C for 5 min and allowed to cool to room temperature. The tubes were 
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centrifuged and then the mixture was loaded into individual wells of SDS-PAGE gel by a 1-
100 µl micro-syringe. Protein standard (Precision Plus, Bio-Rad) was used as a marker. 
 
2.13.10 SDS-PAGE gel composition 
An SDS-PAGE gel with an acrylamide concentration of 12.5 % w/v was used as a resolving 
gel. An SDS-PAGE gel with an acrylamide concentration of 4.5% w/v was used as the 
stacking gel. 
 
The preparation of the resolving gel (12.5%) was as following: 
Chemicals Concentration volume/ gel 
dH2O   4.22 ml 
Tris-HCl (pH 6.8)  1.5M (w/v) 2.5 ml 
SDS  10% (w/v) 0.1 ml 
Acrylamide (38.67%)/ 
Bis-Acrylamide(1.33%) 
40% (w/v) 3.135 ml 
APS (fresh) 
ammonium persulfate  
10% (w/v) 0.05 ml 
TEMED (N,N,N,N-
teramethylenediamine) 
 0.01 ml 
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The preparation of the stacking gel (4.5%) as following: 
 
 
 
 
 
 
 
 
 
 
SDS-PAGE electrophoresis was performed using a Mini-PROTEAN Tetra Cell 
electrophoresis system. Protein gel electrophoresis was achieved with two steps: step I was at 
60 V for 30 min and step II was at 180 V for 60 min. 
 
2.13.11 SDS-PAGE gel staining and de-staining 
The gel was transferred and immersed into a container with Coomassie brilliant blue solution 
on a shaker for 1 h. The gel was then immersed in de-staining solution overnight. The SDS-
PAGE gel was then photographed using a scanner. The gel was stored in 5% acetic acid at 
4oC. 
 
 
 
 
 
Chemicals Concentration volume/ gel 
dH2O   3.11 ml 
Tris-HCl (pH 6.8)  0.5 M (w/v) 1.25 ml 
SDS  10% (w/v) 0.05 ml 
Acrylamide (38.67%) + 
Bis-Acrylamide (1.33%) 
40% (w/v) 0.563 ml 
APS (fresh)  10% (w/v) 0.025 ml 
TEMED   0.005 ml 
72 
 
Chapter 3 : Genetic diversity of C. concisus and detection of 
putative virulence genes 
3.1 Introduction 
Although C. concisus has been detected in several infected sites in humans, it has not been 
recognised as a pathogen. It is not clear whether all C. concisus strains or specific groups are 
associated with human infections. When the work described in this chapter commenced, there 
was only one sequenced C. concisus strain available (13826) (Fouts et al. 2007). The genome 
of C. concisus 13826 contains several genes similar to virulence genes found in the C. jejuni 
genome (Kalischuk et al. 2011; Pawelec et al. 2000; van Vliet et al. 2001). The sequence of 
this strain was used to design most of the primers sets to amplify putative virulence genes. 
Later, several other sequenced C. concisus strains became available in the NCBI database 
(Deshpande et al. 2011; Deshpande et al. 2013) and this sequence information was used in a 
bioinformatics study in order to understand the possible genetic variations between C. 
concisus isolates. 
The Muyzer primer sets that amplify 16S rDNA were originally designed to detect and 
analyse the genetic diversity of mixed bacterial populations in environmental samples such as 
soil and water using the PCR-DGGE technique (Muyzer et al. 1993; Muyzer et al. 1998). 
This technique was also used to detect and group extremely fastidious bacteria including C. 
concisus using either pure or mixed DNA (section 1.9.3) (Cornelius et al. 2012; Petersen et 
al. 2007). 
An earlier study in our laboratory showed that the sequence of a DNA fragment from a C. 
concisus isolate obtained from a patient with diarrhoea (RCH3) partially contained the 
sequences of cjaC and followed by shikimate 5-dehydrogenase gene according to alignment 
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with strain 13826, but the two genes are separated in the genome of strain 13826. Primers for 
amplification this fragment were designed based on the sequence of C. concisus RCH3 
(Istivan, unpublished data). The presence of cjaC and other putative virulence genes such as 
cjaA, dnaJ and zot has not been fully investigated in C. concisus isolates (section 1.10.2). 
The aims of the experiments conducted for this chapter were to: 
(i) Confirm the identity of C. concisus oral and faecal isolates used in this study. 
(ii) Apply PCR-DGGE to a collection of oral and faecal C. concisus isolates using the 
two commonly used Muyzer primer sets, in order to detect and type the isolates. 
(iii) Investigate sequence differences in cjaC and its adjacent genes using primers 
based on DNA fragments obtained from C. concisus RCH3 and 13826 by PCR. 
(iv) Search for the putative virulence genes (cjaA, dnaJ and zot) in the genomes of C. 
concisus isolates from the same collection of oral and faecal isolates by PCR 
using primers based on strain 13826. 
(v) Perform bioinformatics analysis of putative virulence genes (cjaC, cjaA, dnaJ and 
zot) using the recently published C. concisus sequences to identify the presence 
and sequence difference of these genes. 
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3.2 Materials and Methods 
3.2.1 Bacterial isolates and reference strains 
The bacterial isolates and reference strains used in this chapter are described in section 2.4.1. 
PCR-DGGE typing was performed on 14 selected C. concisus isolates (ATCC 51561, ATCC 
51562, RCH6, RCH3, RCH11, RCH15, RCH20, RCH26, O8, O9, O10, O11, O13 and O17) 
and the following bacterial reference strains were used as controls: C. mucosalis ATCC 
43264, C. jejuni 81116, C. coli NCTC 11366 and E. coli ATCC 25922. All C. concisus 
isolates listed in Table 2.1 (section 2.4.1) were screened for the presence of cjaC, cjaA, dnaJ 
and zot. 
 
3.2.2 Confirmation the identity of C. concisus isolates used in the study 
Molecular identification was performed by two PCR amplification methods. The first PCR 
employed the Pcisus (5&6) primer set targeting the GyrB gene as was described by Matsheka 
et al. (2001), while the second PCR was performed by using primer set (MUC1 and 
CON1/CON2) targeting the 23S rDNA gene that was described by Bastyns et al. (1995). 
These primer sets amplifying the 23S rDNA gene were used to confirm the bacterial identity 
and assign C. concisus isolates into the genomospecies A and B as described by Istivan et al. 
(2004). The DNA extraction and PCR amplification protocols are described in sections 2.5 
and 2.7, and the primer set sequences are listed in Table 2.2. 
 
3.2.3 Typing C. concisus isolates by DGGE 
DNA was extracted from the tested C. concisus isolates and Campylobacter reference strains 
growing on HBA. Then, two Muyzer primer sets were used for the PCR-DGGE (Muyzer 1, 
341F-GC & 518R and Muyzer 2, 341F-GC & 907R) for amplifying segments of the 16S 
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rDNA gene for typing C. concisus isolates (Table 2.2 and Figure 3.1). Lambda DNA (PstI) 
was used was used as a reference maker (section 2.9.2). The PCR products were analysed by 
DGGE as described by Muyzer et al. (1998). The obtained PCR products from all C. concisus 
isolates were also mixed together and analysed by DGGE. The PCR amplification and DGGE 
protocols are described in section 2.10. The results obtained from DGGE gels were analysed 
by Phoretix ID software (TotalLab, Newcastle upon Tyne, UK) to generate similarity 
dendrograms between the tested isolates and to group the lanes upon banding patterns using 
the Unweighted Pair Group method with Mathematical Averages (UPGMA) clustering. 
Sorenson’s coefficient was used for pairwise calculation between the DNA bands. 
 
3.2.4 Detection of cjaC and investigation of the RCH3 fragment sequence location 
Six primer sets were designed to detect cjaC and to investigate the RCH3 fragment location 
in the genome of C. concisus 13826, as follows: primer sets I and II were designed based on 
strain 13826 DNA sequence and used to amplify parts of the cjaC gene (CCC13826_0963) 
(800 and 300 bp), primer sets III and IV were designed based on RCH3 sequence and used to 
amplify the RCH3 fragment (330 and 270 bp) from all C. concisus isolates, and primer sets V 
and VI were designed to investigate the location of cjaC (CCC13826_0963) and it is adjacent 
gene (CCC13826_0963) in C. concisus 13826. All these primer sets (six) were used to 
amplify the DNA regions from all C. concisus isolates listed in Table 2.1. The sequences of 
primer sets are described in Table 2.2 and their targeted regions are shown in Figure 3.2. The 
PCR conditions and protocols are described in section 2.7. 
To investigate location of cjaC and its adjacent genes in several C. concisus isolates to be 
compared with C. concisus 13826, the obtained PCR products from amplifying the genomic 
DNA of selected C. concisus isolates (ATCC 51562, RCH3, RCH6, RCH26 and O11) were 
sequenced using primer sets I, II, III and VI. 
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3.2.5 Detection and identification of cjaA, dnaJ and zot 
Based on the sequence of C. concisus 13826, CjaA primer set was designed to amplify part 
(1200 bp) of cjaA (CCC13826_0664) and its adjacent gene (glutamine transport ATP-binding 
protein GlnQ, CCC13826_0663) to investigate the location of cjaA. CjaAT primer set was 
designed to detect the cjaA gene (CCC13826_0664) (299 bp). DnaJ and DnaJT primer sets 
were designed to amplify 900 and 304 bp of dnaJ (CCC13826_0965), and the ZoT primer set 
was used to amplify 335 bp of zot (CCC13826_2276). The sequence of primer sets and their 
corresponding genomic regions are listed in Table 2.2 and shown in Figure 3.1. The PCR 
conditions and protocols are described in section 2.7. 
 
3.2.6 Bioinformatics analysis following the recent publications on C. concisus 
sequences for cjaC, cjaA and dnaJ 
This analysis was performed to provide an explanation for the failure of PCR amplification 
with some primer sets used in this study to amplify the genes in all of the C. concisus isolates 
and to examine the level of genetic variation within genomospecies A and B of C. concisus 
isolates. Gene sequence analysis was performed on cjaC, cjaA and dnaJ of the fully 
sequenced C. concisus strains available in the NCBI data-base site as described in section 
1.9.4 and Table 1.3. For cjaC, DNA and amino acid sequences obtained from RCH6 were 
also aligned with sequence of all published C. concisus strains. 
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Figure  3.1: Genomic mapping of the designed primers sets (CjaA, CjaAT, DnaJ, 
DnaJT, ZoT, Muyzer 1 and Muyzer 2). The arrows represent the targeted genes based on 
the genome of C. concisus strain 13826. Intermittent boxes in start of arrows refer to that the 
genes (cjaA, dnaJ, zot and 16S rDNA) are apart in the genome of strain 13826. 
 
 
Figure  3.2: Genomic mapping of the primer sets designed and used to amplify the cjaC 
gene and its flanking region based on C. concisus reference strain 13826 genome. The 
arrows represent the targeted genes on the genome of C. concisus strain 13826. Intermittent 
boxes in the start of arrows refer to that the genes (shikimate 5-dehydrogenase and the 
hypothetical protein genes) are apart in the genome of strain 13826. The targeted DNA 
regions for primer sets III and IV were designed based on RCH3 DNA sequence. 
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3.2.7 Softwares used for data analysis 
The NCBI data-base site was used to obtain and align the DNA and amino acid sequences of 
the genes of interest in sections 3.2.4, 3.2.5 and 3.2.6. ExPASY was used to translate 
nucleotide sequences to amino acid sequences (section 3.2.6) (Artimo et al. 2012). Molecular 
evolutionary genetics analysis (MEGA) software was used for the gene sequence alignments 
and generation of phylogenetic trees by the neighbour-joining dendrogram (Felsenstein 
1989). For alignment and phylogenetic analysis of DNA and amino acids, default parameters 
were used as follows: for DNA, gap opening penalty of 15 and gap extension penalty of 6.66 
were used. For amino acids, opening penalty of 10, gap extension penalty of 0.2, gap 
separation distance of 4 and protein weight matrix of Gonnet were used. 
 
3.3 Results 
 
3.3.1. Confirmation of the identity of C. concisus isolates 
Although a PCR product was obtained from all C. concisus isolates DNA with either 
MUC1/CON1 (genomospecies A) or MUC1/CON2 (genomospecies B), the Pcisus (5 & 6) 
primer set failed to amplify a PCR product from the DNA of one C. concisus isolate 
(RCH20). 
 
3.3.2 Typing C. concisus by DGGE 
Using Muyzer primer set 1 (518R & 341F-GC), a PCR product was obtained from the DNA 
of all isolates and reference strains (Appendix I). The Phoretix ID software assigned all 
Campylobacter spp. isolates to four distinct groups that were defined as group I, II, III and IV 
(Figure 3.3 and Table 3.1). All C. concisus genomospecies B isolates fell into group II. Most 
of genomospecies A isolates were allocated to group I by DGGE, while three (RCH3, RCH26 
and O17) were allocated to group II by DGGE. The mixture (Mix) of the DNA products also 
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presented the isolates in two separate bands (two groups) (Figure 3.3). C. mucosalis (ATCC 
43264) represented a distinct group (III), while C. jejuni (81116) and C. coli (NCTC 11366) 
were both allocated to group VI. Moreover, E. coli (ATCC 25922) showed a unique band, 
which partly covered by smudge (see the black arrow) as can be seen in Figure 3.3 and Table 
3.1. 
Using of the second primer set (Muyzer primer set 2, 341F-GC & 907R), a PCR product was 
also obtained from all isolates (Appendix II). The Phoretix ID software used to analyse the 
DGGE gels defined four groups that were also designated I, II, III and IV (Figure 3.4); 
however distribution of isolates and reference strains between groups differed from the 
distribution generated by Muyzer primer set 1 (Table 3.1). The C. concisus isolates fell into 
two groups (I & II), with all those C. concisus isolates belonging to genomospecies B in 
group II and most genomospecies A isolates in group I. C. concisus strains ATCC 51562 and 
RCH20 (both from genomospecies A) fell into group II. The mixture (Mix) of the DNA 
products also presented the isolates in two separate bands (two groups) (Figure 3.4). C 
mucosalis ATCC 43264 fell into group I and C. jejuni 81116 and C. coli (NCTC 11366 into 
group III & IV respectively (Table 3.1 and Figure 3.4). 
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Figure  3.3: PCR-DGGE dendrogram using Muyzer primer set 1 (341F-GCA & 518R) 
targeting the 16S rDNA gene in C. concisus and other bacterial reference strains. 
Dendrogram analysis was generated by Phoretix ID software to analyse DGGE gel results. 
Mix: DNA mixtures from all C. concisus isolates used. 51561 and 51562 are C. concisus 
ATCC strains. RCH: clinical C. concisus isolates obtained from children with diarrhoea at the 
Royal Children’s Hospital. O: C. concisus oral isolates from healthy volunteers. CM: C. 
mucosalis (ATCC 43264). CJ: C. jejuni (81116). CC: C. coli (NCTC 11366). EC: E. coli 
(ATCC 25922). I-V are bacterial groups generated from DGGE gel analysis by the software. 
B: C. concisus isolates belonging to genomospecies B. Other C. concisus isolates not marked 
as B, belong to genomospecies A. The black arrow is to show the location of E. coli band as it 
partly covered by smudge. 
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Figure  3.4: PCR-DGGE dendrograms using Muyzer primer set 2 targeting 16S rDNA 
in C. concisus and other Campylobacter reference strains. Dendrogram analyses were 
generated by Phoretix ID software for analysing PCR-DGGE gel results. ATCC 51561 and 
ATCC 51562: C. concisus reference strains. RCH: Royal Children’s Hospital. O: oral 
isolates. CM: C. mucosalis (ATCC 43264), CJ: C. jejuni (81116), CC: C. coli (NCTC 11366) 
and E. coli (ATCC 25922), respectively. I-V are groups generated by the software. B: C. 
concisus isolates belonging to genomospecies B. Other C. concisus isolates are not marked as 
B
, belong to genomospecies A. 
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Table  3.1: C. concisus groups were generated by PCR-DGGE analysis using Muyzer 
primer sets I and II. 
 
No. Isolate Genomospecies Muyzer 1 
(170 bp) 
Muyzer 2 
(562 bp) 
1. 51562 A I II 
2. RCH3 A II I 
3. RCH15 A I I 
4. RCH20 A I II 
5. RCH26 A II I 
6. O9 A I I 
7. O10 A I I 
8. O17 A II I 
9. 51561 B II II 
10. RCH6 B II II 
11. RCH11 B II II 
12. O8 B II II 
13. O11 B II II 
14. O13 B II II 
15. CM NA III I 
16. CJ NA IV III 
17. CC NA IV IV 
18. EC NA V NA 
 
I, II, III and IV: generated groups by PCR-DGGE analysis using Muyzer primer sets 1 
and 2. A & B: genomospecies. In each case, groups I and II were defined by the software. 
CM: C. mucosalis ATCC 43264. CJ: C. jejuni 81116. CC: C. coli NCTC 11366. EC: E. 
coli ATCC 25922. O; oral isolates. RCH: the Royal Children’s Hospital isolates. NA: not 
applicable. 
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3.3.3 Detection of cjaC and investigation of the RCH3 fragment sequence location 
3.3.3.1 Detection of cjaC (based on strain 13826) 
Using primer set I, cjaC could only be amplified from genomospecies B isolates (Table 3.2 
and Appendix III); however, primer set II designed to amplify 300 bp from the centre of 
cjaC, amplified cjaC from both genomospecies A and B, with the exception of six isolates 
belonging to genomospecies A (RCH3, RCH4, RCH5, RCH7, O12 and O17) (Table 3.2 and 
Appendix IV). 
One reference strain (ATCC 51561) and one clinical isolate (RCH6), both from 
genomospecies B, were nominated as representatives for cjaC sequencing as their DNA 
could be amplified by both primer sets (I and II). The sequenced products obtained using 
primer set I are shown in Appendices V and VI. Alignment of 746 bp (nucleotide number 248 
to 995) segments of cjaC of C. concisus ATCC 51561 and RCH6 to strain 13826 using Clone 
Manager software showed that the three sequences were highly similar with identities of 96% 
and 95%, respectively. 
As primer set II was able to amplify cjaC from isolates belonging to genomospecies B and 
some isolates from genomospecies A, PCR product (295 bp) of C. concisus ATCC 51562 
(from genomospecies B) was sequenced to confirm the identity of this PCR product 
(Appendix VII). The aligned sequence was 90% identical to the corresponding sequence of 
C. concisus 13826. 
 
3.3.3.2 Investigating the RCH3 fragment sequence location 
To investigate why the sequence of DNA fragment (containing one part of cjaC and part 
from shikimate 5-dehydrogenase genes) obtained from RCH3 did not exist in the genome of 
C. concisus 13826, primer sets III and IV were designed (based on RCH3 sequence) to 
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amplify the flanking region between cjaC and shikimate 5-dehydrogenase genes (Figure 3.2). 
Using primer set III to amplify 330 bp, PCR products were only obtained from 
genomospecies A isolates with the exception of O12 and O17 (Table 3.2 and Appendix VIII). 
Also, using primer set IV to amplify 270 bp of the same region (Figure 3.2 and Appendix 
IX), the PCR products were only obtained from genomospecies A isolates with the exception 
of RCH19 (Table 3.2). 
The PCR sequenced products obtained with primer set III (330 bp) from the three 
genomospecies A isolates (ATCC 51562, RCH3 and RCH26) were 293 bp in length 
(Appendix X). Alignments of the three sequences showed 95% identity between these 
isolates with nucleotide sequence variation in at least 10 different locations (Appendix X). 
The variations in the sequences were very high when compared with C. concisus 13826 as the 
alignments with the corresponding C. concisus 13826 sequence revealed that the first 116 bp 
matched the first 119 bp of cjaC with an identity of ~88%; whereas the last 46 bp matched 
the end of the shikimate 5-dehydrogenase gene with an identity of ~85%. 
To investigate presence of the cjaC gene (CCC13826_0963) and its adjacent (encoding a 
hypothetical protein (CCC13826_0962)) (Figure 3.2), primer sets V (514 bp) and VI (600 bp) 
were designed based on genome of C. concisus 13826 sequence. Using primer set V, PCR 
products were only obtained from 15.2% of C. concisus isolates (ATCC51561, RCH6, 
RCH11, O8 and O11) within genomospecies B. Furthermore, the PCR product of C. concisus 
ATCC 51561 was smaller in size (~330 bp) with less intensity than the other products (Table 
3.2 and Appendix XI). Moreover, using primer set VI to cover an extended genomic region 
(600 bp) including a larger section of the gene encoding a hypothetical protein 
(CCC13826_0962) and a slightly larger section of CjaC (CCC13826_0963) than was 
obtained by primer set V, DNA of only two genomospecies B isolates (RCH6 and O11) were 
amplified. The amplified region from RCH6 was in the expected size, while the region 
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amplified from the DNA of O11 was larger in size (1700 bp) than predicted (Table 3.2 and 
Appendix XII). This larger PCR product was sequenced (Appendix XIII). Alignment with C. 
concisus 13826 DNA in the NCBI data-base showed homology (85%) to 244 bp of cjaC 
(CCC13826_0963) and the three adjacent genes encoding hypothetical proteins 
(CCC13826_0960, CCC13826_0961 and CCC13826_0962). The obtained sequence 
homologies over the three hypothetical protein genes are as follows; CCC13826_0962 was 
matched by 665 bp, CCC13826_0961 was matched by 143 bp and CCC13826_0960 was 
matched by 192 bp. 
It is uncertain why primer set VI amplified a 600 bp PCR product from RCH6 and a 1700 bp 
PCR product from O11, while no PCR product was amplified from other isolates. It is 
unlikely that the forward primer did bind at the two DNA regions of the genome based on the 
PCR results as either only one PCR product or no PCR product was obtained from the 
isolates. It could be that, in the case of some isolates, the reverse primer bound at location 
CCC13826_0960 in the genome instead of CCC13826_0962. It would be difficult to 
investigate the effects of such variations in this region of C. concisus phenotype as the genes 
involved in this area do not encode for proteins with known functions. 
 
3.3. 4 Detection and identification of cjaA, dnaJ and zot 
The CjaA primer set amplified the DNA region from the majority of isolates (94%) except 
RCH15 and RCH23 (both from genomospecies A) (Table 3.3 and Appendix XIV). Using 
primer set CjaAT (Figure 3.1), the DNA region was amplified from all isolates with the 
exception of five isolates belonging to genomospecies A and four of these isolates were from 
faeces (Table 3.3 and Appendix XV). 
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Table  3.2: PCR amplification of DNA from the genome of C. concisus isolates using 
different primer sets targeting the regions of cjaC (CCC13826_0963) gene and its 
flanking regions. 
Strain’s name
 
Set I Set II Set III
 
Set IV Set V Set VI 
ATCC 51561* + + - - +⃰ - 
RCH 6* + + - - + + 
RCH 11* + + - - + - 
O8* + + - - + - 
O11* + + - - + +° 
O13* + + - - - - 
O16* + + - - - - 
ATCC 51562 - + + + - - 
RCH 3 - - + + - - 
RCH 4 - - + + - - 
RCH 5 - - + + - - 
RCH 7 - - + + - - 
RCH 9 - + + + - - 
RCH 12 - + + + - - 
RCH 15 - + + + - - 
RCH 19 - + + - - - 
RCH 20 - + + + - - 
RCH 23 - + + + - - 
RCH 24 - + + + - - 
RCH 25 - + + + - - 
RCH 26 - + + + - - 
O1 - O7 - + + + - - 
O9 & O10 - + + + - - 
O12 - - - + - - 
O14 - + + + - - 
O17 - - - + - - 
C. mucosalis - - - - - - 
C. jejuni - - - - - - 
C. coli - - - - - - 
 
C. mucosalis: ATCC 43264, C. jejuni: 81116, C. coli; NCTC 11366, O: oral isolates. 
RCH: the Royal Children’s Hospital. NA: not applicable. ⃰: small PCR product. °: 
large PCR product. *: genomospecies B. 
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Primer set DnaJ (covering 900 bp) could only amplify dnaJ from genomospecies B isolates. 
C. jejuni and C. coli genomic DNA also showed small nonspecific light bands (400 bp) 
(Appendix XVI). However, the second primer set (DnaJT, covering 304 bp) successfully 
amplified the gene from all C. concisus isolates except two from genomospecies A (O9 and 
O14) as shown in Appendix XVII and Table 3.3. 
Using primer set ZoT, the zot gene could only be detected in 9% of isolates (RCH6, RCH11 
and RCH26). The gene was amplified from these three isolates regardless of genomospecies 
as two were from genomospecies B (RCH6 and RCH11) and one belonged to genomospecies 
A (RCH26). The zot gene could not be detected in any oral isolates (Figure 3.5 and Table 
3.3). 
In summary, these results show that C. concisus isolates are genetically highly diverse. 
Primers sets I, II, III, IV, V and VI amplified the target DNA regions in the proportions at 
21.2%, 81.8%, 72.7%, 72.7%, 15.2% and 6.1% respectively. Primers sets ZoT, CjaA, DnaJT 
and CjaAT amplified the target DNA regions in the proportions at 9%, 94%, 94% and 85% 
respectively. Primers sets I and DnaJ could be used for DNA detection of genomospecies B 
as they successfully detected all isolates from genomospecies B; whereas primers sets III and 
IV could be used for genomospecies A identification, since they detected 92.3% (24/26) and 
96.2% (25/26) of isolates from genomospecies A. 
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Figure  3.5: PCR amplification of zot in genomic DNA of C. concisus isolates using the 
ZoT primer set. PCR products were loaded onto a 1.5% (w/v) agarose gel for 
electrophoresis. It was then stained in ethidium bromide and visualised by a UV trans-
illuminator. PCR product size was 355 bp. MK: lambda DNA marker. 61 & 62: C. concisus 
(ATCC 51561 &51562). 3, 4, 6, 11, 15, 20 & 26: RCH isolates. CM: C. mucosalis (ATCC 
43264). CJ: C. jejuni (81116). CC: C. coli (NCTC 11366,). O: oral isolates. *: genomospecies 
B. 
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Table  3.3: PCR amplification results using DNA obtained from C. concisus isolates with 
different primer sets for the regions of cjaA, dnaJ and zot. 
Strain’s name
 
CjaA CjaAT DnaJ DnaJT ZOT 
ATCC 51561*  + + + + - 
RCH 6* + + + + + 
RCH 11* + + + + + 
O8* + + + + - 
O11* + + + + - 
O13* + + + + - 
O16* + + + + - 
ATCC 51562 + - - + - 
RCH 3 + + - + - 
RCH 4 + + - + - 
RCH 5 + + - + - 
RCH 7 + + - + - 
RCH 9 + + - + - 
RCH 12 + + - + - 
RCH 15 - - - + - 
RCH 19 + + - + - 
RCH 20 + - - + - 
RCH 23 - + - + - 
RCH 24 + + - + - 
RCH 25 + + - + - 
RCH 26 + - - + + 
O1 - O7 + + - + - 
O9  + + - - - 
O10 + + - + - 
O12 + + - + - 
O14 + + - - - 
O17 + - - + - 
C. mucosalis - - - - - 
C. jejuni - - - - - 
C. coli - - - - - 
 
RCH: the Royal Children’s Hospital isolates. ATCC: American Type Culture Collection 
strains. C. mucosalis: ATCC 43264. C. jejuni: 81116. C. coli: NCTC 11366. O: C. concisus 
oral isolates. +: DNA amplification product was obtained, -: No DNA amplification product 
was obtained. NA: not applicable. *: genomospecies B. 
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3.3.5 Bioinformatics analysis following the recent publications of C. concisus 
sequence 
Based on primer sets MUC1 and CON1 or CON2, all fully sequenced C. concisus strains 
available on the data base (section 1.9.4) belonged to genomospecies B, with the exception of 
strain ATCC 51562 which belonged to genomospecies A. Searching through the NCBI data-
base site showed that genes all examined in this study (cjaC, cjaA and dnaJ) with the 
exception of zot, were present in all the sequenced strains. 
CjaC 
Alignment of the cjaC sequence of the published C. concisus strains and RCH6 (746 bp) 
revealed an identity of ≥96% between all strains with the exception of C. concisus strain 
ATCC 51562, which showed only identity of 88%. Each strain showed a unique nucleotide 
sequence of this gene. All strains showed changes in nucleotide sequences at ≤42 bp 
positions; whereas, in C. concisus strain ATCC 51562 the changes were at 129 positions. 
The NCBI data-base site, used to investigate the impacts of nucleotide changes on amino 
acids sequence differences in CjaC, revealed an identity of 99% for all strains with the 
exception of strain ATCC 51562 which had identity of only 95%. Amino acids substitutions 
occurred at 1-5 positions in each strain with the exception of strain ATCC 51562, which 
showed changes at 15 amino acid positions. Excluding strain ATCC 51562, five amino acid 
substitutions were located at positions 31, 42, 49, 133, 161, 205 and 234. 
Neighbour-joining dendrogram analysis showed that cjaC gene and corresponding amino 
acids sequences could classify the strains into two main groups (I and II). All the strains were 
allocated into group II excluding ATCC 51562, which fitted into group I (Figures 3.6 and 
3.7). 
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DnaJ 
Analysis of dnaJ sequence and corresponding amino acid sequences revealed that all the 
strains had different nucleotide sequences. Identity scores of the gene ranged from 95-96% 
(mismatching in ≤61 bp) with the exception of ATCC strain 51562, which had a score of 
86% (mismatching in 160 bp). Amino acid sequences of all strains were 99% identical with 
the exception of ATCC 51562, which was 95% identical to the other strains. This strain had 
changes at 20 amino acid positions (similarity at 11 and mismatching at 9). In contrast, the 
other strains had changes at 3-5 amino acid positions and mismatching was at one location. 
The corresponding dendrograms also showed that both DNA and amino acid sequences could 
classify the strains into two main groups (I and II) (Figures 3.8 and 3.9). The majority of the 
strains were allocated into group II excluding strain ATCC 51562, which fitted in group I. 
CjaA 
Alignment of the DNA sequences of cjaA in the sequenced genomes of the C. concisus with 
the sequence of C. concisus 13826 showed that all strains have different nucleotide sequence. 
For all the strains, the identity was ≥95% (the changes were at ≤40 bp positions), with the 
exception of C. concisus ATCC 51562 that had an identity score of 88% (the changes 
included 104 bp). A neighbour-joining dendrogram analysis divided the strains into two main 
groups, with C. concisus strain ATCC 51562 in dendrogram group I and all other strains in 
group II (Figure 3.10). 
The alignments of the amino acid sequences translated from cjaA nucleotide sequences 
showed that the identities were at ≥98% in the strains excluding C. concisus ATCC 51562, 
which was 95% identical. Neighbour-joining dendrogram analysis also divided C. concisus 
ATCC 51562 into an individual group I while other strains fell into group II (Figure 3.11). 
 
92 
 
Summary of sequencing analysis 
Based on primers designed from the only sequence that was available in the NCBI data base 
at the commencement of this study (NCBI 13826), it was thought that the studied putative 
virulence genes might not be possessed by some C. concisus isolates. Although two primer 
sets designed based on strain 13826 sequence to amplify cjaC (I and II) and dnaJ (DnaJ and 
DnaJT), these genes could not be detected in all the studied C. concisus isolates. After the 
sequences of seven more strains became available, in particular ATCC 51562 
(genomospecies A), all genes except zot were found to be present in all sequenced stains. The 
data obtained from amplification of using the designed primer sets suggested that there was 
considerable sequence variation between the genomospecies A and B and this was confirmed 
by neighbour-joining phylogenetic analysis of the sequences that later became available. The 
central region of cjaC, cjaA and dnaJ appears to be more conserved than the 5ˋ and 3ˋ 
extremities of the genes as all the primer sets (II, DnaJT and CjaAT), designed to target the 
centre of these genes were able to amplify them from most of C. concisus tested isolates. 
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Figure  3.6: Neighbour-joining dendrogram for cjaC sequences obtained from nine C. 
concisus strains. I and II are the main groups of C. concisus strains that can be generated by 
neighbour-joining dendrogram. Group I includes the C. concisus genomospecies A strain 
51562, while group II includes genomospecies B strains. 
 
Figure  3.7: Neighbour-joining dendrogram for the amino acid sequences translated 
from the cjaC gene obtained from the data base of eight sequenced C. concisus strains 
and RCH6. I and II are the main groups of C. concisus strains that can be generated by 
neighbour-joining dendrogram. Group I includes the C. concisus genomospecies A strain 
(ATCC 51562), while group II includes genomospecies B strains. The whole genome 
sequence of strain 13826 is complete and available in the NCBI data-base site. Strains 51561, 
51562, UNSW1, UNSW2, UNSW3, UNSWCS and UNSWCD are Whole-genome shotgun 
contigs (WGS) available in the NCBI data-base site. Strain RCH6 gene was sequenced in this 
study. 
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Figure  3.9: Neighbour-joining dendrogram for the amino acid sequences translated 
from the dnaJ gene obtained from eight sequenced C. concisus strains available in the 
NCBI data-base site. I and II are the main groups of C. concisus strains that could be 
generated by neighbour-joining dendrogram. Group I includes the C. concisus genomospecies 
A strain 51562, while group II includes genomospecies B strains. The whole genome 
sequencing of strain 13826 is complete and available in the NCBI data-base site. Strains 
51561, 51562, UNSW1, UNSW2, UNSW3, UNSWCS and UNSWCD are WGS available in 
the NCBI data-base site. 
Figure 3.8: Neighbour-joining dendrograms for dnaJ sequences obtained from eight 
sequenced C. concisus strains available in the NCBI data-base site. I and II are the 
main groups of C. concisus strains that can be generated by neighbour-joining 
dendrogram. Group I includes the C. concisus genomospecies A strain 51562, while 
groups II includes genomospecies B strains. 
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Figure  3.10: Neighbour-joining dendrogram for cjaA sequences obtained from eight C. 
concisus strains available in the NCBI data-base site. I and II are the main groups of C. 
concisus strains that could be generated by neighbour-joining a dendrogram. Group I 
comprises the C. concisus genomospecies A strain 51562 while group II includes 
genomospecies B strains. 
 
Figure  3.11: Neighbour-joining dendrogram based on the amino acid sequences 
translated from cjaA of sequenced C. concisus strains available in the NCBI data-base 
site. The strains used were whole genome sequenced including strain 13826 which is a 
completed whole genome sequence while 51561, 51562, UNSW1, UNSW2, UNSW3, 
UNSWCS and UNSWCD (available in the NCBI data-base site as WGS). I and II are the 
main groups of C. concisus strains that can be generated by neighbour-joining dendrogram. 
Group I comprises the C. concisus genomospecies A strain 51562 while group II includes 
genomospecies B strains. 
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3.4 Discussion 
PCR-DGGE analysis and PCR amplification of several putative virulence genes were applied 
to a panel of C. concisus isolates obtained from two different sites (the oral cavity and 
intestine) to investigate their genetic diversity. The study also investigated the prevalence of 
these genes and their sequence variation in genomospecies A and B using the published 
genomes of C. concisus strains. The results of the current study consistently enhanced our 
awareness of the large genetic heterogeneity of C. concisus isolates obtained from faecal 
(diarrhoeic patients) and oral (healthy volunteers) specimens. 
In the confirmation of the identity of C. concisus isolates used in the study, all the isolates 
were amplified with either MUC1 and CON1 or MUC1 and CON2, which agreed with 
Istivan et al. (2004) findings. It is noteworthy that for one C. concisus isolate (RCH20) no 
product was amplified using Pcisus primer (5 & 6), which has not been reported before.  
DGGE typing of C. concisus 
The DNA of all C. concisus tested isolates was amplified using both Muyzer primer sets (1 
and 2) to amplify 16S rDNA; thus, these primer sets could be used to detect C. concisus in 
mixed DNA extracted from clinical samples. The data obtained in this study from DGGE 
analysis suggested that using Muyzer primer set 1 with C. concisus isolates is more accurate 
than using Muyzer primer set 2 as C. mucosalis could not be distinguished from C. concisus 
group II isolates generated by DGGE analysis using Muyzer primer set 2. It is noteworthy 
that three C. concisus isolates possessing zot were assigned to group II by DGGE using 
Muyzer primer set 1. 
Based on the results from the DGGE gel dendrogram analysis using both Muyzer primer sets, 
all genomospecies B isolates were assigned into one group, confirming the findings of Istivan 
et al. (2004). However, genomospecies A isolates fell into the two groups (I and II) on 
DGGE analysis, which is inconsistent with previous the genomospecies typing based on 23S 
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rDNA (Istivan et al. 2004). C. concisus genomospecies A isolates assigned to group I by 
DGGE using Muyzer primer set 1 were different from those allocated to group I using 
Muyzer primer set 2. The possible reason for the difference is that in the DGGE technique, 
regions of the 16S rDNA were used, while Istivan et al. (2004) used 23S rDNA. Thus, the 
results of genotyping of C. concisus isolates possibly depend on the DNA region used. 
A previous study found that PCR-DGGE was also able to assign three C. concisus reference 
strains into two DGGE groups (Petersen et al. 2007); however, another study found all C. 
concisus isolates were assigned in one group using the same technique (Cornelius et al. 
2012). Other genetic typing methods such as MLST and RAPD also assigned C. concisus 
isolates in two main groups (Ismail et al. 2012; Matsheka et al. 2006; Miller et al. 2012). 
However, it is unclear whether the groups generated by these techniques allocate C. concisus 
isolates in the same genomospecies A and B. 
Putative virulence genes in C. concisus isolates 
The putative virulence genes (cjaC, cjaA, dnaJ and zot) were amplified in 81.8%, 85%, 94% 
and 9%, respectively of C. concisus isolates using primer sets targeting the central region of 
these genes. However, based on the bioinformatics analysis performed in this study using the 
published genomes of C. concisus strains, it was found that all of these genes were present 
with an exception of zot, which was only detected in 37.5% (3/8) of the isolates. Therefore, 
cjaC, cjaA and dnaJ are probably possessed by the majority of C. concisus isolates, while zot 
are carried by the minority of the isolates. 
In this study, the detection rates of cjaC, cjaA and dnaJ were improved with primer sets that 
amplified the centre of these genes, while Kaakoush et al. (2011a) could not show any 
difference when they used two primer sets to detect zot from C. concisus isolates that were 
designed to amplify 979 bp and 790 bp of the gene (1125 bp). The possible reasons for these 
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discrepancies are that the sequences of these genes are heterogeneous within C. concisus 
isolates or that some of the genes are not possessed by all of the isolates. 
Conflicting results were shown also in detection of genes by PCR in C. jejuni and C. coli. 
CjaC and cjaA could not be amplified from 33.3% of C. jejuni clinical isolates (Pawelec et al. 
2000). It has also been recognised that specific primers that were designed for cjaC based on 
the nucleotide sequence of C. coli do not amplify the gene from other species like C. jejuni 
(Garvis et al. 1996; Pawelec et al. 1998; Pawelec et al. 2000). In C. jejuni, it was reported 
that there is genotypic variation without any phenotypic change, including the CjaC protein 
function and the specific antibody reaction (Pawelec et al. 2000). The change in the gene 
sequence in C. concisus also may not result in phenotypic changes such as morphological 
characteristics or bacterial growth on HBA. 
Moreover, the detection rate of dnaJ was 64% and 11% in C. jejuni and C. coli clinical 
isolates respectively (Hamidian et al. 2011), while in another study, the detection rate of the 
gene in C. jejuni isolates by PCR was 100% (Chansiripornchai et al. 2009). 
The detection rates of cjaC, cjaA and dnaJ in the faecal isolates were 76%, 76% and 100%, 
and in the oral isolates they were 88%, 94% and 88%, respectively. There was no significant 
difference in the detection rates of these genes between the faecal and oral isolates. However, 
the zot gene was only detected in faecal isolates. 
There are conflicting reports on the prevalence of zot among C. concisus isolates from faeces. 
Excluding the oral isolates in this study, zot detection in faecal isolates was 20% of faecal 
isolates, which was similar to a previous study finding (22%, 3/17) that also investigated the 
gene in faecal isolates (Kalischuk et al. 2011). However, Kaakoush et al. (2011b) could not 
detect zot in any of C. concisus (4 isolates obtained from intestinal biopsies and 3 faecal 
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isolates). These results could be explained if zot displays sequence variation or is possessed 
by minority of C. concisus isolates. 
Location of RCH3 fragment in C. concisus genome 
In this study, primer sets III and IV were designed based on DNA fragment obtained from 
RCH3 (determined to be a genomospecies A strain) to amplify parts of cjaC and the 
shikimate 5-dehydrogenase genes (Istivan, unpublished data). These primer sets detected the 
majority of genomospecies A isolates, but none of genomospecies B isolates. Based on strain 
13826 genome sequence (a genomospecies B strain) the gene adjacent to the cjaC gene 
(CCC13826_0963) encodes a hypothetical protein (CCC13826_0962), while the shikimate 5-
dehydrogenase gene (CCC13826_0229) is apart from cjaC. Therefore primer set V was 
designed to amplify parts of cjaC and the gene encoding the hypothetical protein gene 
(CCC13826_0962). Primer set V could detect the majority of genomospecies B isolates 
(71.4%), while none of genomospecies A isolates were amplified. It was initially thought that 
either cjaC or the shikimate 5-dehydrogenase gene might be located in different parts of the 
genome of genomospecies A isolates compared with B isolates. In addition, it can be 
suggested that genomospecies A strains might possess a second copy of cjaC since the total 
number of genes in the C. concisus UNSWCD genome was less than the total number of 
genes in the genome of C. concisus 13826 (Kaakoush et al. 2011a). However, the whole 
genome sequence of the C. concisus strains revealed that all strains possessed cjaC and the 
shikimate 5-dehydrogenase genes in a non-contiguous organisation, except for C. concisus 
ATCC 51562, which has the genes in an adjacent location in the genome (Deshpande et al. 
2013). The order of these genes varied, even within genomospecies B. In the genome of C. 
concisus ATCC 51561, UNSW2, UNSW3, UNSWCS and UNSWCD, the genes were in 
different contigs, but in C. concisus strain UNSW1 they were present on the same contig with 
another gene in between (Deshpande et al. 2013). The data suggested that the shikimate 5-
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dehydrogenase is apart from cjaC in the genome of genomospecies B isolates while in the 
majority of genomospecies A isolates, the genes are adjacent. On other hand, it seemed from 
the data obtained in this study that the location of cjaA is similar in most of C. concisus 
isolates; as the DNA region that included cjaA and its adjacent gene (glutamine transport 
ATP-binding protein GlnQ) was detected in the majority of the tested isolates (94%, 31/33) 
using primer set CjaA (based on strain 13826 sequence). 
Diversity of putative virulence genes in published genomes of C. concisus 
Neighbour-joining phylogenetic analysis for sequenced C. concisus available on the data base 
for the dnaJ, cjaA and cjaC DNA revealed none of these genes is identical between the 
strains and all of these genes are highly heterogeneous within genomospecies A and B. The 
phylogenetic analysis for the sequence of translated amino acids of these genes also showed 
diversity between genomospecies A and B strains, but this diversity is less within same 
genomospecies isolates. The diversity between the two genomospecies A and B is vast. Both 
phylogenetic analysis of DNA and the corresponding amino acids presented two main groups 
(I and II), which was consistent with phylogenetic analysis for 23S rDNA and the 
peptidoglycan biosynthesis pathway genes of these isolates (Deshpande et al. 2013; Istivan et 
al. 2004). However, the phylogenetic analysis for the 16S rDNA gene allocated these isolates 
into three groups (Deshpande et al. 2013), which contradicted DGGE results and 
genomospecies (A and B). These outcomes could be because the whole of the 16S rDNA 
gene (1550 bp) was used in the phylogenetic analysis, whereas DGGE analysis targeted ~920 
bp of the 16S rDNA gene. The phylogenetic analysis based on 23S rDNA agreed with the 
gene groups investigated in this study, whereas analysis based on the 16S rDNA gene 
generated unique groups. Now that whole genome sequencing is available, there will be a 
demand for additional whole genome sequencing of C. concisus genomospecies A isolates as 
only one strain has been sequenced (ATCC 51562). 
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Similar results have been reported for other members of Campylobacterales. The most 
genetically divergent member is Helicobacter pylori based on the whole genome sequencing 
(Bjrkholm et al. 2001; Marshall et al. 1998). It was reported that PCR may not amplify DNA 
from all H. pylori isolates as the sequences of several genes such as flagellin (flaA and flaB) 
and urease (ureA, ureB and ureC) varied between strains (Marshall et al. 1998). 
In summary, this study revealed that the cjaC, cjaA and dnaJ genes exist in the majority of C. 
concisus isolates. However, zot was found in only 20%-25% of C. concisus isolates. DNA 
sequence variations possibly led to PCR amplification failure to detect virulence genes in 
some C. concisus isolates. The variations are vast between genomospecies A and B, and even 
in corresponding amino acids, although a lesser extent than DNA sequence variations. PCR-
DGGE based on the 16S rDNA gene using Muyzer primer sets, clustered C. concisus isolates 
into two distinguishable groups. The results of PCR assays suggested that although the 
detection of putative virulence genes could be improved by the second designed primer set 
designed based on strain 13826 to amplify sequences in the centre of the gene, there were 
some specific genomospecies A stains that cannot be detected using either primer set. It is 
suggested that targeting the central part of putative virulence genes might improve the 
detection, but this needs more confirmations. In using of the two methods (PCR-DGGE and 
PCR amplification), no differences between C. concisus isolates were recognised between 
being oral or faecal with the exception of the detection of zot. 
Future directions 
Based on 23S rDNA, genomospecies A was the most prevalent in both oral and faecal 
isolates, with prevalence of 75% and 82.4%, respectively, which was not statistically 
significant. Further studies are required to evaluate the virulence of C. concisus clinical 
isolates within each genomospecies or group. The DGGE technique could be used to separate 
C. concisus isolates to groups, but more studies are required to determine whether detection 
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of C. concisus groups in mixed bacterial DNA is feasible and to investigate any difference in 
the virulence state of the generated groups. Sequencing cjaC, dnaJ and cjaA of other C. 
concisus isolates, particularly from genomospecies A to be used in the phylogenetic analysis 
to support this study findings. In addition, whole genome sequencing for more 
genomospecies A strains is required as only one strain has been sequenced up to date. 
Performing protein studies on the studied genes would be essential to investigate if the 
protein properties are similar within the two genomospecies. 
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Chapter 4 : The interaction between C. concisus and host 
epithelial cells in vitro 
4.1 Introduction 
Several studies have reported that pathogenic Campylobacter spp. such as C. jejuni are able 
to adhere to and invade epithelial cells in vitro and this process is dependent on the 
expression of several virulence factors (Bereswill et al. 2002; Ketley 1997; Russell et al. 
1993). The association of C. concisus with human diseases is still unclear; hence, 
investigating the possible virulence factors in C. concisus in vitro could be an initial step to 
characterise the potential role of C. concisus in human infections. 
C. concisus strains differ in their ability to invade intestinal epithelial cell lines and C. 
concisus UNSWCD was the most invasive examined in one study (Man et al. 2010a). 
Interestingly, faecal and oral C. concisus isolates obtained from healthy individuals were able 
to attach, but were unable to invade human cell lines, unlike isolates obtained from biopsies 
and the oral cavity of CD patients (Ismail et al. 2012; Kaakoush et al. 2011b). Given that C. 
concisus isolates are genetically heterogeneous; a specific group is possibly involved in 
human infections. 
In in vitro studies of invasion, the highest reported invasion level of C. concisus was reported 
at a minimum of six hours and it was associated with cytoskeletal change in the epithelial 
cells, and an increase in the inflammatory factors TNF-α and IFN-γ (Kaakoush et al. 2011b). 
The elevation of these inflammatory factors has also been previously noted as a part of the 
clinical features of CD patients (Fuss et al. 1996; Murch et al. 1993). 
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This part of the study aimed to: 
I. Establish a C. concisus growth curve to assess the conditions for optimal growth and 
to establish a reproducible recovery procedure from broth cultures. 
II. Assess and compare the capacity for adhesion and invasion of INT407 cells of a panel 
of C. concisus faecal and oral isolates belonging to genomospecies A and B. 
III. Investigate the expression of putative virulence genes (cjaC, cjaA, dnaJ and zot) by C. 
concisus isolates (detected positive for these genes in chapter 3) grown in different 
synthetic media and in INT407 cells to possibly assess virulence state as there are no 
published reports on the expression of these putative virulence genes from C. 
concisus. 
 
4.2 Materials and Methods 
4.2.1 Growth curve 
C. concisus strain ATCC 51562 was selected for performing the growth curve study. The 
strain was grown on HBA for 48 h as described in section 2.4.2. Five to seven colonies were 
suspended in 1 ml of brain heart infusion broth (BHI) and the OD600 value was adjusted at 0.1 
(0.5 McFarland) using an Eppendorf BioPhotometer. From the suspension, 100 µl was 
inoculated into each of ten tubes containing 0.9 m1 of BHI. The tubes were then incubated 
under standard growth conditions as described in section 2.4.2. The OD600 value of the 
growing culture was measured and recorded at 0 h and 4 h (to detect the lag phase) and was 
then measured every 12 h for 9 days. The bacterial viability (CFU) was also determined at the 
same time as the OD600 reading. To assess the CFU value at each time point, serial dilutions 
were performed by spreading 100 µl aliquots of bacterial cultures onto a HBA plate as a 
lawn, followed by incubation under the specific growth conditions indicated in section 2.4.2 
for C. concisus. Three independent experiments were performed in duplicate. 
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In addition during the performance of the growth curve, C. concisus growth was tested on 
Columbia agar base (CA) without the addition of blood. C. concisus growth on CA was 
examined by the preparation of lawn culture from fresh bacterial growth on HBA, and 
inoculated onto CA. 
 
4.2.2 Invasion and adhesion assays 
INT407 cells are a derivative of cells obtained from a malignant tumour in the small intestine 
of a human embryo (Henle et al. 1957). These cells can maintain the morphological and 
immunological characters of intestinal crypt cells and grow in vitro as a monolayer with 
formation of tight junctions (Grönroos et al. 1998; Henle et al. 1957; Nickerson et al. 2001). 
Thus, it was proposed that INT407 cells would be an appropriate model for C. concisus 
infection and for investigating differences in adhesion and invasion between isolates from 
genomospecies A & B. 
Bacterial isolates and strains used in the adhesion and invasion assays were: 10 C. concisus 
isolates and two Campylobacter reference strains (C. jejuni 81116 and C. coli NCTC 11366). 
Five C. concisus isolates were from genomospecies A (ATCC 51562, RCH3, RCH26, O10 
and O12) and same number of C. concisus isolates was from genomospecies B (ATCC 
51561, RCH6, RCH11, O11 and O13). C. concisus isolates RCH6, RCH11 and RCH26 
possess the zot gene (section 3.3.4). Invasion and adhesion assays were performed as 
described in section 2.11.5. 
A C. concisus isolate with an invasion index ≥1 (section 2.11.5) was considered to be an 
invasive as described by Ismail et al. (2012), based on a previous study that showed that C. 
jejuni strains with an invasion index of ≥1 had clinical symptoms in infected pigs, similar to 
human symptoms (Ismail et al. 2012; Larson et al. 2008). 
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4.2.2 Gene expression studies 
Initially, levels of gene expression were determined for C. concisus ATCC 51561 (three 
independent experiments in duplicate). For the three remaining C. concisus isolates (ATCC 
51562, RCH6 and RCH26), one experiment was performed. The targeted genes (cjaC, cjaA, 
dnaJ and zot) were amplified with primer sets II, CjaAT, DnaJT and ZoT (Table 2.2). 
Relative gene expression was determined using semi-quantitative SYBR green assay, using 
atpA (ATP synthesis F1 complex alpha subunit) as a housekeeping gene. Based on the 
sequence of C. concisus strain 13826, the sequence of the AtpA forward primer was 5ˋ-
TGGCGCTATGGACTACACAA-3ˋ and the sequence for the AtpA reverse was 5ˋ-
TCAAAGATCCAGCGCCTAGT-3ˋ to amplify a 300 bp product. 
RNA was extracted from C. concisus grown on HBA and CA. In addition, C. concisus RNA 
was extracted from bacterial cells maintained in INT407 cells growing in DMEM/FBS 
(DMEM+INT407) and DMEM/FBS (DMEM). 
To extract C. concisus RNA, bacterial suspensions from 48 h old cultures on HBA or CA 
were prepared in Columbia broth and the OD600 values were adjusted to 0.1. The bacterial 
pellets were collected from 10 ml of the bacterial suspension, washed twice by re-suspension 
in PBS and centrifugation. The cleaned bacterial pellets were then subjected for RNA 
extraction as described in section 2.12.3. 
To extract RNA from bacterial cells maintained with INT407 cells, C. concisus cells were 
introduced to DMEM+INT407 and DMEM as explained in the adhesion and invasion assays 
(section 2.11.5). After the incubation for 6 h, C. concisus cells were obtained by collecting 
(from 20 wells of the plate for each bacterial isolate) the medium from both plates containing 
DMEM+INT407 and DMEM. The medium containing C. concisus cells was centrifuged at 
5000 x g for 4 min. The supernatant was discarded and the pellet was used for RNA 
extraction as described in section 2.12.3. In the same way DMEM of wells containing 
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INT407 cells (no bacterial cells were added) was collected as above to be used as control 
negative template (to insure the bacterial primers do not attach and amplify cDNA that may 
be synthesised from INT407 cells). 
cDNA synthesis was described in section 2.12.4. A standard curve was generated by 
performing serial dilutions from genomic DNA. Three dilutions (descending by 50 folds) 
were generated starting from 0.2, 0.004 and 0.00008 ng/µl. In each RT-PCR reaction, 5 µl 
were used. RT-PCR conditions were described in section 2.12.5. 
 
4.2.4 Determination of the lowest number of bacterial cells yielding sufficient RNA for 
cDNA synthesis. 
In order to determine the lowest number of bacterial cells from which sufficient RNA for 
cDNA synthesis could be extracted, bacterial suspensions of C. concisus ATCC 51562 were 
prepared as following 109, 107, 105 and 103 CFU. Initially, the bacterial concentration was by 
adjusting by OD600 value to 0.1, which had been previously determined to contain 108 CFU. 
 
4.2.6 Data analysis 
The mean and standard deviation (SD) of datasets, and growth curves were plotted using 
Microsoft Excel. Statistical analysis was performed using GraphPad Prism 6 software (USA) 
using unpaired T-test where appropriate to calculate P values for invasion/adhesion assays 
and gene expression study. A value of P <0.05 was considered significant. 
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4.3 Results  
4.3.1 Growth curve  
Based on the OD600 reading, mid-log phase was at 2.5 days (OD600: 0.243 ~log 8.91 CFU) as 
shown in Figures 4.1. 
In addition, it was found that C. concisus cells from either fresh culture or frozen stock were 
able to grow on fresh CA, which has not been reported previously. The colony size and shape 
on CA were similar to those of colonies grown on HBA (Figure 4.2). 
 
4.3.2 Adhesion and invasion assays 
The adherence of C. concisus isolates (ATCC 51561, O12 and O11) and C. coli NCTC 11366 
to INT407 cells was significantly higher than the reference strain (C. jejuni 81116) (P <0.05) 
(Figure 4.3). The adherence value of the remaining isolates (ATCC 51562, RCH3, RCH6, 
RCH11, RCH26, O10 and O13) was similar to C. jejuni 81116 (P >0.05). P value represents 
the calculation of statistical significance between two or more compared values, P <0.05 
refers to significant difference between the compared values while P >0.05 refers to no 
significant difference between the compared values. 
When the invasion capability of the above isolates was assessed, the isolates were different in 
their ability to invade INT407 cells. C. concisus ATCC 51561 and O12, and C. coli NCTC 
11366 demonstrated significantly higher invasion rates than C. jejuni 81116 (P <0.05), while 
RCH6 and RCH26 had significantly lower invasion rates than C. jejuni 81116 (P <0.05) 
(Figure 4.4). 
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Figure  4.1: Growth curve of C. concisus ATCC 51562 monitored by OD600. C. concisus 
ATCC 51562 was cultured in BHI and OD600 readings were taken at intervals for up to 9 
days, data points represent the mean of three independent experiments; error bars show SEM. 
The curve presents mid-log phase at 2.5 days. 
 
Figure  4.2: Growth of C. concisus on Columbia agar base (CA) without the addition of 
blood. Three day-old C. concisus colonies on a CA plate (A) and on a HBA plate containing 
5% defibrinated horse blood (B). The colonies appear grey in colour and 1-2 mm in size on 
both plates. 
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Figure  4.3: Adherence of C. concisus isolates to INT407 epithelial cells. Bacterial strains 
were mantained with INT407 cells for 6 h. Bars represent the mean of the percentage of 
adherent bacterial cells. The data are representative of three independent experiments 
performed in triplicate; error bars represent SEM. The adherence value of each 
Campylobacter spp. strain was compared to C. jejuni 81116 (the black bar) to calculate the 
significance. The number of stars represent the power of statistical significance (*: P <0.05, 
**: P <0.01, ***: P <0.001 and ****: P <0.0001). 51561 & 51562: C. concisus reference 
strains ATCC 51561 and 51562. RCH: C. concisus faecal isolates collected from the Royal 
Melbourne Children’s Hospital. O12, O10, O11 and O13 were oral isolates. C. coli is C. coli 
NCTC 11366. G.A: genomospecies A. G.B: genomospecies B. All C. concisus tested isolates 
were able to adhere to INT407 cells with similar percentage to C. jejuni or higher. 
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Figure  4.4: Invasion of C. concisus isolates into INT407 epithelial cells. Bacterial strains 
were mantained with INT407 cells for 6 h. Bars represent the mean of the percentage of 
invaded bacterial cells. The data are representative of three independent experiments 
performed in triplicate; error bars represent SEM. The invasion value of each Campylobacter 
spp. strain was compared to C. jejuni 81116 (the black bar) to calculate the significance. Stars 
represent the power of statistical significance (*: P <0.05, **: P <0.01 and ***: P <0.001). 
51561 & 51562: C. concisus strains ATCC 51561 and 51562. RCH3, RCH6, RCH26, and 
RCH11: C. concisus faecal isolates collected from the Royal Melbourne Children’s Hospital. 
O12, O10, O11 and O13 were oral isolates. C. coli is C. coli NCTC 11366. G.A: 
genomospecies A. G.B: genomospecies B. All tested isolates were able to invade INT407 
cells with different proportions. The invasion proportion of RCH6 and RCH11 (possessing 
zot) was significantly lower than C. jejuni 81116. 
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The results showed that C. jejuni 81116, C. concisus isolates (O10, and O12) and C. coli 
NCTC 11366 were invasive strains. Moreover, there was no statistically significant 
difference in the invasive index values of two C. concisus isolates (O10 and O12) and C. coli 
NCTC 11366 as compared to C. jejuni 81116 (P >0.05), while other C. concisus isolates 
demonstrated a significantly lower invasive index values (P <0.05) as shown in Figure 4.5. 
Interestingly the lowest invasive index values were recorded for C. concisus clinical isolates 
(RCH6, RCH11 and RCH26) that possessed zot, while the oral isolates (O10 and O12) had 
the highest invasive index values. 
Collectively, although C. jejuni 81116 and C. concisus O10 (an oral isolate) showed low 
incidences in adherence and invasion, their invasive index values were significantly higher, 
meaning that most of the attached cells were able to translocate into INT407 cells. The 
invasive index value of 0.95 for C. concisus ATCC 51561 was the highest compared to other 
C. concisus clinical isolates. Overall, two isolates (O10 and O12) from C. concisus 
genomospecies A had invasive (index invasive values >1), while none of genomospecies B 
isolates reached the invasive index value. The data also suggested that the presence of zot did 
not enhance the invasive capabilities of C. concisus isolates in INT407 cells. Furthermore, the 
majority of C. concisus tested isolates were more likely to be adherent than invasive when 
compared to the adherence and invasion of C. jejuni 81116 and C. coli NCTC 11366. 
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Figure  4.5: Invasive index value of C. concisus isolates infected into INT407 epithelial 
cells. Bars represent the mean of the invasive index values of bacterial cells. Data are 
representative of three independent experiments performed in triplicate; error bars represent 
SEM. The invasive index value of each Campylobacter spp. strain was compared to C. jejuni 
81116 (the black bar) for significance calculation. Stars represent the power of statistical 
significant (*: P <0.05, **: P <0.01 and ***: P <0.001). 51561 & 51562: C. concisus 
reference strains ATCC 51561 and 51562. RCH3, RCH6, RCH26 and RCH11: C. concisus 
faecal isolates collected from the Royal Melbourne Children’s Hospital. O12, O10, O11 and 
O13 were oral isolates. C. coli: C. coli NCTC 11366. G.A: genomospecies A. G.B: 
genomospecies B. Invasion index values (≥1) above the dashed horizontal line in red colour 
represent invasive Campylobacter strains, while invasion index values (<1) below the dashed 
horizontal line in red colour represent non-invasive Campylobacter strains. Invasive strains 
were C. jejuni 81116, two oral C. concisus isolates (O10 and O12) and C. coli NCTC 11366. 
All invasive C. concisus isolates were from genomospecies A and did not possess zot. 
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4.3.3 Expression analysis of putative virulence factors using semi-quantitative real time 
PCR (RT-PCR) 
The lowest number of bacterial cells that yielded sufficient RNA for cDNA synthesis at a 
detectable level for the RT-PCR was ≥105 CFU (Figure 4.6). The RT-PCR protocols were 
optimised to detect and amplify cjaC, cjaA, dnaJ and zot from cDNA. Purified RNA was also 
tested to ensure that residual genomic DNA was removed (Appendix XVIII). Melting curve 
analysis was used to confirm the specificity of SYBR green PCR products. As an additional 
control, PCR products obtained from the SYBR green assays were visualised by gel 
electrophoresis to ensure that a single product of the correct size was present. An example for 
the RT-PCR products is presented for the housekeeping gene (ATP synthesis F1 complex 
alpha subunit) in Appendix XVIII. 
 
4.3.3.1 Expression analysis of putative virulence genes of C. concisus ATCC 51561 using 
semi-quantitative real time PCR 
The gene expression level detected in C. concisus cultures grown on HBA was used as the 
baseline, and this value was arbitrarily set to 1.0. A minimum of 2-fold change in gene 
expression as compared to the expression on HBA was considered a significant change 
(either up or down regulated). 
The expressions of cjaC and cjaA in C. concisus cells grown on CA were slightly up-
regulated, but they were less than 2-fold when compared with baseline expression on HBA. 
This finding indicated that the expressions of these genes may not be significantly affected in 
the absence of blood in growth media. Moreover, the expressions of cjaC and cjaA were 
slightly down-regulated (<2-fold) in bacterial cells maintained in DMEM+INT407 cells and 
DMEM (Figure 4.7). 
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Figure  4.6: RT-PCR amplification products obtained from cDNA synthesised from 
RNA extracted from serially diluted bacterial suspensions. This experiment was 
performed to detect the lowest number of bacterial cells that yielded sufficient RNA for 
cDNA synthesis. RT-PCR amplification products of cDNA were obtained from atpA that was 
extracted from serial dilution of C. concisus ATCC 51562 cells. RT-PCR products collected 
from the bacterial dilutions were loaded on a 1.5% (w/v) agarose gel for electrophoresis. The 
gel was then stained in ethidium bromide and visualised by a UV trans-illuminator. PCR 
product size was 300 bp. Lanes 109, 107, 105 and 103: the bacterial dilutions. (+): control 
positive. (-): no template control. MK: lambda DNA marker. The lowest number of bacterial 
cells that yielded sufficient RNA for cDNA synthesis at detectable level for the RT-PCR was 
≥105 CFU. 
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Similar to cjaC and cjaA, there was no significant difference in the expression of dnaJ in 
bacterial cells grown on CA when compared to bacterial cells grown on HBA. However, the 
expression of dnaJ was significantly down-regulated in bacterial cells maintained in 
DMEM+INT407 cells and in DMEM (values of -3.5 and -6.7 respectively) (Figure 4.7). This 
may be due to the use of DMEM as a growth medium because HBA and CA may be more 
suitable for C. concisus growth than in DMEM. 
Generally, the expression of all tested genes (cjaC, cjaA and dnaJ) in C. concisus cells 
maintained in DMEM+INT407 and in DMEM was significantly down-regulated compared to 
the expression in cells growing on CA (Figure 4.7). In addition, the expression of dnaJ in C. 
concisus cells maintained in DMEM was compared to the expression in cells maintained in 
DMEM+INT407 cells. It was found that there was a significant down-regulation in the 
expression of dnaJ in the bacterial cells maintained in DMEM compared to in the bacterial 
cells maintained in DMEM+INT407 cells (3.2-fold, P <0.05) (Figure 4.7). 
In summary, growth of C. concisus ATCC 51561 on CA showed no significant change in the 
regulation of the tested genes, which was supportive for growing C. concisus on CA. DnaJ 
encodes a stress protein and is considered as a virulence-associated gene. The results of 
expression studies for this gene showed that there was a significant down-regulation in dnaJ 
in the bacterial cells maintained in DMEM and in DMEM+INT407; however the down-
regulation in DMEM alone was significantly lower than in DMEM+INT407, which 
suggested a possible role of dnaJ in C. concisus virulence. 
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Figure  4.7: Gene expression of putative virulence genes of ATCC 51561 relative to 
expression on HBA. Bars represent the mean of the values of the fold change for cjaC, cjaA 
and dnaJ in bacterial cells grown on HBA, CA and, in bacterial cells mantained in 
DMEM+INT407 cells and DMEM medium alone. Data are representative of three 
independent experiments preformed in triplicate; error bars represent SEM. In this 
experiment relative gene expression from C. concisus ATCC 51561 grown on HBA was used 
as a reference (the black bar) for significance evaluation. The star represents the power of 
statistical significant (P <0.05). The two dashed blue lines show the two fold changes for up-
regulation and down-regulation. CA: Columbia agar base. RNA was collected after 48 h in 
the bacterial growth on HBA and CA while it was collected after 6 h of bacterial maintained 
in DMEM+INT407 and DMEM. No significant change in the expression of cjaC and cjaA 
genes. The expression of dnaJ was significantly down-regulated in DMEM+INT407 and 
DMEM. Also, dnaJ was significantly down-regulated in bacterial cells maintained in DMEM 
compared to in bacterial cells maintained in DMEM+INT407. 
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4.3.3.2 Screening for the expression of the putative virulence genes in four C. concisus 
strains using semi-quantitative real time PCR.  
After the expression level of putative virulence had been determined in the reference strain C. 
concisus ATCC 51561, ATCC 51562, RCH6 and RCH26 were selected for similar 
expression analysis. Gene expression of C. concisus ATCC 51562, RCH6 and RCH26 
relative to that of ATCC 51561 was calculated. cDNA of cjaA could not be amplified from C. 
concisus ATCC 51562 and RCH26, as was also the case for genomic DNA (section 3.3.4). 
Other genes (cjaC and dnaJ) were found to be expressed in all tested strains but their gene 
expression levels varied (Figure 4.8). There were no significant differences in regulation of 
cjaC in any bacterial strains growing on CA compared to HBA. 
C. concisus ATCC 51561 had the highest levels of gene expression amongst all tested strains 
when they were maintained in DMEM+INT407. C. concisus isolates RCH6 and RCH26 
(possessing zot) showed a significant down-regulation in the expression of cjaC, cjaA and 
dnaJ on HBA, CA and DMEM+INT407 (exception cjaA of RCH26, which could not be 
amplified). The expression of zot could not be detected even in isolates known to possess the 
gene in chapter 3 (RCH6 and RCH26). 
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Figure  4.8: Gene expression of putative virulence genes in C. concisus relative to the 
expression of C. concisus ATCC 51561 grown in HBA, CA and with INT407 cells. The 
aim of the study was to investigate the expression of various genes (cjaC, dnaJ and cjaA) 
from C. concisus (ATCC 51562, RCH6 and RCH26) relative to C. concisus strain ATCC 
51561. The bars are the fold changes of gene expression of one experiment that was 
performed and analysed once. The two dashed blue lines show the two-fold changes for up-
regulation and down-regulation. The RNA was collected after 48 h growth on HBA and CA 
while it was collected after 6 h of bacterial cells maintained in to DMEM+INT407. C. 
concisus ATCC 51561 had the highest level of expression of all tested genes, but the 
difference was only statistically significant for bacterial cells maintained in DMEM+INT407. 
C. concisus RCH6 and RCH26 (possessing zot) had statistically significant down-regulation 
of their tested genes on HBA, CA and DMEM+INT407. 
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4.4 Discussion 
Several studies have used different media to grow C. concisus including BHI broth and 
Brucella broth (Gunther et al. 2009; Lavrencic et al. 2012). In this study, C. concisus grew 
well on CA, a basic non-enriched medium without the addition of 5% defibrinated horse 
blood. Thus CA can be used for the maintenance of C. concisus strains in laboratories, 
particularly for resuscitating the bacterial isolates from frozen stocks, which can reduce the 
cost of C. concisus cultivation in laboratories. However, more studies are required to confirm 
whether CA can be used to retrieve C. concisus from clinical samples. 
There had been no previous reports of growth curves for C. concisus in the literature, but 
growth curves for C. jejuni 81-176 in Mueller-Hinton (MH) broth have shown a rapid early 
growth peaking at 23 h (Sellars et al. 2002; Szymanski et al. 2002; Wright et al. 2009). In the 
present study, C. concisus growth in BHI was at a slower rate and required ~4 days to reach 
the peak of the growth curve (Figures 4.1). The mid-log phase in C. concisus was up to 2.5 
days, longer than for C. jejuni. 
In this study, C. concisus isolates demonstrated adhesion rates between 0.047% - 7.4% to 
INT407 cells. Previously, Kaakoush et al. (2011b) examined the adhesion and invasion 
capabilities of C. concisus isolates using different cell line (Caco-2 cells) at a MOI of 200 
(three isolates obtained from intestinal biopsies of CD patients and four isolates obtained 
from faeces of patients with gastroenteritis), and reported adhesion rates between 0.11% - 
4.6%. However, the faecal and oral C. concisus isolates used in this study showed lower 
invasion rates than reported by Kaakoush et al. (2011b). In using another cell line (CHO), 
Musmanno et al. (1998) found that two faecal C. concisus isolates were unable to adhere to 
and invade this cell line although one of the isolates was able to produce a cytotoxic effect 
when introduced into CHO cell line. The difference in the proportion of invasion between C. 
concisus isolates observed in these studies could be due to the reduced MOI of 100 (bacterial 
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cells per one host cell). It may also be the isolates that were obtained from intestinal biopsies 
were more invasive than faecal and oral isolates or using different cell lines. 
In this study, the invasion and adhesion of C. concisus isolates did not show a clear difference 
between genomospecies A and B, or even between the oral or faecal isolates. Also, Kalischuk 
et al. (2011) did not demonstrate variations in the adherence to T84 cells between faecal 
genomospecies A and B isolates obtained from patients with diarrhoea and healthy controls. 
However, the same study indicated that the isolates belonging to genomospecies B were more 
invasive than genomospecies A. Moreover, the invasion rate for 46.6% (7/15) of C. concisus 
isolates was equivalent to that reported for C. jejuni 81-176 (Kalischuk et al. 2011). 
In this study, two C. concisus oral isolates obtained from healthy volunteers were found to 
reach invasive index value >1, which has not been reported in the literatures. Ismail et al. 
(2012) found that 50% of C. concisus oral isolates obtained from IBD patients were invasive 
as they were able to reach the invasive index value, while none of C. concisus oral isolates 
obtained from healthy controls were invasive. The authors concluded that invasive C. 
concisus isolates colonised the oral cavity of patients with IBD only. 
The INT407 cell line has been recognised to be contaminated with Hela cells (Lacroix 2008); 
however, it is still widely used in studying adhesion and invasion capabilities of 
campylobacters, in particular C. jejuni (Boehm et al. 2015; Chandrashekhar et al. 2015; 
Eucker et al. 2012; Javed et al. 2010). It was reported that C. jejuni was able to adhere to and 
invade Hela and INT407 cells with equivalent efficiency (Buelow et al. 2011; Eucker et al. 
2012). Based on the invasion to Caco-2 and HT29-Cl.16E, Fearnley et al. (2008) found C. 
jejuni strains could be differentiated to hyper-invasive and low-invasive strains, relative 
differences also were retained when INT407 cells were used to test the same strains. In this 
current study, the results obtained from using INT407 cells were reproducible when three 
independent experiments were performed in triplicate. In addition C. jejuni 81116 and C. coli 
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NCTC 11366 were used as controls to compare the potential invasiveness of C. concisus 
isolates. However, conflicting results between studies may occur due to using different cell 
lines such as INT407 cells, Caco-2 and HT-29 for adhesion and invasion assays. 
The putative virulence genes cjaC (histidine up-take), cjaA (cysteine up-take), dnaJ 
(virulence-association) were selected because they were predicted to be involved in bacterial 
survival in unusual environments or bacterial virulence. The results of the present study 
found that the expression of cjaC and cjaA was slightly changed in C. concisus ATCC 51561 
cells grown on CA compared to the expression on HBA. Based on the expression of virulence 
factor, Malik-Kale et al. (2008) also found that the pathogenesis of C. jejuni can be induced 
by the change of growth conditions. The expression of cjaC was up-regulated, while the 
expression of cjaA was down-regulated in a C. jejuni strain grown on Mueller-Hinton agar 
containing 0.1% deoxycholate (Bile salt) (Malik-Kale et al. 2008). The current study found 
that there was no significant difference in expression of cjaC and cjaA when C. concisus 
ATCC 51561 was grown either on CA or when it was maintained in DMEM+INT407 or in 
DMEM alone, suggesting that expression of these genes is steady during C. concisus growth 
in different media and is not affected by introducing C. concisus to host cells. 
Although, in the comparison of the expression results obtained from C. concisus ATCC 
51561 cells grown on CA with the bacterial cells maintained in DMEM+INT407 or in 
DMEM showed small differences (within 2 to -2 fold, Figure 4.7), the results showed that the 
expression of cjaC, cjaA and dnaJ in bacterial cells maintained in DMEM+INT407 cells or in 
DMEM was significantly down-regulated compared with bacterial cells grown on CA. The 
variation in the results could be due to the time of RNA collection as in bacterial cells grown 
on CA was after 48 h, while the RNA of the bacterial cells maintained in DMEM+INT407 or 
in DMEM was collected after 6 h. Another point is that DMEM may not be a suitable 
medium for C. concisus growth as CA. 
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In this study, the expression of dnaJ in C. concisus ATCC 51561 cells maintained in DMEM 
was significantly reduced compared with the expression in those bacterial cells maintained in 
DMEM+INT407. Previously a C. jejuni dnaJ mutant was reported to be unable to colonise 
the chicken gut (Konkel et al. 1998). Moreover, dnaJ was reported to be up-regulated in C. 
jejuni cells grown in Mueller-Hinton broth incubated at 42°C as compared to 37°C (Stintzi 
2003). Thus based on the results of this study and Konkel et al. (1998) study, the expression 
of dnaJ is possibly associated to the bacterial interaction with host cells. 
In this study, the expression of the putative virulence genes was generally significantly higher 
in C. concisus ATCC 51561 than others isolates (ATCC 51562, RCH6 and RCH26) when the 
isolates were maintained in DMEM+INT407. Moreover, ATCC 51561 presented higher 
adhesion and invasion proportion values than ATCC 51562, RCH6 or RCH26. C. concisus 
ATCC 51561 was also the most invasive faecal isolate. Although C. concisus ATCC 51561 
was isolated from the faeces of a healthy control, it was shown to be more virulent than other 
faecal isolates obtained from faeces of patients with diarrhoea. Furthermore, C. concisus 
isolates RCH6 and RCH26 (possessing zot) had a significant down-regulation in the 
expression of each of the three tested genes (cjaC, cjaA and dnaJ) on HBA, CA and 
DMEM+INT407. They were also amongst isolates that exhibiting the lowest values for 
adhesion and invasion proportion. 
Wyszynska et al. (2004) demonstrated the presence of CjaC and CjaA proteins in the 
periplasm and suggested they could be exposed to the cell outer membrane of the bacterial 
cell. Although these proteins are exposed on the bacterial outer membrane, they do not seem 
to be involved in the interaction with host cells. In contrast dnaJ may be associated with 
bacterial virulence as the expression was significantly decreased in bacterial cells maintained 
in medium without the host cells, compared to those exposed to INT407 cells. 
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In summary, from the growth curve of C. concisus ATCC 51562 in Columbia broth, the mid-
log phase occurred at 2.5 days. This information will assist future studies to determine 
suitable media or conditions for bacterial growth requirements and the phase of toxin 
production. In addition, C. concisus can be grown in ordinary synthetic medium such as CA 
without the addition of horse blood, which will reduce the cost of, and facilitate C. concisus 
growth in laboratories. Moreover, this study revealed that C. concisus of both genomospecies 
(A & B) were able to invade INT407 cells, but genomospecies A isolates displayed higher 
invasive index than genomospecies B isolates. The data obtained also showed that healthy 
volunteers can carry invasive C. concisus isolates in their oral cavity. Furthermore, these 
isolates had an invasive index value close to that of pathogenic C. jejuni 81116 and C. coli 
NCTC 11366 strains. Remarkably, C. concisus isolates possessing zot demonstrated the 
lowest invasive index value, suggesting that zot is not involved in host cell adherence and 
invasion, at least in vitro. Furthermore, to our knowledge it was the first relative expression 
assay study performed on the putative virulence genes such as cjaC, cjaA and dnaJ. It was 
found that the expression of these genes can be slightly induced by the alteration of the 
composition of the growth media. The dnaJ gene is probably a virulence factor as its 
expression was reduced when C. concisus introduced to a tissue culture medium without 
INT407 cells compared to the medium with INT407 cells. As C. concisus strains are well 
known to be divided into at least two main genomospecies, further studies on growth curves 
may include isolates from genomospecies B to investigate whether there is any difference in 
the growth curve patterns. This study provides a foundation for investigating relative gene 
expression by C. concisus and further studies should be undertaken in order to characterise 
additional predicted virulence genes. 
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Chapter 5 : Detection and characterisation of C. concisus in 
clinical samples collected from healthy adults and patients with 
IBD 
5.1 Introduction 
To date, only a few studies have investigated the presence of C. concisus in adults with IBD 
and there is a lack of information regarding C. concisus colonisation in sites throughout the 
entire human gastrointestinal tract in these patients. A recent study on adults with IBD 
attempted isolation of C. concisus from one site (caecal biopsies) and detection of C. concisus 
by PCR in four intestinal anatomic sites (Mahendran et al. 2011). Other studies were 
conducted on biopsies of paediatric patients with IBD collected from the distal colon 
(rectum/sigmoid) and caecum (Hansen et al. 2013; Zhang et al. 2009). 
Certain groups of C. concisus could have possible pathogenic roles in IBD. The prevalence of 
genomospecies of C. concisus that colonise different sites of the human digestive tract has 
not been investigated in IBD patients (Hansen et al. 2013; Mahendran et al. 2011; 
Mukhopadhya et al. 2011; Zhang et al. 2009). Additionally, there is controversy regarding 
which C. concisus strains or group is more virulent (Kalischuk et al. 2011). 
Previous studies have reported very low isolation rate of C. concisus from intestinal biopsies 
(Mahendran et al. 2011; Zhang et al. 2009), which could be either due to low sensitivity of 
the culture techniques or that only low number of C. concisus colonise the gastrointestinal 
tract. Molecular techniques to amplify 16S rDNA have previously resulted in high detection 
rate (Mahendran et al. 2011; Mukhopadhya et al. 2011; Zhang et al. 2009). 
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The purposes of the experiments described in this chapter were to: 
I. Determine the prevalence of C. concisus in adults with IBD. 
II. Determine the regions of the gastrointestinal tract colonised by C. concisus. 
III. Determine whether there are any genomospecies differences between C. concisus 
strains colonising gastrointestinal and oral sites in IBD patients compared to 
control participants. 
IV. Investigate the prevalence of zot (a putative virulence gene) in IBD patients and 
control participants. 
V. Investigate the prevalence of C. concisus groups obtained from the detection of 
the DNA region between cjaC and the adjacent gene (CCC13826_0962) encoding 
a hypothetical protein in genomospecies B isolates to determine whether there was 
any association between those groups and IBD. 
VI.  Investigate the relationship between C. concisus isolates from the mouth and 
gastrointestinal tract of the same patient using SDS-PAGE. 
 
5.2 Materials and Methods 
5.2.1 Assessment of the effects of PicoPrep on C. concisus 
PicoPrep (Fresenius Kabi, Australia) is sodium picosulfate powder that is normally used as an 
oral solution for bowel preparation prior to the endoscopy procedure. This experiment was 
conducted to find whether PicoPrep might inhibit and reduce C. concisus survival in 
intestinal specimens. C. concisus were grown on HBA using the disc diffusion method. C. 
concisus isolates (ATCC 51562, RCH6 and RCH24) were nominated as representatives of 
both C. concisus genomospecies (A and B), the experiment was performed in triplicate. A 
sachet content (15.5 g) of PicoPrep was dissolved as recommended for the bowel preparation 
in 250 ml of sterile dH2O. Then, several dilutions were made as follows: 1:0, 1:2, 1:4, 1:8 and 
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1:10. Bacterial growth was initiated by freshly suspending 1-2 colonies into a tube containing 
1 ml brucella broth and incubating under optimal conditions of C. concisus as stated in 
section 2.4.2 for 5 h. A HBA plate was inoculated by spreading 100 µl from the bacterial 
culture; following that, five sterile discs were placed on and were then saturated with 50 µl of 
one of the following concentrations of PicoPrep: 124 (1:0), 62 (1:2), 31.2 (1:4), 15.2 (1:8) 
and 5.2 (1:10) mg/ml. Plates were incubated under C. concisus growth conditions as 
described in section 2.4.2 for 4 days. 
 
5.2.2 Recovery and survival of C. concisus after storage at 4°C 
This experiment was performed to investigate the effect of low temperature (4°C) on the 
recovery and survival rates of C. concisus as this temperature can be used as a model for the 
transportation temperature or short storage between collection of biopsies and laboratory 
culture. C. concisus ATCC 51561 (a genomospecies B strain) and C. concisus ATCC 51562 
(a genomospecies A strain) were nominated to reflect both genomospecies for this 
experiment. 
Bacterial suspensions were prepared in 5 ml of Columbia broth (CB) from C. concisus strains 
grown for 48 h old HBA. The suspensions were adjusted to 0.1 OD600 and stored refrigerated 
at 4°C. To detect the survival rate at this temperature, C. concisus CFU value was determined 
after storage in CB at 4°C for up to 15 days; and samples were tested at times 0 h, 7 h, 24 h, 
48 h, 120 h, 192 h, 288 h and 360 h. 
 
5.2.3 Sample size 
In order to determine the sample size that is necessary to achieve statistical significance, 
power analysis was conducted with assistance of the RMIT University Statistics Consultancy 
Group. The power analysis was conducted using GPower 3.1 (Faul et al. 2007), this package 
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very comprehensive for estimation of sample size. Individual power analyses were conducted 
for each of the four specimens (biopsy, faeces, gum swab and blood) that were to be collected 
from each patient at the same time. The sample size estimate was based on the results 
achieved in previous studies found in the literature (Man et al. 2010b; Zhang et al. 2009) 
where the bacterium was identified in intestinal biopsies and stool samples from patients and 
control groups which were nominated at the start of the study. Power analysis indicated that 
117 samples were required for the patient (study) group, and 83 samples from control group. 
 
5.2.4 Recruitment of participants 
Participants in this study were recruited from patients attending the Gastroenterology clinic at 
Austin Health, Heidelberg, Victoria. Laboratory work was undertaken at RMIT University, 
Melbourne, Victoria. The lead clinician was Dr. Georgina Paizis. Ethics approval for this 
study was granted by Austin Health HREC (No. H2012/04518). The approved application 
was then endorsed by RMIT University HREC. 
 
5.2.5 Criteria for inclusion in the study 
Participants considered to participate in the study were adults deemed to require endoscopy 
procedures for clinical indications (such as for the diagnosis of intestinal diseases) purposes. 
The participants were divided into two groups as follows: IBD patients who were suffering 
from either CD or UC, and control participants (those who were undergoing endoscopic 
surveillance for family history of colorectal cancer or polyps, or a personal history of colonic 
polyp). 
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5.2.6 Sample collection 
Participants were given relevant written information on this study, purpose, risks and 
potential benefits, and signed a consent form prior to sample collection. This study involved 
collection of intestinal biopsies, stool, blood and gum samples from each participant at the 
same session as the endoscopy procedure. 
Standard sized of intestinal biopsies (3-5 mm) were collected from different sites of the 
gastrointestinal tract during the endoscopy procedure. In most of the participants, samples 
were collected from seven intestinal sites: terminal ileum, caecum, ascending colon, 
transverse colon, descending colon, sigmoid colon and rectum (Figure 5.1). For a few 
participants, two other sites (duodenum and stomach) were also included as shown in Figure 
5.1. The biopsies were taken by endoscopy using standard procedures; clean washed forceps 
was used between each biopsy of each participant (Figure 5.1). The collected biopsy was then 
kept in a sterile container containing CB in ice. 
Faecal samples were aspirated by the endoscopy instrument during the procedure and 
collected into sterile containers. Gum samples were collected during the endoscopy session 
using the Copan E-swabs (Copan Italia, Italy). Blood samples were collected through a 
cannula inserted during the procedure as part of colonoscopy preparations. The blood sample 
was collected into a sterile tube without anticoagulants. 
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Figure  5.1: Anatomic sites of the intestinal biopsies collected from participants enrolled 
in the study. Biopsies were collected by endoscopy. The right photo shows the standard 
forceps for biopsy collection (Wogahn 2015). Sites 1-7 are for the intestinal biopsies 
collected routinely by endoscopy from most of the participants while sites 8-9 were stomach 
and duodenum biopsies, which were only collected from four participants by gastroscopy 
(VanAmburg 2014). 
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5.2.7 Sample coding 
The participants’ information was collected at Austin Health and was specifically labelled to 
be re-identifiable only by Austin Health’s staff. Austin Hospital codes and patient names 
were not provided in this study. Instead, codes were used to refer to Austin Hospital (AUS) 
such as, stool (S), biopsy (B), gum samples (G) and blood (BO). The bacterial isolates were 
designated with lower case letters as a, b, c. For example, specimens from participant 1 and 
isolates were AUS1-Sa, AUS1-Ba and AUS1-Ga, respectively. 
 
5.2.8 Processing of clinical samples in the laboratory 
All procedures on collected samples were performed in a class II biological safety cabinet. 
I. Intestinal biopsies 
In general, each fresh biopsy (immediately after the collection) was cut by a new sterile 
scalpel into several parts (3-4 parts) as following: 
1. Part 1: was used for DNA extraction to detect C. concisus DNA. 
2. Part 2: was cultured directly onto HBA medium by streaking to isolate viable C. 
concisus (Figure 5.2). 
3. Part 3: was inoculated into enrichment broth (3 ml Ham’s F-12 with 10 µl/ml 
vancomycin) to isolate C. concisus as described by Kaakoush et al. (2011b) (Figure 
5.2). 
4. Part 4: any extra material left from the biopsy was stored in -80°C. 
Parts 2 and 3 cultures were incubated for 48 h under C. concisus growth conditions as stated 
in section 2.4.2. After the incubation of part 3 cultures, 200 µl of the broth was introduced 
onto a cellulose acetate filter (0.65 µm) placed on HBA with 10 µl/ml vancomycin. The filter 
was kept for 45-60 min to allow C. concisus to pass through then it was carefully removed 
and the plates were streaked and incubated as described in section 2.4.2. 
132 
 
II. Gum samples 
In this study, ‘the Cape Town protocol’ described by Lastovica et al. (2000) for C. concisus 
isolation from faecal samples was modified and used for C. concisus isolation from gum 
samples as follows: approximately a 100 µl of homogenised liquid medium from the Copan 
E-swab was added onto a cellulose acetate filter (0.65 µm) placed onto HBA (three HBA 
plates were prepared for each swab using a total of 300 µl of the liquid medium). The filters 
were removed and discarded after 45-60 min (Figure 5.2). The inoculated plates were 
incubated as explained in section 2.4.2. The remaining 400 µl of the E-swab liquid medium 
was used for DNA extraction to detect C. concisus DNA. 
III. Faecal samples 
Faecal samples were treated based on their consistency to retrieve C. concisus by culture. 
Semi-solid samples were liquefied in Columbia broth and were diluted at ~1:3; whereas, 
liquid samples were not diluted. Each sample was cultured onto three HBA plates by adding 
~150 µl onto cellulose acetate filter (0.65 µm) placed onto a HBA plate for 45-60 min to 
allow the bacterium to swim through the filter to the HBA (Figure 5.2) as described in ‘Cape 
Town protocol’ (Lastovica et al. 2000). The plates were incubated as described previously in 
section 2.4.2 for growing C. concisus. One hundred and fifty milligram from the remaining 
faecal sample was used for DNA extraction. 
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Figure  5.2: Processing strategy of collected biopsies, faecal and gum samples for 
isolation of C. concisus. Faecal specimens were cultured following the ‘Cape Town 
protocol’ by filtration onto HBA (horse blood agar). The ‘Cape Town protocol’ was modified 
and used to isolate C. concisus from gum samples. Intestinal biopsies were cut to 4 pieces. 
The first and second pieces were cultured directly onto HBA and into Ham’s F-12 medium. 
The third piece was used for DNA extraction. The fourth piece was stored at -80. Then after 2 
days incubation, Ham’s F-12 medium contained bacterial growth was filtrated onto HBA. 
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I. Blood 
Blood samples were allowed to clot and then centrifuged at 2000 g for 10 min to collect the 
serum, which was stored at -80°C. The serum was not included in this study because of time 
limitations. 
 
All cultured HBA plates (from biopsies, faeces and gum samples) were incubated for 2-4 
days; then examined to detect any suspected C. concisus colonies. Each suspected pure 
colony was subcultured on a HBA plate to propagate the bacterial isolates using the 
identification tests stated in section 2.4.3 and for DNA extraction for PCR confirmation. 
The identity of the obtained C. concisus isolates was confirmed by Multiplex PCR (m-PCR) 
as previously described by Huq et al. (2014). In the m-PCR, four primer sets including 
(C412-F/C1288-R, Pcisus (5 & 6), HipO-F/HipO-F and CC18F/CC519R) were used to detect 
Campylobacter genus, C. concisus, C. jejuni and C. coli, respectively (Table 2.2). The m-
PCR protocol was performed as described in section 2.7. 
DNA extraction from intestinal biopsies and gum samples was performed using the ‘Isolate II 
Genomic DNA kit’ (Bioline, Australia), while DNA extraction from faecal samples was done 
using the ‘Isolate Faecal DNA Kit’ (Bioline, Australia) following the manufacturer’s 
instructions. 
 
5.2.9 Direct detection of C. concisus in the clinical samples by PCR 
5.2.9.1 DNA estimation 
The DNA quantity of each sample was standardised by diluting the DNA in nuclease free 
water (Bioline) prior to performing PCR. In each 25 µl PCR reaction, 40 ng DNA was used.  
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5.2.9.2 PCR conditions 
C. concisus DNA was detected using nested PCR (two step) that was described by Man et al. 
(2010b). The two primer sets were the Campylobacter genus-specific primer set (C412F and 
C1228 R for PCR step I) and C. concisus species-specific primer set (Concisus F and 
Concisus R for PCR step II) (Table 2.2). The amplification protocol was achieved by two 
steps as follows: 
PCR Step I 
This step was performed as described by the method of Linton et al. (1996) which amplified 
an ~800 bp fragment of the 16S rDNA gene using the primer set C412F and C1228. 
PCR Step II 
This step was performed as described by Man et al. (2010b) by amplification of a 560 bp 
fragment inside the 16S rDNA gene using the Concisus-F and Concisus-R primer set. 
The sequences of the primer sets C412F/C1228R and Concisus-F/Concisus-R are described 
in Table 2.2. PCR I and II conditions as they were described by Man et al. (2010b). 
 
5.2.10 Genomic typing of C. concisus isolates obtained from clinical samples 
Determination of C. concisus genomospecies A or B was as described by Istivan et al. (2004) 
and detailed in section 3.2.2. 
5.2.11 Detection of genomospecies B directly in the collected clinical samples 
A new nested PCR technique (GB-PCR) was developed to detect genomospecies B directly 
from clinical samples. GB-PCR was designed to amplify the cjaC region. The first PCR step 
(GB-PCR1) was to amplify 800 bp region of cjaC using primer set I; then the second step 
PCR (GB-PCR2) was to amplify 300 bp (inside the 800 bp region of cjaC) using primer set 
II. The sequences and the locations of these primer sets (I and II) were described in Table 2.2. 
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GB-PCR1 reactions were performed in a volume of 25 µl using 5 pmol of each primer 
(GeneWorks, Australia), using the ‘MyTaqTMDNA’ Polymerase (Bioline, Australia). The 
reaction mix contained 1 µM of deoxy-nucleotidetriphosphates mixture, 3 mM MgCl2, 0.7 U 
of Taq polymerase, and 40 ng of the extracted DNA. Thermal cycling conditions were as 
follows: 2 minutes at 95ºC, thirty cycles of 15 seconds at 94°C, 15 seconds at 54°C and 30 
seconds at 72°C, followed by the final extension of 7 min at 72°C. 
GB-PCR2 reactions were performed as above except for the DNA template concentration, 
which was 1 µl from PCR1 for biopsies and faecal samples, while in gum samples 1 µl was 
used after a dilution of 1:100 (as C. concisus DNA concentration is very high in gum samples 
compared to other samples). Thermal cycling conditions were as follows: 2 minutes at 95°C, 
forty cycles of 15 seconds at 94°C, 15 seconds at 64.9°C and 30 seconds at 72°C, followed 
by the final extension of 7 min at 72°C. 
 
5.2.12 Detection of zot in the C. concisus isolates obtained from clinical samples 
The PCR technique was performed as described in section 3.2.5 using ZoT primer set 
(Kalischuk et al. 2011) to amplify (355 bp) zot. Then for zot sequencing, genomic DNA was 
subjected to another PCR using primer set ZoT-F/ZotA2-R to amplify 1055 bp of the gene 
sequence as described previously by Mahendran et al. (2013) and stated in Table 2.2. PCR 
conditions were described in sections 2.7. The PCR products were purified and prepared for 
DNA sequencing as described in section 2.8. 
 
5.2.13 Detection of zot directly in clinical samples by nested PCR 
A new nested PCR (Z-PCR) technique was developed to detect zot directly from clinical 
samples in two steps. Two primer sets were designed to amplify zot. In the first PCR step (Z-
PCR1) the primers were ZoT-F and ZotA2-R (Table 2.2
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amplify a 1055 bp amplicon (Kalischuk et al. 2011; Mahendran et al. 2013). In the second 
PCR step (Z-PCR2) primer set (ZotB) was designed in this study to amplify 300 bp of zot 
(Table 2.2). 
The Z-PCR1 reaction was performed in a volume of 25 µl using 10 pmol of each primer 
(GeneWorks, Australia), using the ‘MyTaqTMDNA’ Polymerase (Bioline, Australia). The 
reaction mix contained 1 µM of deoxy-nucleotidetriphosphates mixture, 3 mM MgCl2, 0.7 U 
of Taq polymerase, and 40 ng of DNA extracted from each clinical sample. Thermal cycling 
conditions were as follows: 2 minutes at 95°C, thirty cycles of 30 seconds at 94°C, 30 
seconds at 52°C and 2 min at 72°C, followed by the final extension of 7 min at 72°C. 
The Z-PCR2 reaction was performed as stated in PCR2 in section 5.2.11 except for the DNA 
template, which was 1µl from Z-PCR1. Thermal cycling conditions were as follows: 2 
minutes at 95°C, forty cycles of 30 seconds at 94°C, 30 seconds at 58°C and 1 min at 72°C, 
followed by the final extension of 7 min at 72°C. 
 
5.2.14 Characterisation of the cjaC flanking region in C. concisus isolates 
Detection of the DNA region between cjaC and its adjacent gene (CCC13826_0962) which 
encodes for a hypothetical protein was performed using primer set VI as described in section 
3.2.4. This was undertaken because some C. concisus isolates from genomospecies B were 
found to have different nucleotide sequences as indicated in chapter 3 and were allocated into 
3 distinctive groups. PCR conditions and protocol were also described in section 2.7. 
 
5.2.15 SDS-PAGE to investigate the similarity or differences between C. concisus 
oral and enteric isolates obtained from the same participant 
Whole cell lysates for SDS-PAGE were prepared to investigate the relatedness between C. 
concisus isolates obtained from gum, faeces and intestinal biopsy samples collected from the 
138 
 
same participant at the same session. The SDS-PAGE technique was undertaken as described 
in section 2.13. 
SDS-PAGE was used to compare the protein profiles obtained from multiple isolates from 
different sites of the same patient. Although diversity of DNA sequence among different 
isolates was demonstrated, the differences may not be translated into differences in protein 
profiles, as some could be silent mutations. C. concisus isolates were also found to be 
genetically heterogeneous as shown in chapter 3. The use of SDS-PAGE profiles might 
therefore show less dissimilarity between the isolates, which may give a better view on the 
relatedness between isolates colonising different sites of the same patient at the same time. 
 
5.2.16 Data analysis 
Statistical analysis was performed with GraphPad Prism 6 software (USA) using Chi-square 
(2-tailed test) or the Fisher’s exact test (2-tailed test) to calculate P values between IBD 
patients and control participants. Two-way ANOVA was used for the comparison of the 
survival rate in between the strains of C. concisus. A value of P <0.05 was considered 
significant. The NCBI data-base site was used to align and find the tested DNA regions and 
amino acid sequences. The Clone manager suite software was used for the alignment of 
sequences. MEGA software was used for the tested gene sequence alignment and for 
generating phylogenetic trees by the neighbour-joining dendrogram (Felsenstein 1989). 
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5.3 Results 
5.3.1 Assessment of the effects of the PicoPrep on C. concisus growth 
No zone of inhibition was observed around the discs with different concentrations of the 
PicoPrep. Therefore, it was concluded that the PicoPrep had neither bacteriostatic nor 
bactericidal properties against C. concisus isolates in vitro at ≤124 mg/ml and would not be 
expected to interfere with isolation of C. concisus from the intestinal samples in this study. 
 
5.3.2 Survival of C. concisus in the specimen transport conditions at 4°C 
The recovery rate of C. concisus ATCC 51562 was log10 8.05 and log10 7.83 for C. concisus 
ATCC 51561 at the start (0 h) (P >0.05). Furthermore, the bacterial number recovered for 
both strains was not affected significantly by 7 h storage at 4°C compared to the starting 
inoculum (P >0.05). However, the number was reduced significantly after 7 h for C. concisus 
ATCC 51562 and after 24 h for C. concisus ATCC 51561 compared to the starting inoculum 
(P <0.05) (Figure 5.3). Thus, it was concluded that the number of C. concisus recovered was 
not significantly reduced during the first 7 h storage at 4°C. In summary, the recovery of C. 
concisus from clinical samples was not significantly affected for ≤7 h for either 
genomospecies A or B, enabling reasonable time for clinical sample collection, transport on 
ice and processing. 
The comparison in the survival rate between the two strains over 360 h storage at 4°C 
revealed that there was no statistically significant difference in the recovery rate (P >0.05) 
during the first 48 h storage. However, the survival rate of C. concisus ATCC 51561 was 
reduced significantly compared to C. concisus ATCC 51562 between 120 h-360 h (P <0.05) 
(Figure 5.3). The survival of genomospecies A isolates is possibly longer than genomospecies 
B isolates. 
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Figure  5.3: Retrieval and survival of C. concisus at low/transport temperature (4°C). 
Recovery rate of C. concisus strains ATCC 51561 and 51562 suspended in CB and storage at 
4°C for 360 h. The survival of the strains at 4°C was monitored by log10 of CFU. The values 
represented by the bars are the mean of the CFU values obtained from three independent 
experiments. Error bars represent SEM. The number of stars represent the power of statistical 
significance (*: P <0.05, **: P <0.01, ***: P <0.001 and ****: P <0.0001). There was no 
significant difference in the reduction of survival number during the first 7 h for both C. 
concisus strains (ATCC 51561 and 51562). There was a significant difference between the 
two strains after 120 h (P <0.05). 
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5.3.3 Patient demographics 
Fifty one participants were enrolled in this study, including 37 IBD patients (26 CD and 11 
UC) and 14 control participants who attended the Gastroenterology clinic at Austin Health 
between August 2012 and February 2014. The average age of the IBD patients and control 
participants was 46.5±18 and 58±18 years, respectively. The average age of CD and UC was 
45±13 and 50±27 years, respectively. There was no statistically significant difference in the 
age between the patients and control participants (P =0.0963). The proportion of males with 
CD and UC was 38.5% and 54%, respectively. Additional information about the participants 
is detailed in Appendices XIX and XX. 
 
5.3.4 Sample collection 
A total of 350 gastrointestinal biopsies, 48 faecal samples and 51 gum samples were collected 
during the study (Table 5.1). Routinely, in the collection of biopsies, seven sites were 
included, which were terminal ileum, caecum, ascending colon, transverse colon, descending 
colon, sigmoid colon and rectum. In addition four biopsies were collected from stomach of a 
control participant (AUS35) and three IBD patients (AUS4, AUS10 and AUS36). Three 
duodenal biopsies were also collected from two IBD patients, (AUS22 and AUS36) and a 
control participant (AUS35) (Tables 5.1 and 5.2). Some routine biopsies could not be 
obtained because of the participants’ medical condition or surgical removal in the intestine as 
follows; three biopsies of terminal ileum (two control participants and one UC patient), seven 
caecal biopsies (CD patients), an ascending colon biopsy (CD patient), a transverse colonic 
biopsy (CD patient) and a rectal biopsy (control participant) were unavailable. Moreover, 
four faecal specimens (three IBD and a control participant) were unavailable. 
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Table  5.1: Numbers of participants and collected specimens in the study. 
 
 
 
 
 
 
 
 
Table  5.2: Number of biopsies collected from each intestinal anatomic site. 
 
 
TI: Terminal ileum. TX: transverse colon. M: male. F: female. 
 
 
 
 
 
Biopsy 
details 
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5.3.5 Detection, characterisation and further analysis of C. concisus in collected 
clinical samples 
Isolation, detection and characterisation of C. concisus in the samples were divided into four 
sections as follows: 
Section I: The prevalence of C. concisus in the collected samples was assessed using two 
techniques: conventional culture method to isolate the live bacterium, and PCR to detect the 
bacterial DNA in the clinical specimens. 
Section II: The prevalence of genomospecies A & B in the obtained C. concisus isolates from 
the clinical samples in section I. In this section also a nested PCR targeting cjaC was 
developed to investigate the prevalence of genomospecies B in the clinical samples where C. 
concisus DNA was detected (in section I). 
Section III: The prevalence of C. concisus isolates possessing zot was investigated. In 
addition, the prevalence of zot in clinical samples (in the extracted DNA of these clinical 
samples) using the developed nested PCR was assessed. Moreover, PCR products obtained 
from amplifying zot in DNA extracted from selected C. concisus isolates were sequenced and 
analysed. 
Section IV: The prevalence of different C. concisus groups based on the sequence of cjaC 
and its flanking region. A PCR technique was applied using primer set VI (as described in 
section 3.3.3.2) to amplify this region from C. concisus isolates, which were previously 
identified to be genomospecies B as this region was found to be heterogonous in this 
genomospecies. As discussed in chapter 3, this primer set was not successful in amplifying a 
PCR product in C. concisus isolates from genomospecies A. 
Section V: SDS-PAGE profiles of whole cell lysates of C. concisus isolates obtained from 
clinical samples of the same patient at the same time were compared (including intestinal 
biopsies, faeces and gum samples) to further determine the relatedness between isolates. 
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5.3.5.1 Section I: Detection of C. concisus 
The suspected 2-4 day old colonies appeared metallic in colour, 1-3 mm in diameter and 
undulate/rough/entire in shape. It was also noticed that C. concisus colonies grown at the 
same time can infrequently appear in different sizes and colours on HBA. It was observed 
that heavy mixed growth was fairly common in bacterial cultures from the biopsies and faecal 
specimens even after the filtration technique as shown in Figures 5.4 and 5.5. Each suspected 
C. concisus colony was subcultured onto HBA prior the confirmation. All C. concisus 
prospective colonies were negative for catalase, unable to grow aerobically and oxidase 
positive. 
 A. In biopsies 
In a total of 350 biopsies collected from 51 participants, only three C. concisus isolates were 
obtained from three biopsies of three different IBD patients (AUS22, AUS48 and AUS51) 
(Table 5.3 and Appendix XXI). Two isolates were obtained from 2/75 biopsies of 11 UC 
patients (the first isolate was obtained by culturing the biopsy directly onto HBA, while the 
second isolate was obtained by enrichment of the biopsy in Ham’s F-12). The third isolate 
(obtained by enrichment culture of the biopsy in Ham’s F-12) was obtained from 1/178 
biopsies collected from 26 patients with CD. No C. concisus isolates were obtained from 97 
biopsies collected from the 14 control participants. The first and second C. concisus isolates 
(AUS22-Bd2 and AUS48-Ba) were obtained from a duodenal biopsy and ascending colonic 
biopsies of UC patients (AUS22 and AUS48). The third isolate (AUS51-Bd) was obtained 
from a descending colonic biopsy of a CD patient (AUS51). This is the first reported isolation 
of C. concisus from the duodenum and ascending colon. 
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Figure  5.4: Example of mixed bacterial growth obtained from an intestinal biopsy. The 
biopsy was cultivated onto a HBA plate and incubated in microaerobic condition containing 
H2 (the growth condition of C. concisus) for 2 days. The small grey colonies (white arrows) 
were isolated and subjected to further C. concisus identification tests. 
 
 
 
 
 
Figure  5.5: Representative mixed bacterial growth obtained from a faecal sample after 
filtration technique. The sample was cultivated on a HBA plate by filtration technique (2 
days incubation in microaerobic condition containing H2). The small grey colonies were 
subjected to further tests for C. concisus identification. 
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C. concisus DNA was detected in intestinal biopsies in 29 out of 37 IBD patients (23/26 CD 
and 6/11 UC patients). In seven IBD patients (AUS1, AUS3, AUS5, AUS6, AUS7, AUS8 
and AUS13), the bacterium was detected in all seven intestinal anatomic sites. While C. 
concisus was detected in at least two intestinal anatomic sites in seven patients (AUS4, 
AUS14, AUS29, AUS36, AUS50, AUS51 and AUS52), it was only detected in a single 
anatomic site in three patients (AUS9, AUS10 and AUS39). DNA of Campylobacter spp. 
was amplified by PCR step I as stated in section 5.2.9.2 from a biopsy collected from 
transverse colon of patient AUS46 and it could not be amplified by the second PCR as stated 
in section 5.2.9.2 PCR step II. C. concisus was identified in two biopsies collected from the 
stomach and duodenum. In general, C. concisus could be detected in all of the targeted 
anatomic sites of the gastrointestinal tract and the detection rate was the highest in the 
rectum. 
In three out of the 14 control participants (AUS11, AUS30 and AUS35) C. concisus was 
detected in at least two intestinal anatomic sites. In addition, none of control participants had 
the bacterium in all collected biopsies. The highest detection rate of C. concisus was in the 
descending and transverse colon; whereas C. concisus could not be detected in the terminal 
ilium in any of control participants. 
 
B. Faecal samples 
By conventional culture techniques of faecal samples, a total of eight C. concisus isolates 
were obtained from 48 faecal specimens. Seven isolates were obtained from three IBD 
patients and one isolate was obtained from a control participant (1/12); whereas, C. concisus 
could not be isolated from faecal specimens of 11 patients with UC (0/11) (Table 5.3). To our 
knowledge, this was the first study that isolated C. concisus from faeces of adults with IBD. 
However, when molecular methods (PCR) were used the C. concisus DNA was detected in 
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faecal samples from most of the participants except five IBD patients (three CD and two UC 
patients) and four control participants. 
 
C. Gum samples 
C. concisus was isolated from the majority of the participants and the number of colonies 
varied between the participants, but in most cases several colonies were obtained from the 
same participant (1-8 isolates). A total of two hundred and five isolates were obtained from 
the gum samples of 51 participants. A total of 164 (80 %) C. concisus oral isolates were 
collected from IBD patients (115 isolates from CD and 49 isolates from UC patients) and a 
total of 41 (20%) C. concisus oral isolates were collected from control participants. C. 
concisus was isolated from 86% (32/37) of the gum samples of IBD patients [it was isolated 
in 85% (22/26) of CD patients and in 91% (10/11) of UC patients], while it was isolated from 
64% (9/14) of control participants (Appendix XXI). Therefore, based on these outcomes it 
seemed that the colonisation of C. concisus is higher in IBD patients than in control 
participants, but the difference was not statistically significant (Table 5.4). Multiple C. 
concisus isolates were obtained from the oral cavity of all the participants except two patients 
(AUS21 and AUS51) and a control participant (AUS40), which only one isolate was obtained 
(Appendix XXI). However, when molecular methods (PCR) were used, C. concisus DNA 
was detected in all collected gum samples of IBD patients while it could not be detected in 
one control participant. 
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Table  5.3: Proportion of C. concisus isolation from intestinal samples collected from 
IBD patients and control participants by culture technique. 
 
Patient groups Biopsy isolates Faeces isolates All Intestinal isolates  
IBD 8% (3/37) 5.7% (2/37) 13.5% (5/37) 
Controls 0% (0/14) 7.8% (1/13) 7% (1/14) 
Total 6% (3/51) 6.3% (3/48) 12% (6/51) 
 
 
 
 
 
Table  5.4: Proportion of C. concisus isolation from gum samples collected from IBD 
patients and control participants by culture technique. 
 
Recruits groups C. concisus isolation/participant C. concisus isolates  
IBD  86% (32/37) 80% (164/205)  
Controls 64% (9/14) 20% (41/205) 
Total 80% (41/51) 205 
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Overall, the prevalence of C. concisus as detected by PCR in intestinal biopsies was 
significantly higher in IBD patients with a proportion of 59.5% (22/37) than in control 
participants with a percentage of 21.4% (3/14) (P =0.0073) (Figure 5.6). There was no 
substantial difference in C. concisus detection rate between CD (61.5%; 16/26) and UC 
patients (54.5%; 6/11). In faeces, C. concisus prevalence was 85.3% (29/34) in IBD patients 
and was 69.2% (9/13) in control participants (P =0.237) (Figure 5.6). In the oral cavity, the 
bacterium was detected in 100% of patients with IBD, and in 92.9% of control participants, 
which was not significantly different (Figure 5.6). 
The study also looked at the prevalence of C. concisus DNA in biopsies that were collected 
from the seven anatomic sites of the intestinal tract. In all investigated intestinal anatomic 
sites, C. concisus had a higher prevalence in IBD patients than in control participants. The 
prevalence of C. concisus in terminal ilium, sigmoid colon and rectum of IBD patients was 
significantly higher than in control participants (P =0.0201, 0.0405 and 0.0188, respectively) 
(Figure 5.7). Although, the prevalence of C. concisus in all seven intestinal anatomic sites 
except the sigmoid colon was higher in CD patients than in UC patients, the difference was 
not statistically significant. C concisus could not be detected in any biopsy collected from the 
terminal ilium of control participants (Figure 5.7). 
There was a statistically significant higher detection rate of C. concisus in the biopsies and 
faecal samples by PCR than by culture technique, while in gum swabs the detection rate of C. 
concisus was not significantly different between the two methods (Figure 5.8). The 
significant difference could be due to the higher sensitivity of PCR than culture, in particular 
when the bacterium is fastidious and present in very small numbers. In addition 
campylobacters could be present in viable but non-culturable form in the intestine. 
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Figure  5.6: Detection rate of C. concisus by PCR in collected clinical samples. C. 
concisus DNA was detected in biopsies, faecal samples and gum samples of patients with 
IBD and control participants using nested PCR technique targeting the 16S rDNA gene. Bars 
represent C. concisus DNA detection rate in at least one of seven biopsies collected from 
each individual participant, while in faeces and gum swabs C. concisus detection was in one 
sample of each patient. The Fisher’s exact test (2-tailed test) was used to calculate P values. 
*: the power of significant difference as compared with control participants (controls) (P 
<0.05). C. concisus prevalence in biopsies of IBD patients was significantly higher than in 
control participants. 
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Figure  5.7: Detection rate of C. concisus by PCR in biopsies collected from seven 
intestinal anatomic sites. C. concisus DNA was detected directly in intestinal biopsies 
collected from different anatomic sites of patients with IBD and control participants using 
nested PCR targeting the 16S rDNA gene. Bars represent C. concisus DNA detection rate in 
at least one biopsy of each individual participant. The Fisher’s exact test (2-tailed test) was 
used to calculate P value. Stars are the power of significant difference as compared with 
control participants (controls) (P <0.05). The prevalence of C. concisus in intestinal biopsies 
collected from terminal ileum, sigmoid colon and rectum of IBD patients were significantly 
higher than in biopsies collected from the same sites of control participants. C. concisus could 
not be detected in the terminal ileum of control participants. 
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Figure  5.8: A comparison between the detection of C. concisus by culture and PCR in 
the collected clinical samples. C. concisus detection was by culture and by PCR in biopsies, 
faecal samples and gum swabs of patients with IBD and control participants. Culture bars 
represent C. concisus detection rate in any of seven sites of intestinal biopsy, a faecal sample 
and a gum sample of each individual participant by filtration technique. PCR bars represent 
DNA detection rate in at least one out of seven biopsies, a gum sample and a faecal sample of 
an individual participant by nested PCR. The Fisher’s exact test (2-tailed test) was used to 
calculate P values. The number of stars are the power of significant difference as compared 
with control participants (control) (*: P <0.05, **: P <0.01, ***: P <0.001 and ****: P 
<0.0001). Detection rate of C. concisus in biopsies and faecal samples by PCR was 
significantly higher than culture. 
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5.3.5.2 Section II: Molecular typing of C. concisus isolates and C. concisus DNA in 
clinical samples 
A. Genotyping of C. concisus isolates 
The results showed that the majority of the isolates were from genomospecies B (64%; 
132/205). The prevalence of genomospecies B in the oral cavity of IBD patients was 
significantly higher than in the oral cavity of control participants with a percentage of 71% 
(116/164) and 39% (16/41) respectively (P <0.0001). The prevalence of genomospecies B 
was also significantly higher in the oral cavity of IBD patients (in both CD and UC patients) 
than genomospecies A as shown in Figure 5.9 (P <0.0001). Despite the prevalence of 
genomospecies A was higher in control participants than genomospecies B, there was no 
significant difference between the two genomospecies (Figure 5.9). It was found that 23% of 
CD patients, 36% of UC patients and 21% of control participants were colonised by multiple 
genomospecies. 
The prevalence of genomospecies B isolates obtained from the intestinal specimens (biopsies 
and faeces) of IBD patients was 54% (11 isolates obtained from six participants). Participant 
AUS5 (a CD patient) had both genomospecies (six isolates) in faeces, participant AUS22 (a 
UC patient) had genomospecies A and others (AUS4, AUS47, AUS48 and AUS51) had 
genomospecies B. Thus, the majority of the participants had genomospecies B in the 
intestinal tract, as was found for the gum samples. AUS5 had both genomospecies (A & B) in 
the faeces and the gum while others had either genomospecies A or B as shown in Appendix 
XXI. 
B. Detection and typing of C. concisus genomospecies B in clinical samples 
A nested PCR was developed to amplify cjaC (GB-PCR) and used to investigate the 
prevalence of genomospecies B in the extracted DNA from biopsies, faecal samples and gum 
samples. This nested PCR was only applied on the specimens that C. concisus DNA was 
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detected previously in section 5.3.5.1. The primer sets initially were applied on several 
reference strains including C. concisus ATCC 51561, ATCC 51562, RCH3, RCH4, RCH6, 
RCH11, RCH15, RCH20, RCH26, C. mucosalis ATCC 43264 and E. coli ATCC 25922 
(Table 2.1) to confirm the specific amplification of C. concisus genomospecies B DNA as 
shown in Figures 5.10 (A and B). Then GB-PCR (cjaC nested PCR) was applied on the 
clinical specimens as demonstrated in Figures 5.11 (A and B). To confirm GB-PCR 
specificity, a random GB-PCR product obtained from biopsy of AUS7 patient (ascending 
colon) sequence showed identity of >95% to C. concisus cjaC gene of C. concisus 13826. 
Genomospecies B was detected in 35.1% (13/37) of patients with IBD (Figure 5.12). The 
highest prevalence was in descending colon, while the lowest prevalence was in transverse 
colon and ascending colon. Furthermore, genomospecies B DNA was detected in the two 
stomach biopsies collected from participants AUS4 and AUS36 respectively. In AUS36 the 
genomospecies was also detected in a duodenal biopsy. Genomospecies B was identified in 
all the gum samples of IBD patients, while it was detected in 55.9% of the faecal specimens 
of those patients (Figure 5.12). 
In the control participants, genomospecies B DNA was identified in 1/14 (7%, AUS35) 
biopsies. In addition, this genomospecies DNA was detected in 78.6% (11/14) in gum 
samples, while in faecal specimens, 23.1% (3/13) of the participants had the genomospecies 
B DNA (Figure 5.12). 
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Figure  5.9: Prevalence of genomospecies A and B in C. concisus isolates obtained from 
gum samples. Bars are C. concisus genomospecies detected by amplifying the 23S rDNA 
gene (MUC1 and CON1/CON2) from C. concisus isolates obtained from gum samples of 
IBD patients and control participants. The statistical analysis calculation (presented as stars in 
black colour) was based on the comparison between the prevalence of genomospecies A and 
genomospecies B strains in IBD patients, while the statistical analysis calculation (presented 
as stars in red colour) was based on the comparison between the prevalence of 
genomospecies A or B strains in IBD patients and in control participants (controls). Fisher’s 
exact test (2-tailed test) was used to calculate P values. Stars indicate the level of significant 
difference between genomospecies A and genomospecies B (*: P <0.05, **: P <0.01, ***: P 
<0.001 and ****: P <0.0001). The prevalence of genomospecies B isolates was significantly 
higher than genomospecies A isolates in IBD patients (P <0.0001) whilst the prevalence of 
genomospecies A isolates was higher than genomospecies B isolates in control participants, 
but it was not statistically significant differences. In addition, the prevalence of 
genomospecies A isolates was significantly higher in control participants than in the IBD 
patients; however, the prevalence of genomospecies B isolates was significantly higher in 
IBD patients when compared to the control participants. 
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(A) 
 
 
 
(B) 
 
Figure  5.10: Application of cjaC by the developed cjaC nested PCR for typing C. 
concisus genomospecies B reference strains. The PCR products obtained from amplifying 
cjaC from genomic DNA as a template. In (A), PCR products (800 bp) were obtained from 
the amplification of cjaC by the first step nested PCR using primer set I. In (B), PCR 
products (300 bp) were obtained from the amplification of the first step PCR product using 
primer set II. PCR products were loaded on a 1.5% (w/v) agarose gel for electrophoresis. The 
gel was then stained in ethidium bromide and visualised by a UV trans-illuminator. Lanes 1-
9: C. concisus strains ATCC 51561, ATCC 51562, RCH3, RCH4, RCH6, RCH11, RCH15, 
RCH20 and RCH26, respectively. Lanes 10-12: C. mucosalis (ATCC 43264), E. coli (ATCC 
25922) and no template control. Genomospecies A strains were ATCC 51562, RCH3, RCH4, 
RCH15, RCH20 and RCH26, while genomospecies B strains were ATCC 51561, RCH6 and 
RCH11. Lane 13: lambda DNA marker. 
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(B) 
 
Figure  5.11: Detection of C. concisus genomospecies B in clinical samples using the cjaC 
nested PCR. The PCR products obtained from amplifying cjaC from the clinical samples. In 
(A), PCR products (800 bp) were obtained from the amplification of cjaC by the first step 
nested PCR using primer set I. In (B), PCR products (300 bp) were obtained from the 
amplification of the first step PCR product using primer set II. PCR products were loaded on 
a 1.5% (w/v) agarose gel for electrophoresis. It was then stained in ethidium bromide and 
visualised by a UV trans-illuminator. Lanes 1-9: AUS7 specimens (biopsies of terminal 
ileum, caecum, ascending colon, transverse colon, descending colon, sigmoid colon and 
rectum; then, the faecal and gum samples). Lanes 10, 12, 13, 14, 15, and 16: AUS8 
specimens (biopsies of terminal ileum, descending colon, sigmoid colon and rectum; then the 
faecal and gum samples). Lanes 17-20: ATCC 51561, ATCC 51562, RCH11, and no 
template control. Lane 11: lambda DNA marker. 
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Figure  5.12: Detection rate of C. concisus genomospecies B DNA in clinical samples by 
the cjaC nested PCR. Bars represent the detection rate of C. concisus genomospecies B in 
extracted DNA from biopsies, faecal samples and gum samples collected from patients with 
IBD (CD and UC) and control participants (controls) by the developed nested PCR to amplify 
cjaC. The Fisher’s exact test (2-tailed test) was used to calculate P values. The number of 
stars are the power of significant difference of genomospecies B detection in IBD patients 
compared to the control participants (P <0.05). The prevalence of genomospecies B in all 
clinical samples (biopsies, gum samples and faecal samples) of IBD patients was 
significantly higher than in the control participants. 
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In summary, in section II genomospecies B isolates were predominant in all clinical samples 
of IBD patients, while in control participants genomospecies A isolates were predominant. In 
the oral cavity of IBD patients, the isolation of C. concisus strains belonging to 
genomospecies B was significantly higher than genomospecies A (P <0.0001). In contrast, 
the majority of oral isolates from the control participants were from genomospecies A (P 
=0.0766). Moreover, the detection of genomospecies B DNA in the clinical samples showed 
that the prevalence of genomospecies B was significantly higher in IBD patients than in the 
control participants, [biopsies (P =0.0456), faeces (P =0.0438) and gum samples (P= 0.003)]. 
Therefore both techniques demonstrated that in all clinical samples of IBD patients, 
genomospecies B was present in a higher prevalence than in control participants, which was 
statistically significant indicating the possible association between genomospecies B and 
IBD. 
 
5.3.5.3 Section III: Detection of zot in C. concisus isolates and in clinical samples 
A. Detection of the zot gene in C. concisus using one step PCR 
A PCR technique described in section 3.2.5 was performed to amplify zot in the C. concisus 
isolates (Kalischuk et al. 2011). The gene was only amplified from eight isolates obtained 
from the gum samples of five participants (3 IBD patients and 2 controls) (Table 5.5). The 
gene could not be amplified from the intestinal isolates. The majority of the isolates (75%, 
6/8) that possessed zot belonged to genomospecies A (Table 5.5). Overall, the proportions of 
C. concisus isolates that had zot in IBD patients and control participants were 3.1% (5/164) 
and 7.3% (3/41) respectively, which were not statistically significant. 
B. Detection of zot in clinical samples by nested PCR 
The nested PCR was applied to all clinical samples for which C. concisus DNA could be 
amplified (section I), an example for zot amplification in biopsies, faecal and gum samples by 
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nested PCR is shown in Figure 5.13 (A and B). The detection rate of zot in the clinical 
samples was 45.1% (23/51): 12.1% (11/91) of the biopsies, 40% (20/50) of gum samples and 
23.7% (9/38) of the faecal samples. There was no significant difference in the detection rate 
of zot in biopsies of IBD patients (8.1%) and control participants (7.1%). In addition, there 
was no significant difference in the detection rate of zot in gum samples of IBD patients 
(37.8%) and of the control participants (42.9%), (Figure 5.14). 
As C. concisus possessing zot could not be isolated from biopsies or faecal samples, a 
comparison in the detection rate of zot was performed between the culture and PCR 
techniques in the gum samples. The detection rate of zot in the gum samples of IBD patients 
by PCR (37.8%) was significantly higher than the detection rate by culture technique (8%) (P 
=0.0047). The detection rate of zot in the gum samples of the control participants by PCR 
was higher than by culture technique, but the difference was not statistically significant (P 
=0.6351 and P =0.2087, respectively) (Figure 5.15). 
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Table  5.5: C. concisus isolates obtained from gum samples possessing zot. 
 
Isolates no. G. species Recruit group 
AUS7-Ga A UC 
AUS23-Gc B CD 
AUS23-Gd A CD 
AUS26-Ga B Control 
AUS31-Ga A UC 
AUS31-Gb A UC 
AUS47-Ga A Control 
AUS47-Gb A Control 
Total 8 isolates 5 recruits 
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(A) 
 
 
 
(B) 
 
Figure  5.13: Detection of zot in clinical samples using the zot nested PCR. The clinical 
samples were intestinal biopsies, gum samples and faecal samples. In (A) the amplification of 
zot from extracted DNA of clinical samples by the first step nested PCR using primer set 
ZoT-F/ZotA2-R to amplify 1055 bp. In (B) the amplification of zot from the first step PCR 
by the second step nested PCR to amplify 300 bp of zot using primer set ZotB. PCR products 
were loaded on a 1.5% (w/v) agarose gel for electrophoresis. It was then stained in ethidium 
bromide and visualised by a UV trans-illuminator. Lanes: 1-9 AUS7 specimens (biopsies of 
terminal ileum, caecum, ascending colon, transverse colon, descending colon, sigmoid colon 
and rectum; then the faecal sample and gum sample). Lanes: 10-15: AUS8 specimens 
(biopsies of terminal ileum, descending colon, sigmoid colon and rectum; then the faecal 
sample and gum sample). Lane16: gum sample of AUS9. Lane 17: RCH6. Lanes 18 and 19: 
ATCC 51561 and no template control. Lane 20: lambda DNA marker. 
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Figure  5.14: Detection rate of zot directly in the clinical samples by the zot nested PCR. 
Bars represent detection rate of zot in the extracted DNA from the clinical samples. The 
clinical samples were biopsies, faecal samples and gum samples collected from patients with 
IBD (CD and UC) and the control participants (controls). The data shows that there is no 
significant difference in the detection rate of zot between the IBD patients and the control 
participants in any of the clinical sample. 
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Figure  5.15: A comparison between the detection rate of zot directly in gum samples by 
PCR and in isolates obtained by culture of gum samples. Bars represent detection rate of 
zot in C. concisus isolates obtained from gum samples and directly in the gum samples by 
PCR. The gum samples were collected from patients with IBD (CD and UC) and control 
participants (controls). The Fisher’s exact test (2-tailed test) was used to calculate P values. 
The number of stars are the power of significantly different detection rates between culture 
and PCR techniques (P <0.05). In gum samples of IBD patients, there is a significant 
difference between the detection rate of zot by PCR directly from the samples and cultured C. 
concisus. 
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C. Sequence analysis of the zot gene from C. concisus isolates  
One oral isolate from each participant was selected with the exception of two isolates 
belonging to different genomospecies (A and B) were obtained from participant AUS23. The 
PCR products of zot gene obtained from four isolates (AUS7-Ga, AUS23-Gc, AUS23-Gd and 
AUS26-Ga) were sequenced and used in the analysis. The PCR products from RCH6, 
RCH11 and RCH26 (previously detected to possess the gene in section 3.3.4) as well as from 
mention above isolates, which also possessed zot were sequenced. 
Useable sequence was obtained from a 966 bp region of zot gene for each of the C. concisus 
isolates. The sequenced region (5´-3´) started at locus number 91 and terminated at position 
number 1056 based on published C. concisus 13826 sequence. Of seven other isolates 
available via WGS on the NCBI data-base site only UNSW3 and UNSWCS were found to 
possess zot. Alignment of the 966 bp of the zot sequence was performed using Clone manager 
suite software and the clinical isolates were compared to the sequence of the published strains 
(C. concisus 13826, UNSWCS and UNSW3). The results of this alignment are shown in 
Appendix XXII. From the ten isolates, two (13826 and RCH6) had identical sequences and 
the identity for another two was ≥94% (AUS23-Gc; 97% and AUS26-Ga; 94%). The identity 
for the remaining six isolates was between 87%-89%. There were at least 75 positions in zot 
where there were nucleotide substitutions in more than two strains (Appendix XXII). 
The identity of zot sequences in genomospecies A and B was investigated in seven isolates 
from genomospecies B (13826, UNSWCS, UNSW3, RCH6, RCH11, AUS23-Gc and 
AUS26-Ga) and three isolates (RCH26, AUS7-Ga and AUS23-Gd) belonging to 
genomospecies A. The identity was higher between the isolates from genomospecies A 
(>94%) than those belonging to genomospecies B (>88%). 
The amplified nucleotide sequences of zot from ten isolates were also compared by the 
neighbour-joining dendrogram (Figure 5.16). Two main groups (I and II) could be generated 
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by this method (Figure 5.16). Each group was classified into two subgroups (Ia, Ib, IIa and, 
IIb) based on the generated clades. Group I included genomospecies B and genomospecies A 
isolates; however, genomospecies B isolates (UNSWCS, RCH11 and UNSW3) formed 
subgroup Ia, while all genomospecies A (RCH26, AUS7-Ga and AUS23-Gd) were allocated 
in subgroup Ib. Other genomospecies B isolates (13826, RCH6, AUS26-Ga and AUS23Gc) 
were allocated to group II. Surprisingly; subgroup IIa consisted of only one isolate from the 
gum of a control participant (AUS26-Ga) (Figure 5.16). 
The nucleotide sequence of zot in the ten tested C. concisus isolates were translated into 
amino acid sequences and aligned to investigate whether the nucleotide polymorphisms had 
caused major changes in the protein sequence. The DNA sequence (966 bp) resulted in 
translation of 322 amino acids (from amino acid number 24-348). Amino acid sequence 
variation was observed between all test isolates and C. concisus 13826 reference strain except 
that the sequence of RCH6 was identical to that of C. concisus 13826. The other isolates 
identities ranged from 89%-99% regardless of whether they belonged to genomospecies A or 
B. Amino acid changes occurred at 4 to 35 loci per isolate in compared with C. concisus 
13826 sequence as presented in Table 5.6. 
A neighbour-joining dendrogram based on the amino acid sequences were showed similar 
results to those obtained by DNA sequence analysis; all isolates were assembled into two 
main groups and each group into two subgroups (Figure 5.17). 
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Figure  5.16: Neighbour-joining dendrogram based on zot nucleotide sequences of C. 
concisus isolates. UNSW3, UNSWCS and 13826 are C. concisus whole genome sequenced 
strains (Accession No. ANNE00000000, ANNG00000000 and CP000792.1). RCH6, RCH11 
and RCH26 are faecal isolates from children with gastroenteritis. AUS7-Ga, AUS23-Gc and 
AUS23-Gc are oral isolates from patients IBD. AUS26-Ga is an oral isolate form a control 
participant. *: genomospecies A isolates. I and II: C. concisus isolates groups generated by 
the dendrogram. a and b refer to subgroups generated by the dendrogram. 
 
Figure  5.17: Neighbour-joining dendrogram based on amino acid sequences of zot in C. 
concisus isolates. UNSW3, UNSWCS and 13826 are C. concisus whole genome sequenced 
strains (Accession No. ANNE00000000, ANNG00000000 and CP000792.1). RCH6, RCH11 
and RCH26 are faecal isolates from children with gastroenteritis. AUS7-Ga, AUS23-Gc and 
AUS23-Gc are oral isolates from patients IBD. *: genomospecies A isolates. I and II: C. 
concisus isolates groups generated by the dendrogram. a and b refer to subgroups generated 
by the dendrogram. 
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Table  5.6: Alignment of the amino acid sequences of zot in oral, faecal and reference C. 
concisus strains versus C. concisus 13826. 
 
 
Strain  
 
 
Isolate 
source 
 
Disease 
 
Genom. 
species 
Amino acid (aa) changes no. 
 
Similar 
aa  
Mismatch 
aa 
Total 
Loci no. 
Identities 
% 
UNSW3 Intestine CD B 14 21 35 89 
UNSWCS Intestine gastroenteritis B 14 20 34 89 
RCH6 Intestine gastroenteritis B 0 0 0 100 
RCH11 Intestine gastroenteritis B 14 19 33 90 
RCH26 Intestine gastroenteritis A 15 19 34 89 
AUS7-Ga Gum UC A 15 19 34 89 
AUS23-Gc Gum CD A 3 1 4 99 
AUS23-Gd Gum CD B 15 19 34 89 
AUS26-Ga Gum Control B 7 10 17 95 
 
UNSW3, UNSWCS and 13826 are C. concisus strains, which their whole genome sequences are available in the 
NCBI data-base site under Accession No. ANNE00000000, ANNG00000000 and CP000792.1. RCH6, RCH11 
and RCH26 are faecal isolates from children with gastroenteritis. AUS7-Ga, AUS23-Gc and AUS23-Gc are oral 
isolates from IBD patients. AUS26-Ga is an oral isolate from a control participant. 
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In summary, the DNA and amino acid sequence analysis of zot revealed that the gene was 
extremely heterogeneous, which may have an effect on the protein stracture. The differences 
in the sequences were mainly linked to genomospecies type. One isolate that possessed zot 
was from a control participant. The isolate occupied a unique phylogenetic position 
(subgroups IIa) when compared to the other clinical isolates, possibly resulting in a different 
gene product compared to IBD patient isolates. 
 
5.3.5.4 Section IV: Detection of cjaC and its flanking region in genomospecies B isolates  
As the majority of C. concisus isolates detected in clinical samples were from genomospecies 
B (Figure 5.9), a PCR was used to type the isolates. Primer set VI was able to type C. 
concisus isolates from genomospecies B into three different groups as follows: in group I 
isolates, the PCR product size was 600 bp (as predicted) while in group II isolates, the PCR 
product size was 1700 bp. In group III (majority of the isolates), there was no PCR product. 
The prevalence of group II isolates was significantly higher in control participants than in 
patients IBD (P <0.002), but there was no significant differences in the prevalence of groups 
I and III between control participants and patients IBD (Figure 5.18). This finding supports 
the previous results in section 3.3.3.2 showing that group II could be detected only in an oral 
isolate (O11) obtained from a healthy individual. Therefore, group II isolates could be more 
likely to colonise the oral cavity of healthy volunteers and might be good candidates to be 
used as C. concisus non-aggressive isolates in laboratory experiments. 
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Figure  5.18: Screening of cjaC and its flanking region in genomospecies B isolates 
obtained from gum samples. The detection rate of C. concisus isolates groups generated 
from amplifying the cjaC gene and its flanking region (CCC13826_0962). The bars are the 
detection rate of the cjaC gene and its flanking region by PCR using primer set VI in C. 
concisus isolates obtained from gum samples collected from patients with IBD (CD and UC) 
and control participants (controls). The number of stars are the power of significant 
difference in the patients as compared to control participants (<0.05). Group I: the region was 
amplified from the isolates DNA with a size of 600 bp. Group II: the region was produced 
from the isolates DNA with a large size of 1700 bp. Group III: the region could not be 
amplified from the isolates DNA. The prevalence of group II in control participants was 
significantly higher than in IBD patients. 
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5.3.5.5 Section V: Investigation of the similarity between oral and intestinal C. concisus 
isolates obtained from the same participant using SDS-PAGE 
C. concisus was isolated from both gum and intestinal samples of six participants (11.6%) 
(Table 5.7 and Appendix XXI). The similarity between the isolates from the same participant 
was investigated using the whole cell lysates protein (WCLP) profile analysis using SDS-
PAGE. Thirty-nine bacterial isolates (22 oral and 11 intestinal) and six reference strains, 
including two C. concisus strains (ATCC51561 and 51562), three other campylobacters (C. 
mucosalis ATCC 43264, C. jejuni 81116, C. coli NCTC 11366) and E. coli ATCC 25922 
were used in this study (Table 5.7). 
All seven C. concisus isolates obtained from AUS4 (an IBD patient) showed identical WCLP 
patterns. This result may indicate that AUS4-Sf (isolated from faeces) translocated from the 
oral cavity to the gastrointestinal tract (Figure 5.19). Similar results were shown by WCLP 
patterns of C. concisus isolates obtained from AUS5 (an IBD patient) as the oral and faecal 
isolates showed identical WCLP patterns (Figure 5.20). On the other hand, the C. concisus 
isolates from intestinal biopsies of AUS22 (an IBD patients), AUS48 and AUS51 showed 
different WCLP patterns from the oral isolates, although they belonged to the same 
genomospecies [Figure 5.21 (lane 6) and Figure 5.22 (lanes 5 and 7)]. In AUS47 (a control 
participant), WCLP patterns of each isolate showed distinguishable patterns although all 
belonged to the same genomospecies (Figure 5.23). 
WCLP analysis was performed for bacterial reference strains (C. concisus ATCC 51561, 
ATCC 51562, C. mucosalis ATCC 43264, C. jejuni 81116, C. coli NCTC 11366 and E. coli 
ATCC 25922) to visualise the variations through C. concisus strains (genomospecies A and 
B) and, common isolated bacteria from the gastrointestinal tract including other 
campylobacters and E. coli. All the bacterial strains demonstrated unique WCLP patterns 
(Figure 5.24). None of the WCLP patterns of C. concisus clinical isolates matched WCLP 
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patterns of bacterial species other than C. concisus. The highest variable area for the WCLP 
in the gels was located between 25-50 KD. 
Collectively, C. concisus isolates from biopsies showed unique WCLP patterns when 
compared to the orals isolates. WCLP patterns of faecal isolates were generally similar to 
these at the oral isolates of the same patients (AUS4 and AUS5), except for isolates from 
AUS47 (a control participant). It is interesting that the WCLP patterns of the faecal isolates 
was very similar to WCLP patterns of ATCC 51561 strain (previously isolated from the 
faecal sample of a healthy control). It is thus possible that isolates from biopsies could 
produce certain proteins that facilitate their colonisation in the intestinal tract. 
It is noteworthy that isolating C. concisus from the oral cavity was not linked to the ability to 
isolate it from intestinal sites as in some participants one isolate yielded from the gum sample 
and biopsy. However in other participants, several C. concisus colonies obtained from the 
gum sample, but C. concisus could not be isolated from the biopsies or faeces. In addition C. 
concisus isolates that yielded PCR products with primer set VI often demonstrated individual 
protein patterns, for example AUS47-Gc belonged to group I, while AUS51-Bd fitted into 
group II. Further work needs to be done to include more C. concisus isolates belonging to 
each group based on using primer set VI, to investigate whether they have the same WCLP 
patterns or different patterns. 
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Table  5.7: C. concisus isolates from intestinal and oral samples of the same participant 
and used in whole cell protein profile analysis. 
Patient 
code 
Isolates Source G.S  Patient 
code 
Isolates Source G.S  
AUS4 
(UC) 
AUS4-Ga Gum B AUS22 
(UC) 
 
AUS22-Ga  Gum B 
AUS4-Gc Gum B AUS22-Gb  Gum A 
 AUS4-Gk  Gum B AUS22-Gc  Gum B 
AUS4-Gg  Gum B AUS22-Gd   Gum B 
AUS4-Gm   Gum B AUS22-Gf   Gum B 
 AUS4-Gn Gum B AUS22-Bd2  Biopsy A 
AUS4-Sf Faeces B AUS47 
(Control) 
AUS47-Ga Gum A 
AUS5 
(CD) 
 
 
 
 
 
 
AUS5-Ga  Gum A AUS47-Gb Gum A 
AUS5-Gc  Gum A AUS47-Gc Gum B 
AUS5-Gd  Gum B AUS47-Sa Faeces B 
AUS5-Ge    Gum B AUS48 
(UC) 
AUS48-Ga Gum B 
AUS5-Sa   Faeces A AUS48-Gb Gum B 
AUS5-Sc  Faeces A AUS48-Gd Gum B 
AUS5-Sf   Faeces A AUS48-Ge Gum B 
AUS5-Sd    Faeces B AUS48-Ba Biopsy B 
AUS5-Sb Faeces B AUS51 
(CD) 
AUS48-Ga Gum B 
 
   AUS51-Bd Biopsy B 
 
G.S: genomospecies. 
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Figure  5.19: SDS-PAGE for whole cell protein profiles of C. concisus isolates from gum 
and faecal samples collected from patient AUS4. The gel was visualised by Coomassie 
blue stain. Lane 1: protein marker. Lanes 2-8: C. concisus isolates (AUS4-Ga, AUS4-Gc, 
AUS4-Gk, AUS4-Gg, AUS4-Gm, AUS4-Gn and AUS4-Sf, respectively). All the isolates 
were obtained from gum samples except lane 8, which was from faeces. The isolates were 
obtained from patient with CD. All the protein profiles of the oral and faecal isolates were 
identical. 
 
 
 
Figure  5.20: SDS-PAGE for whole cell protein profile of C. concisus isolates obtained 
from a gum and faecal samples collected from patient AUS5. The gel was visualised by 
Coomassie blue stain. Lane 1: protein marker. Lanes 2-10: C. concisus isolates (AUS5-Ga, 
AUS5-Gc, AUS5-Sa, AUS5-Sc, AUS5-Sf, AUS5-Gd, AUS5-Ge, AUS5-Sb and AUS5-Sd, 
respectively). Lanes 2-6: C. concisus isolates belong to genomospecies A, while lanes 7-10: 
C. concisus isolates belong to genomospecies B. Lanes 4, 5, 6, 9 and 10: C. concisus isolates 
from faecal samples, while other lanes were isolated from the gum samples. The isolates were 
from CD patient. Each faecal isolate showed an identical WCLP patterns to at least one of 
oral isolate. The differences in WCLP patterns can only be seen between genomospecies A 
and B. 
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Figure  5.21: SDS-PAGE for whole cell protein profiles of C. concisus isolates from a 
gum sample and biopsy (duodenum) collected from patient AUS22. The gel was 
visualised by Coomassie blue stain. Lanes 1-6: C. concisus isolates (AUS22-Ga, AUS22-Gb, 
AUS22-Gc, AUS22-Gd, AUS22-Gf and AUS22-Bd2 respectively). Lane 6: C. concisus 
isolates from a duodenal biopsy of patient AUS22, while all other lanes were isolated from 
gum sample of UC patient AUS22. Lanes 1 and 6: C. concisus isolates amongst 
genomospecies A, while other lanes are C. concisus isolates belonging to genomospecies B. 
Lane 7: protein markers. White arrows, brackets and circle indicate distinguishable proteins 
bands between C. concisus isolates. The duodenal isolate has a unique protein profile. 
 
 
Figure  5.22: SDS-PAGE for whole cell protein profiles of C. concisus isolates from gum 
samples and biopsies collected from patients AUS48 and AUS51. The gel was visualised 
by Coomassie blue stain. Lanes 1-5: C. concisus isolates from AUS48 (AUS48-Ga, AUS48-
Gb, AUS48-Gd, AUS48-Ge and AUS48-Ba, respectively). Lanes 6 and 7 are C. concisus 
isolates from AUS51 (AUS51-Ga and AUS51-Bd, respectively). Lane 8: protein marker. 
Lanes 5 and 7 are C. concisus isolates from biopsies of ascending colon (AUS48) and 
descending colon (AUS51) of UC and CD patients. The other isolates were obtained for gum 
samples. Here all C. concisus isolates are amongst genomospecies B. White arrows and 
brackets indicate distinguishable proteins bands between C. concisus isolates. The protein 
profile of the isolates obtained from the biopsies are dissimilar to the oral isolates. 
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Figure  5.23: SDS-PAGE for whole cell protein profiles of C. concisus isolates from a 
gum and faecal samples collected from control participant AUS47. The gel was 
visualised by Coomassie blue stain. Lanes 1-4: C. concisus isolates (AUS47-Ga, AUS47-Gb, 
AUS47-Gc and AUS47-Sa, respectively). Lane 5: protein marker. Lanes 1 and 2: C. concisus 
isolates are amongst genomospecies A, while other lanes are C. concisus isolates belonging 
to genomospecies B. Lane 4: a C. concisus isolate was obtained from faecal sample of a 
control participant, while the isolates in the other lanes were obtained from the gum sample. 
White oblongs indicate distinguishable protein bands between C. concisus isolates. The 
protein profile of the faecal isolate is dissimilar to the oral isolates. 
 
 
Figure  5.24: SDS-PAGE for whole cell protein profiles of the Campylobacter spp. 
reference strains used in this study. The gel was visualised by Coomassie blue stain. Lanes 
1 and 2: C. concisus reference strains (ATCC 51561 and 51562). Lane 3-6: C. mucosalis 
ATCC 43264, C. jejuni 81116, C. coli NCTC 11366 and E. coli ATCC 25922, respectively. 
Lane 7: protein marker. C. concisus strain ATCC 51561 was amongst genomospecies B, 
while ATCC 51562 belonged to genomospecies A. 
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5.4 Discussion 
C. concisus is a bacterium that has generated substantial interest following its detection in 
colonic biopsies of children with CD. A number of earlier studies reported that C. concisus 
DNA was detected more frequently in intestinal biopsies of newly diagnosed IBD patients 
than in control participants (Mahendran et al. 2011; Mukhopadhya et al. 2011; Zhang et al. 
2009). However, a recent study reported no substantial difference in the detection rate of C. 
concisus between IBD patients and control participants (Hansen et al. 2013). One reason for 
the differences in these results may relate to the different number of the anatomic sites in the 
intestine where samples were collected in (Hansen et al. 2013; Mahendran et al. 2011; 
Mukhopadhya et al. 2011; Zhang et al. 2009). When the current study was planned in 2010 
there was only a single published research article on the prevalence of C. concisus DNA 
extracted from intestinal biopsies of children newly diagnosed with CD. The study reported 
that the prevalence was higher in CD patients than in control participants (Zhang et al. 2009). 
Therefore, the current study investigated the presence of C. concisus by PCR and culture in 
seven anatomic sites in the intestinal mucosa, as well as faecal and gum samples in adult 
participants. 
In this study, C. concisus was isolated from the intestinal biopsies of 8% (3/37) of IBD, while 
it could not be isolated from control participants. The detection rate of C. concisus DNA was 
59.5% in intestinal biopsies of IBD patients, while it was 21.4% in control participants, (P 
<0.05). In addition C. concisus was isolated from an intestinal biopsy of the duodenum and 
ascending colon for the first time. Recently, a single study reported similar finding on the 
presence of C. concisus in four intestinal biopsies (ileum, caecum, descending colon and 
rectum) of adults with IBD (Mahendran et al. 2011). The study also found a significant 
difference in the detection rate of C. concisus DNA between IBD patients (82%) and control 
participants (48%) (Mahendran et al. 2011). However, in another study which was performed 
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to detect C. concisus in intestinal biopsies of paediatric IBD patients, the bacterium was 
isolated from 3% (3/100) of IBD patients and it failed to reach a significant difference in C. 
concisus detection rate by PCR between IBD patients and control participants (Hansen et al. 
2013). 
In addition, the prevalence of C. concisus in biopsies of adults with CD (61.5%) in this study 
was significantly higher than in control participants (21.4%). This finding is consistent with a 
study conducted on newly diagnosed children with CD (Zhang et al. 2009). However, another 
study performed on intestinal biopsies of adults with CD, did not detect a significant 
difference between CD patients and control participants (Mahendran et al. 2011). 
The differences in the results between this study and the previous studies in the detection rate 
of C. concisus in biopsies of IBD pateints and control participants could be due to the 
inclusion of different intestinal anatomic sites in different studies as in the current study C. 
concisus was found to be more prevalent in the sigmiod colon and rectum than the other 
intestinal anatomic sites. Another reason for the different reported detection rates of C. 
concisus could be the additon of different amounts of DNA as a template from the biopsies. 
Furthermore, nested PCR may be more sensitive than a one-step PCR, which could be 
important if numbers of C. concisus was reduced in the intestinal tract due to the bowel 
preparation prior endoscopy. 
Therefore, as this study used a more comprehensive sampling strategy than previous studies, 
the findings have for the first time expanded the knowledge of C. concisus prevalence in 
several anatomic sites in the gastrointestinal tract of adults with IBD. These results showed 
that C. concisus can be detected in any of these sites including duodenal and stomach 
biopsies. 
In the current study, C. concisus was isolated by culture from gum samples of 86% (32/37) of 
IBD patients and of 64% (9/14) of control participants. The detection rate of C. concisus by 
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PCR was 100% in IBD patients and 97% in control participants. However, the differences in 
detection rate by both culture method and PCR were not statistically significant between IBD 
patients and control participants. A similar finding was reported in a previous study 
conducted on saliva of children and adults with IBD as there was no statistical significance in 
the prevalence of C. concisus between IBD patients and control participants (Zhang et al. 
2010). The preparation for the endoscopy procedure used in this study could have reduced the 
numbers of C. concisus in the oral cavity and may have led to a slight reduction in the 
bacterial isolation rate, compared with the PCR detection rate. 
The isolation rate of C. concisus from faecal samples in the present study was 5.6% (2/36) in 
IBD patients and 8.3% (1/12) in control participants, which was not statistically significant. 
The prevalence of C. concisus DNA in faecal samples of IBD patients was higher than in 
control participants, but the difference did not reach statistical significance. However, a 
previous study recruited faecal samples from children with newly diagnosed CD and found 
that the prevalence of C. concisus DNA in faecal specimens of CD patients (65%) was 
significantly higher than in control participants (33%) (Man et al. 2010b). The variation in 
the detection rate between this study and the past study may be due to the differences in the 
age groups of the participants. 
The findings of this study for the first time revealed that the prevalence of genomospecies B 
was significantly higher in intestinal biopsies and faecal samples of IBD patients than in 
control participants (P <0.05) when a newly developed nested PCR technique to amplify 
cjaC was used. In addition, the prevalence of genomospecies B in C. concisus isolates from 
gum samples of IBD patients was significantly higher than genomospecies A, while in 
control participants, genomospecies A was more prevalent than genomospecies B. Similar 
results were obtained when the new nested PCR was applied to detect genomospecies B. 
These results suggest that a specific genomospecies may be associated with IBD. As the 
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whole genome sequence of a genomospecies A strain (ATCC 51562) has recently become 
available in the NCBI data-base site (Deshpande et al. 2013), the prevalence of this 
genomospecies can be investigated by developing a nested PCR targeting specific genes of 
interest to detect genomospecies A and support the findings of this study. 
The zot gene was suggested to play a role during bacterial infections by mimicking 
intercellular tight cell junctions (Uzzau et al. 2000) and in Campylobacter spp., only C. 
concisus and C. ureolyticus have been reported to possess zot in their genomes (Bullman et 
al. 2013; Kaakoush et al. 2010). The current study found that 8% (3/37) of isolates from the 
oral cavity of IBD patients possessing zot compared with 14% (2/14) of controls. This 
difference did not reach statistical significance. When Mahendran et al. (2013) investigated 
the prevalence of zot within C. concisus oral isolates obtained from IBD patients and control 
participants, they also could not show statistical significance. 
A new nested PCR developed in the present study to detect zot in the extracted DNA from 
clinical samples, also found no statistical significance in the prevalence of zot in clinical 
samples between IBD patients and control participants (P >0.05). Based on the sequence of 
C. concisus 13826, polymorphic forms of zot leading to a substitution of valine to leucine at 
position 270 were reported in C. concisus strains and linked to patients with active IBD 
(Mahendran et al. 2013). However, this study found that this kind of substitution in C. 
concisus isolates obtained from control participants. 
In this study, C. concisus isolates obtained from faecal samples of IBD patients demonstrated 
identical WCLP patterns to oral isolates obtained from the same patients. However, intestinal 
isolates obtained from biopsies of the same patient showed dissimilar WCLP patterns to the 
oral isolates. These differences possibly suggest that isolates obtained from biopsies express 
factors which may facilitate the colonisation of intestinal epithelial cells; however, more 
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work is required to identify the proteins specific to IBD isolates and their function, and to 
compare DNA profiles of isolates from different sites of the same patient. 
As part of the plan for this study, serum samples were also collected from participants when 
the biopsies, faecal samples and gum samples were taken. However due to time limitation no 
experimental analysis was conducted; therefore, further studies are required to perform 
protein immunoreactive studies for C. concisus strains isolated from different locations 
within the same patient. The hypothesis to be investigated was that only patients who have C. 
concisus in biopsies may have immunoreactivity against C. concisus. In addition, interleukins 
and IgM studies are suggested for the patients who had C. concisus in the biopsies and 
compared with results to the patients who do not have the bacterium in their biopsies. 
In summary, C. concisus was detected in intestinal biopsies of IBD patients including from 
new intestinal anatomic sites which have not been investigated by previous studies that 
recruited adults with IBD and control participants. These anatomic intestinal sties were 
ascending colon, transverse colon, sigmoid colon, duodenum and stomach. The study 
revealed that the prevalence of C. concisus in intestinal biopsies of IBD patients was 
significantly higher than in the control participants. In addition it was the first study to look at 
the prevalence of different genomospecies in C. concisus, using DNA collected from clinical 
samples (biopsies, faeces and gum) collected from IBD patients. 
C. concisus was isolated for the first time from biopsies collected from duodenum and 
ascending colon of IBD patients. In addition, this was the first study to reveal that the 
prevalence of genomospecies B strains in clinical samples was significantly higher in IBD 
patients than in control participants while genomospecies A strains were more predominant in 
control participants than in IBD patients suggesting that genomospecies B could be more 
associated with IBD than genomospecies A. The isolation rate of C. concisus from biopsies 
and faeces of IBD patients and control participants was significantly lower compared to the 
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oral cavity. C. concisus isolates even from same genomospecies obtained from biopsies 
showed unique WCLP patterns when compared with oral isolates from the same patient 
unlike faecal isolates whose profiles were identical with the oral isolates, possibly suggesting 
that the isolates obtained from biopsies could have several proteins that facilitate their 
survival in intestinal cells. The prevalence of C. concisus isolates possessing zot was 
extremely low in IBD patients and control participants indicating that the gene might be 
unimportant for bacterial colonisation in the intestinal tract or as has been suggested it may 
have been acquired from other microorganisms (Zhang et al. 2014). It is still unclear whether 
C. concisus has any involvements in IBD or whether patients with IBD are more susceptible 
to being colonised by the bacterium than control participants. 
These findings suggest that further studies are required to confirm the variations of WCLP 
profiles between isolates obtained from biopsies and the oral cavity in the same IBD patient. 
Further genetic analysis also should be considered using C. concisus isolates from 
genomospecies A and B. To my knowledge, this is first study that has isolated C. concisus 
from the intestine and the oral cavity of the same IBD patient at the same time. These 
outcomes suggested that further investigations are required to detect the prevalence of C. 
concisus genetic groups direct from the extracted DNA of clinical samples as its isolation is 
very challenging due to being an extremely fastidious bacterium. In order to achieve this 
completely, whole genome sequencing for other genomospecies A strains is required. 
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Chapter 6 : General discussion 
In the past decade, several studies reported an emergence of C. concisus as a possible 
pathogen in the gastrointestinal tract (Maher et al. 2003; On 2001; Park 2002). C. concisus 
has been detected in patients with gum infection (Kamma et al. 1994; Kamma et al. 2001; 
Tanner et al. 1981) and in the faeces of gastroenteritis patients (Istivan et al. 2004; Lindblom 
et al. 1995; Vandamme et al. 1989). Since 2009, a few studies have reported that the 
detection of C. concisus DNA was significantly higher in intestinal biopsies from patients 
with IBD than from healthy control (Mahendran et al. 2011; Zhang et al. 2009), while other 
studies could not detect a significant difference (Hansen et al. 2013; Hansen et al. 2011). 
These findings do not make it possible to draw a conclusion on the role of C. concisus in 
enteric infections at present. 
C. concisus has been grouped into two genomospecies (A & B) by amplification of the 23S 
rDNA region (Aabenhus et al. 2005a; Istivan 2005; Istivan et al. 2004) and into 3-4 groups 
by AFLP (Aabenhus et al. 2005a; Kalischuk et al. 2011). Genomospecies A and B were 
reported to correspond with group I and II that were based on AFLP analysis (Aabenhus et al. 
2005a). 
Due to the genetic diversity of this species and due to different typing methods used to 
discriminate C. concisus strains, the DGGE technique can be used to investigate and 
differentiate C. concisus in mixed bacterial communities such as the intestine and the oral 
cavity. In the current study, C. concisus isolates were typed into two new groups (I and II) by 
the DGGE technique based on the analysis of the 16S rDNA gene. Genomospecies A isolates 
were assigned into two DGGE groups; however, genomospecies B isolates were all assigned 
into one group. Using different genes to type C. concisus may result in generating diverse 
new groups. 
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The C. concisus genome has been reported to possess several putative virulence genes; cjaC, 
cjaA, dnaJ and zot (Kaakoush et al. 2010). In C. jejuni, cjaC and cjaA encode secreted 
proteins that are immunodominant (Laniewski et al. 2014; Muller et al. 2005; Wyszynska et 
al. 2004). These genes are predicted to be putatively responsible for histidine and cysteine 
up-take in campylobacters (Muller et al. 2005; Wyszynska et al. 2004; Wyszynska et al. 
2007). The dnaJ gene encodes the chaperone protein DnaJ, which has been reported as a 
virulence-associated gene in C. jejuni (Bui et al. 2012; Li et al. 2008). The zot gene encodes 
the zonula occludens toxin, and has been detected in the genome of several C. concisus 
strains (Kaakoush et al. 2010; Kalischuk et al. 2011). This gene is known to increase the 
permeability of intestinal cells in the enteric infection caused by V. cholera (Di Pierro et al. 
2001; Fasano et al. 1995). 
In this study, results of PCR amplification and bioinformatics analysis revealed that the 
majority of C. concisus isolates carry cjaC, cjaA and dnaJ, while zot was possessed by only a 
few isolates. The DNA and amino acid sequences published for cjaC, cjaA and dnaJ were 
found to be substantially different between genomospecies A and B, which might explain the 
failure of PCR to amplify the genes from some C. concisus isolates. Based on alignment of a 
DNA sequence obtained from C. concisus strain RCH3 (genomospecies A) in this study to C. 
concisus strain 13826 (genomospecies B), the location of cjaC is in different parts of the 
genome in genomospecies A and B. This study found that the nucleotide sequence of the 
region between cjaC and the shikimate 5-dehydrogenase genes in genomospecies A is 
unique; therefore, it can be targeted to detect genomospecies A. Using PCR with the panel of 
primer sets based on C. concisus 13826 to amplify the DNA region between cjaC and the 
hypothetical protein gene (CCC13826_0963), it showed that genomospecies B isolates are 
heterogonous. Moreover, cjaA, dnaJ and zot could not be amplified from all C. concisus 
isolates with the primer sets designed based on the C. concisus 13826 sequence. This inability 
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to amplify these genes from all isolates was likely to be due to sequence variations, since 
alignment of published sequences of C. concisus strains (once these became available) 
showed the sequences of these genes to be heterogeneous. 
Neighbour-joining phylogenetic analysis for cjaC, cjaA and dnaJ using DNA and 
corresponding amino acid sequences of published C. concisus strains confirmed that the 
nucleotide sequences of these genes differ between genomospecies A and B, as analysis 
based on all of these genes showed that each genomospecies had its own clade. Phylogenetic 
analysis based on zot was limited since this gene could only be detected in three out of the 
eight whole sequenced C. concisus strains (13826, UNSW3 and UNSWCS), all of which 
were from genomospecies B. The group assignment obtained from zot sequence analysis by 
neighbour-joining phylogenetic analysis was different from that according to 23S rDNA, 
cjaC, dnaJ and cjaA. In addition, isolates possessing zot, were assigned into the same group 
by DGGE analysis based on the PCR product of primer set I. 
The present study found that two oral C. concisus isolates obtained from healthy volunteers 
were invasive to INT407 cells (invasion index values >1). However, Ismail et al. (2012) 
detected C. concisus isolates capable of invading Caco-2 cells in the oral cavity of IBD 
patients, but not from the oral cavity of healthy controls. These differences could be 
explained if the invasion of C. concisus differs based on the used cell line. In this study, C. 
concisus isolates that possessed zot were non-invasive (invasive index value <1). More 
studies are required to determine whether zot is involved in bacterial interaction with 
intestinal cells in vitro. 
In the present study semi-quantitative RT-PCR assays were developed to investigate the gene 
expression of putative virulence genes (cjaC, cjaA, dnaJ and zot). The assays successfully 
detected and evaluated the expression of these genes with the exception of zot, which was not 
expressed under the experimental condition. The expression of cjaC and cjaA was weakly 
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induced by alteration of the growth medium. The expression of dnaJ was found to be 
significantly reduced when C. concisus cells were maintained in DMEM (a tissue culture 
medium) compared to when these bacterial cells were maintained with INT407 cells growing 
in DMEM. These results indicate different expression levels under different growth 
conditions. It is likely that similar differences in expression of virulence genes also occurs in 
vivo in the human host, but more work is required to confirm this. 
A few studies have reported a significantly higher prevalence of C. concisus DNA in 
intestinal biopsies of children newly diagnosed with IBD than in healthy controls (Mahendran 
et al. 2011; Mukhopadhya et al. 2011; Zhang et al. 2009). However, more recent study could 
not show a significant difference in the detection rate of C. concisus in colonic biopsies 
between IBD patients and healthy controls (Hansen et al. 2013). The earlier studies did not 
examine different samples of the gastrointestinal tract and the oral cavity of each IBD patient 
at the same time. Therefore, in the present study samples were collected from intestinal 
biopsies, faeces and gum swabs from patients with IBD at the Austin Hospital and 
transported to RMIT University for laboratory investigations. Prior to sample collection, the 
effect of transportation temperature on the survival rate of C. concisus was investigated as 
this has not been previously reported. A temperature of 4°C was used as a model to 
investigate the effect of transport conditions on C. concisus cell survival. There was no 
significant reduction in C. concisus cell numbers in suspensions stored at 4°C for 7 h, which 
was the required time from sample collection through transportation to processing by culture. 
The rates of retrieval of genomospecies A from bacterial storage at 4°C were significantly 
higher after 2 days at 4°C than for genomospecies B. This suggested that a delay in 
cultivation of clinical samples beyond this point (after 2 days at 4°C) may not show the 
accurate prevalence of genomospecies A and B as genomospecies B had lower survival rates 
than genomospecies A. 
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Previous studies collected biopsies from only a few intestinal sites. For example, Mahendran 
et al. (2011) determined the prevalence of C. concisus DNA in four anatomic sites (ileum, 
caecum, descending colon and rectum), while other studies analysed C. concisus DNA only 
in a colonic biopsy collected from a single site of each IBD patient (Hansen et al. 2013; 
Mukhopadhya et al. 2011; Zhang et al. 2009). In contrast, in the present study, C. concisus 
prevalence was investigated in biopsies from additional anatomical sites in intestinal mucosa 
(the terminal ileum, ascending colon, transverse colon and sigmoid colon) using PCR and 
culture. In some participants, stomach and duodenal biopsies were also collected. 
Furthermore, new PCR techniques were developed to detect C. concisus genomospecies B 
and zot directly from the clinical samples. 
The prevalence of C. concisus DNA in intestinal biopsies of patients with IBD (59.5%) was 
significantly higher than in control participants (21.4%), (P <0.05). Similar results was 
previously shown by Mahendran et al. (2011). Moreover, it was the first study to show a 
statistically significant prevalence of C. concisus DNA in intestinal biopsies of adults with 
CD (61.5%) when compared to healthy controls, while Mahendran et al. (2011) could not 
detect a significant difference between CD patients and controls. These differences could be 
due to using more intestinal anatomic sites from each patient in the current study. In the oral 
cavity, this study and a previous study found no significant differences in the prevalence of 
C. concisus between of patients IBD and healthy controls using PCR and culture (Zhang et 
al. 2010). In faecal samples collected in this study, there was no significant difference in the 
prevalence of C. concisus between IBD patients and control participants, while Man et al. 
(2010b) reported a significant difference between children with CD and control participants; 
these dissimilar results may be due to the different age groups of participants. 
This was the first study to focus on the prevalence of specific genomospecies of C. concisus 
in intestinal biopsies, faeces and gum samples of patients with IBD. Using PCR and culture 
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to detect C. concisus in the oral cavity, the prevalence of genomospecies B was significantly 
higher in IBD patients than in control participants, while genomospecies A isolates were 
more prevalent in control participants than in IBD patients. Similar results were found when 
PCR was applied to detect genomospecies B in intestinal biopsies and faeces, suggesting that 
genomospecies B could be more associated with IBD than genomospecies A as 
genomospecies B has a significant prevalence in all sites of these patients. 
Using PCR, there was no significant difference in the rate of detection of zot in intestinal 
biopsies, faeces or the oral cavity between IBD patients and control participants. Similar 
results were found when zot was investigated in the oral isolates of IBD patients and controls. 
Mahendran et al. (2013) also reported that there was no statistically significant difference in 
the prevalence of zot in C. concisus isolates obtained from IBD patients and control 
participants. Together, these findings suggest that zot might not be associated with IBD. 
As C. concisus isolates are genetically heterogonous, the phenotypic similarity between C. 
concisus isolates obtained from the oral cavity and the gastrointestinal tract of the same 
patient collected at the same time was investigated by whole cell lysate protein profiling 
using SDS-PAGE. C. concisus isolates obtained from biopsies showed unique protein 
profiles compared to the oral isolates from the same IBD patient. However, the protein 
profiles of faecal isolates were identical to those of oral isolates obtained from IBD patients. 
These results suggest that isolates from intestinal biopsies could be different from those 
colonising the oral cavity. 
The conclusive results obtained from IBD indicated that the prevalence of C. concisus in 
intestinal biopsies of IBD patients was significantly higher than in control participants. In 
addition, genomospecies B prevalence in biopsies, faeces and oral cavity of IBD patients was 
significantly higher than in control participants. Based on protein profile analysis, isolates 
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obtained from the biopsies of IBD patients were different from C. concisus isolates 
colonising the oral cavity of the same patient. 
In summary, the DGGE technique separated C. concisus isolates into two new distinct 
groups. Additionally, the putative virulence genes (cjaC, cjaA and dnaJ) may be possessed by 
the majority of C. concisus isolates, but they exhibit nucleotide sequence variations. 
However, zot could be only amplified from few isolates. The location of cjaC in the genome 
of genomospecies A strains was different from its location in the genome of genomospecies 
B strains. Two oral C. concisus isolates obtained from healthy individuals were identified as 
invasive, which is the first time to be reported. In addition, semi-quantitative SYBR green 
assays were developed to evaluate the expression of putative virulence genes in C. concisus 
isolates grown on synthetic media and in isolates maintained in tissue culture medium with 
and without INT407 cells. The expression of cjaC and cjaA was slightly enhanced when the 
bacterial cells were grown in an unenriched medium. However, dnaJ expression was 
significantly reduced in bacterial cells maintained in the tissue culture medium only than in 
bacterial cells maintained in INT407 cells. New nested PCR techniques were developed to 
detect genomospecies B isolates and zot clinical samples. The prevalence of C. concisus was 
significantly higher in biopsies of IBD patients than in biopsies of healthy controls. C. 
concisus was isolated from duodenal and ascending colonic biopsies, for the first time in this 
study. The prevalence of genomospecies B isolates was significantly higher in IBD patients 
(35.1%) than in control participants (7.1%). However, using PCR and culture, there was no 
significant difference in the prevalence of zot between IBD patients and control participants. 
 
Future studies 
It is proposed that the genetic diversity of C. concisus may indicate differences in the degree 
of virulence; however, further studies are required to evaluate differences in virulence 
between genetically diverse isolates and between genomospecies A and B. Additional whole 
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genome sequencing for genomospecies A strains is required to facilitate the detection and 
investigation of putative virulence genes of C. concisus. Proteomic studies on cjaC, cjaA, zot 
and dnaJ gene products should investigate whether there is any difference in the products that 
could affect bacterial virulence. Targeting 23S rDNA by nested PCR, several molecular 
techniques such as DGGE can be used directly to group C. concisus DNA in clinical samples. 
As this study established a foundation for identifying relative gene expression for C. 
concisus, further studies should be undertaken in order to determine the expression levels of 
the other putative virulence genes. Investigations are required to confirm protein profile 
differences between isolates obtained from biopsies and oral isolates of the same patients. 
More investigations are needed to study the pathogenic potential of C. concisus isolates 
obtained from intestinal biopsies and faecal samples of IBD patients compared to isolates 
from the oral cavity of the same patient. Further studies may need to be done using animal 
models with C. concisus isolates to investigate and confirm the pathogenic role of C. 
concisus, in particular those isolated from the intestinal tract and oral cavity of the same IBD 
patient. Generation of targeted mutation for proposed virulence genes in in vitro and animal 
models would also be needed to confirm their role, if any in intestinal disease. Additional 
information would be gained by investigating the host humoral immune response to the C. 
concisus in IBD patients compared with control participants. Furthermore, the 
immunoreactivity of patient sera against proteins from C. concisus isolates obtained from 
different locations (intestinal biopsies, faeces and the oral cavity) against the serum of the 
same patient would provide an insight into whether the immune response is direct against all 
isolates or only isolates obtained from intestinal biopsies. 
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Appendices 
 
Appendix I: PCR products obtained from amplifying the 16S rDNA gene of clinical and 
oral C. concisus isolates using Muyzer primer set 1. 
 
 
PCR products (170 bp) were loaded on a 1.5% (w/v) agarose gel for electrophoresis. It was 
then stained in ethidium bromide and visualised by a UV trans-illuminator. MK: lambda 
DNA marker. 61 & 62: C. concisus (ATCC 51561 & 51562). 3, 6, 11, 15, 20 & 26: RCH 
isolates. CM: C. mucosalis (ATCC 43264). CJ: C. jejuni (81116). CC: C. coli (NCTC 
11366). O: oral isolates. 
 
Appendix II: PCR products obtained from amplifying the 16S rDNA gene of clinical 
and oral C. concisus isolates using Muyzer primer set 2. 
 
PCR products (562 bp) were loaded on a 1.5% (w/v) agarose gel for electrophoresis. It was 
then stained in ethidium bromide and visualised by a UV trans-illuminator. MK: lambda 
DNA marker. NG: negative control. 61 & 62: C. concisus (ATCC 51561 &51562). 3, 6, 11, 
15, 20 & 26: RCH isolates. CM: C. mucosalis (ATCC 43264), CJ: C. jejuni (81116), CC: C. 
coli (NCTC 11366). O: oral isolates. 
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Appendix III: PCR products obtained from amplifying cjaC of clinical and oral C. 
concisus isolates using primer set I. 
 
 
 
Appendix IV: PCR products obtained from amplifying cjaC of clinical and oral C. 
concisus isolates using primer set II. 
 
 
 
Appendices III and IV, the size of PCR products in Appendix III is 800 bp. The size of PCR 
products in Appendix IV is 300 bp MK: Lambda PstI DNA ladder. 61& 62: C. concisus; 
(ATCC 51561 & 51562). 3, 4, 6, 11, 15, 20 & 26: RCH isolates. CM: C. mucosalis (ATCC 
43264), CJ: C. jejuni (81116), CC: C. coli (NCTC 11366). O: oral isolates. A & B: 
genomospecies. (-): no template control. *: genomospecies B. bp: base pair. 
 
 
 
209 
 
Appendix V: Nucleotide sequence of a PCR product obtained from amplifying cjaC of 
C. concisus ATCC 51561 using primer set I (746 bp). 
CCTTAGTATTCACATCTCTTGCCACTTCAGCAGCAGCCGCTTCAAAGATAGCTTTTAGATCATCTGG
AAGTTTTTCATATGCATTTTTGTTGAAGAAAAACTGAGTTTCGCCATCTGGCTCTTGCCAGCCTGTG
TAGTAGTATTTTGCCACTTTGTGAAAGCCAAGTGCCATGTCATAAGCTGGGCTAACCCACTCGACT
GCATCGATAGTGCCCATCTCAAGAGCCATGTAAAGCTCGCCAGTTGGGATAGTGTTGATGTTTGCG
CCAAGTTTAGCGTAAATTTCACCGCCAAAGCCCGGAATTCTTATCTTTAAGCCTTTGATATCATCAA
CTGACTTGATCTCTTTTTTAAACCAGCCGCCCATTTGCATGCCAGTGTTACCAGCTCTAAAAATTTT
GATGTTATATGGGTCAAAAACTTTCGCCTCTAGCTCTTTGCCGCCGCCAAATTCATACCAAGCTGTT
TGCTCGTCGGTATTCATCATAAATGGTGTCGCTGTAAAAAACATAGTCTTAGGGTCTTTGCCCTTGT
AGTAGTAGCTAGCTGTGTAGCCGATGTCGTACTGACCGCTCTTTGCAAAGTCAAGCATCGCAAAAG
GTGACTTGTGCTTTGACGGGTAGTCGATCCTGATCTCGATGCGGCCGTTACTCATCTTTTCGACCTT
CTCTTTTAGCTCTTTTGGCACGTCACCAAGCACTGGCATAGTGCTCTCCCATGAGGTTGCAAGCTTG
AGCTTATAGACT 
 
Appendix VI: Nucleotide sequence of a PCR product obtained from amplifying cjaC of 
C. concisus RCH6 using primer set I (746 bp). 
CCTTAGTATTTACATCTCTTGCCACTTCTGCAGCAGCCGCTTCAAAGATAGCTTTTAGATCATCTGG
AAGTTTTTCATACGCGTTCTTATTGAAGAAAAACTGAGTTTCGCCATCTGGCTCTTGCCAGCCTGTG
TAGTAGTATTTTGCCACTTTGTGAAAGCCAAGTGCCATGTCATAAGCCGGGCTAACCCACTCGACC
GCGTCGATCGTACCCATCTCAAGTGCCATATAAAGCTCGCCAGTTGGGATAGTGTTGATATTTGCG
CCAAGTTTAGCGTAAATTTCACCGCCAAAGCCTGGAATTCTGATCTTTAAACCTTTGATATCATCA
ACTGACTTGATCTCTTTTTTAAACCAGCCGCCCATTTGCATGCCAGTGTTGCCAGCTCTAAAAATTT
TGATGTTATATGGATCAAAAACTTTGGCTTCTAGCTCTTTGCCACCACCAAATTCATACCAAGCTGT
TTGCTCGTCGGTATTCATCATAAATGGTGTTGCTGTAAAGAACATAGTCTTAGGATCTTTGCCTTTG
TAGTAGTAGCTAGCTGTGTAGCCGATATCGTACTGACCGCTCTTTGCAAAGTCAAGCATCGCAAAA
GGTGACTTGTGCTTTGACGGGTAGTCGATCCTGATCTCGATGCGGCCGTTACTCATCTTTTCGACCT
TCTCTTTTAGCTCTTTTGGCACGTCACCAAGCACTGGCATAGTGCTCTCCCATGAGCTTGCAAGCTT
GAGCTTATAGACT 
 
Appendix VII: Nucleotide sequence of a PCR product obtained from amplifying cjaC of 
C. concisus ATCC 51562 using primer set II (295 bp). 
GCCAAGCGCCATGTCATAAGCTGGGCTAACCCATTCGACTGAGTCAATCGTTCCCATCTCAAGAGC
CATGTAAAGCTCACCAGTTGGGATAGTGTTAATGTTAGCGCCAAGTTTAGCGTAAATTTCACCACC
AAAGCCCGGAATTCTTATCTTTAAACCTTTGATATCATCTAGTGATTTTATCTCTTTTTTAAACCAG
CCACCCATTTGCATGCCGGTATTTCCAGCTCTAAAAATTTTGATATTGTATGGATCGTAAACTTTTG
CCTCAAGCTCTTTGCCGCCGCCAAATTCA 
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Appendix VIII: PCR products obtained from amplifying cjaC of C. concisus clinical and 
oral isolates using primer set III. 
 
 
 
Appendix IX: PCR products obtained from amplifying cjaC of clinical and oral C. 
concisus isolates using primer set IV. 
 
 
 
Appendices VIII and IX, the size of PCR product in Appendix VIII is 330 bp. The size of 
PCR products in Appendix IX is 270 bp. Lambda PstI DNA ladder. 61& 62: C. concisus: 
(ATCC 51561 & 51562). 3, 4, 6, 11, 15, 20 & 26: RCH isolates. CM: C. mucosalis (ATCC 
43264), CJ; C. jejuni (81116), CC: C. coli (NCTC 11366). O; oral isolates. A & B: 
genomospecies. *: genomospecies B. (-): no template control bp: base pair. 
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Appendix X: The alignment of cjaC nucleotide sequences obtained from PCR products 
obtained from C. concisus strains (51562, RCH3 and RCH26) using primer set III. 
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Appendix XI: PCR products obtained from amplifying cjaC and its adjacent gene 
(CCC13826_0962) of C. concisus clinical and oral isolates using primer set V. 
 
 
 
Appendix XII: PCR products obtained from amplifying cjaC and its adjacent gene 
(CCC13826_0962) of C. concisus clinical and oral isolates using primer set VI. 
 
 
 
Appendices XI and XII, the size of PCR product in Appendix XI is 514 bp except strain 
51561 was 330 bp. The size of PCR product in Appendix XII is 600 and 1700 bp. MK: 
Lambda PstI DNA ladder. 61 & 62: C. concisus; (ATCC 51561 & 51562). 3, 4, 6, 11, 15, 20 
& 26: RCH isolates. CM: C. mucosalis (ATCC 43264), CJ: C. jejuni (81116), CC: C. coli 
(NCTC 11366). O: oral isolates. A & B: genomospecies. *: genomospecies B. (-): no template 
control. bp: base pair. 
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Appendix XIII: Nucleotide sequences of a PCR product obtain from amplifying cjaC 
and its adjacent gene (CCC13826_0962) of C. concisus O11 using primer set VI (1401 of 
1700 bp). 
ATCTCCTTCTCTAGCTTCTCATCAAATACATAAACACCACCATATTTTTTAGCAATGTTCTCTTGCTC
GCTAGTTAGATCAGAAATTCTTATAAAGCCATTAAAATAAGCAAGTGGTAGAAGTATAAATAAGC
AGATAAAAACTATAAATTTGACTTTTTTCATCATAAATCCTTTTAAATTTAAAACTATACAAGATA
GAAATTTCTCATAATCTTATTGTGAATATATTTATAATATTATTAATTTATTATGCTTAGCTAGGTTT
ATTAATTATAAAATTTATCCGAAAAACTCCAAATTTCATTTTCTTCTATATACTCAAAAAAAGCATA
AGCAACATCGGCTATATCAGCATAAACCCTTATTTTATCTACCATCTCTTTATTGTTAAATTTTTAA
GAGTGTTCATTTATTTATCCTTGTCTTTATTGCTGATTTTTTGAAATTTATTGTCTGCTAGATAAAAT
TTATTATCTCCAATTAGTCTTTGAGTGCTTTCTTTGGTAAATTTTATTCCACTTGCTTCATCGCCATA
TAGCCCAAATGTAACTTCTGTATAAAGCGTAGAAACTCCTATACTTATAGTATAATAGTGTCATTG
TCTATATAGAAATATCCTAAATTTATACTTAGATAGTTTTCATATTTATCATAATCTTTACCCATAA
ATTCTTTTAGTTTTTCTTCGTAGTTATTTAAAATTTTGTAGTTATCTATTTTTATATTGTCTTTTCTTG
AGTAGTATCTTTTTCCATTAGATAAAACTCTAGGTAATTTTTCATTAACTGGCGTCATATCAACTGC
ATAACGATTTTCGGCTAATTTTTTACCACTTAAGCCTTTTGTCATTATTCGTCTCTCTTCTTCTCTCTT
GTCTATCTCCTTCTCTAGCTTCTCATCAAATACATAAACACCACCATACTTTTTAGCAATGCTCTCT
TGTTCGCTAGTTAGATCAGAAATTCTTATGAAGCCATTAAAATAAGCAAGTGGTAGCAGTATAAAC
AAGCAGATAAAAACTATAAATTTGACTTTTTTCATCATAAATCCTTTTGAATTTTCACTATTGTCTT
ATCTTTTGCTTTAAAGTCTTATTGTGATTAGTTTTTGTGGTGGTTTTAAATTTTAAAAAGCAGGGAG
AGCTCCCTGCTGTGGTTATTTCTCTTCGTTTGTTTTGATGTAAGCGTAGTCAGAAATTTTAGTCCAC
TCTCTTGCTTTTTTGAGGAAAGCTCTTTGAGACTCGACGATCTCTTTAAATAGTGGATCTTTTGCGC
TCTCTTCATCAAGTAGCTCGTTTGTAGCCTTTTTAAGAGCTGCGATGACCTCTGGTGGGAAAGATTT
TACTTGGATGTCTGGATACTCAGCCTTCATCTTGTCCCAGTACTCTACGTTGCGTAAA 
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Appendix XIV: PCR products obtained from amplifying the DNA region between cjaA 
and the adjacent gene encodes glutamine transport ATP-binding protein GlnQ of 
clinical and oral C. concisus isolates using primer set CjaA. 
 
 
 
 
 
Appendix XV: PCR products obtained from amplifying cjaA of clinical and oral C. 
concisus isolates using CjaAT primer. 
 
 
 
Appendices XIV and XV, the size of PCR product in Appendix XIV is 1200 bp. The size of 
PCR product in Appendix XV is 299 bp. PCR products were loaded on a 1.5% (w/v) agarose 
gel for electrophoresis. It was then stained in ethidium bromide and visualised by a UV trans-
illuminator. MK: lambda DNA marker. 61 & 62: C. concisus (ATCC 51561 &51562). 3, 4, 6, 
11, 15 & 26: RCH isolates. CM: C. mucosalis (ATCC 43264), CJ: C. jejuni (81116), CC: C. 
coli (NCTC 11366). O: oral isolates. 
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Appendix XVI: PCR products obtained from amplifying dnaJ of C. concisus clinical 
and oral isolates using primer set DnaJ. 
 
 
 
Appendix XVII: PCR products obtained from amplifying dnaJ of C. concisus clinical 
and oral isolates using primer set DnaJT. 
 
 
 
Appendices XVI and XVII, the size of PCR product in Appendix XVI is 900 bp. The size of 
PCR product in Appendix XVII is 304 bp. MK: Lambda PstI DNA ladder. 61 & 62: C. 
concisus (ATCC 51561 & 51562). 3, 4, 6, 11, 15, 20 & 26: RCH isolates. CM: C. mucosalis 
(ATCC 43264). CJ: C. jejuni (81116). CC: C. coli (NCTC 11366). O: oral isolates. A & B: 
genomospecies. *: genomospecies B. (-): no template control. bp: base pair. 
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Appendix XVIII: The cDNA amplification of atpA (the housekeeping gene) using Semi-
quantitative SYBR green assay. 
 
 
A- RT-PCR products obtained from amplifying RNA of atpA (300 bp) in C. 
concisus ATCC 51561 using primer sets for AtpA. Lanes 1-3: triplicates of 
bacterial RNA from cells grown on HBA. Lanes 4-6: triplicates of bacterial RNA 
from cells grown on CA. Lanes 7-9: triplicates of bacterial RNA from cells 
maintained to INT407+DMEM. Lanes 10-12: triplicates of bacterial RNA from 
cells maintained DMEM. Lane 13: RNA extracted from INT407+DMEM without 
the bacteria. Lane 14: genomic DNA (control positive). Lane 15: non-template 
control. Lanes 16: lambda DNA marker. 
 
 
 
B- RT-PCR amplification of cDNA obtained from atpA in C. concisus ATCC 
51561 using primer set AtpA. The PCR products size is 300 bp. Lanes 1-3: 
triplicates of bacterial cDNA of cells grown on HBA. Lanes 4-6: triplicates of 
bacterial cDNA of cells grown on CA. Lanes 7-9: triplicates of bacterial cDNA 
from cells maintained in INT407+DMEM. Lanes 10-12: triplicates of bacterial 
cDNA of cells maintained DMEM. Lanes 13-14: genomic DNA (control positive). 
Lane 15: non-template control. Lanes 16: lambda DNA marker. 
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Appendix XIX: Coding and history of IBD patients. 
RMIT 
code 
Disease Austin code Age Sex IBD 
period 
Gum Smoking Treatments 
AUS1 UC 2JT 59 F 20 --- --- Crestor & salazopyrin 
AUS2 CD 8TP 33 M --- --- yes  Prednisolone 
AUS3 CD 5SZ 30 F 7 --- yes Pentasa: anti-inflammatory 
AUS4 CD 7DW 49 M 17 --- yes Prednisolone 
AUS5 CD 12AH 63 F --- gingivitis --- Mesalazine 
AUS6 CD 3DC 48 M 4 --- --- Methotrexate  
AUS7 UC 10MS 27 M 11 --- ---  prednisolone 
AUS8 CD 13DV 34 M 21 --- --- Mesalazine , Imuran 
(immunosuppressive) 
AUS9 CD 15KRA 33 M 31 --- yes  Somac, Imuran, VtiD 
AUS10 CD 17ML 73 F 34 gingivitis --- Azathioprine 
AUS12 CD 20CR 49 F 5 --- --- Azathioprine, pentasa 
AUS13 CD 21NB 48 F 11 --- --- Nexium, motilium 
AUS14 CD 22RH 44 F 4 --- yes Folic acid  
AUS19 UC 30EC 27 F 6 --- --- pentasa   
AUS20 UC JM28 81 F --- --- --- prednisolone 
AUS21 UC RW29 54 M 19 --- --- mesalazine 
AUS22 UC NV30 33 F 5 --- --- methotrexate  
AUS23 CD SDB31 22 F --- --- --- --- 
AUS27 CD MA36 42 M 10 bleeding yes Azathioprine 
AUS28 UC BC35 20 F 4 --- --- Mesalazine & imuran 
AUS29 CD RF39 47 M --- --- yes Symbicort, zoloft 
AUS32 CD FK34 70 F 6 --- --- --- 
AUS31 UC HW42 22 M 20 --- ---  Somac, Imuran & VtiD 
AUS33 CD CH44 40 M 28 --- yes --- 
AUS34 CD 45LH 44 F 17 --- --- --- 
AUS36 CD BS46 66 F 3 --- yes Azathioprine, prednisolone  
AUS37 UC MA50 70 M --- --- --- azathioprine 
AUS39 CD JD52 34 M 10 --- --- Imuran, salofalk,  Diamox, 
Vytorin? 
AUS41 CD TM57 52 F --- --- yes Colazide, micardis 
AUS42 CD RD 61 F 11 --- yes --- 
AUS45 UC RI36 103 M 52 --- --- Azathioprine & pentasa 
AUS46 CD VL64 32 F 16 --- --- Azathioprine, pentasa 
AUS48 UC MS67 57 M --- --- --- Nexium & motilium 
AUS49 CD AK68 27 F 4 --- --- --- 
AUS50 CD DF69 43 M --- --- yes --- 
AUS51 CD KH70 44 F 18 --- --- --- 
AUS52 CD MC71 39 F 22 --- --- Azathioprine, colazal, 
valcyte 
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Appendix XX: Coding and history of control participants. 
RMIT code Austin 
code 
Age Sex Gum smoking Treatments 
AUS11 19JH 82 M --- --- Nexium & motilium 
AUS15 18SC 38 M --- --- folic acid 
AUS17 RT23 28 M --- --- Azathioprine 
AUS18 GL24 63 F --- --- symbicort &  zoloft 
AUS24 NR32 77 M --- --- --- 
AUS25 MA33 48 M --- --- --- 
AUS26 BM34 26 F --- --- --- 
AUS30 WS40 79 M --- --- Azathioprine & 
prednisolone  
AUS35 KT47 65 M --- --- Imuran, salofalk, 
Diamox & vytorin 
AUS38 PMC51 53 M --- --- Colazide & micardis 
AUS40 CL53 50 F --- --- --- 
AUS43 FL61 67 M --- --- Azathioprine & pentasa 
AUS44 FN 78 F --- --- --- 
AUS47 AB65 58 M --- --- --- 
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Appendix XXI: C. concisus isolates obtained from clinical samples (biopsies, faeces and 
gum) of IBD patients and control participants, and primer sets were used for 
confirming and typing these isolates. 
Participant 
code 
Isolate 
code 
Cam. spp 
primers 
Pcisus 
primers 
CON1 
primers 
CON2 
primers 
 VI 
primers 
ZoT 
primers 
AUS1 AUS1-Ga 1 1 0 1 1 L 0 
AUS1 AUS1-Gb 1 1 0 1 1 L 0 
AUS4 AUS4-Ga 1 1 0 1 0 0 
AUS4 AUS4-Gb 1 1 0 1 0 0 
AUS4 AUS4-Gc 1 1 0 1 0 0 
AUS4 AUS4-Gg 1 1 0 1 0 0 
AUS4 AUS4-Gl 1 1 0 1 0 0 
AUS4 AUS4-Gk 1 1 0 1 0 0 
AUS4 AUS4-Gm 1 1 0 1 0 0 
AUS4 AUS4-Gn 1 1 0 1 0 0 
AUS4 AUS4-Sf 1 1 0 1 0 0 
AUS5 AUS5-Ga 1 1 1 0 NA 0 
AUS5 AUS5-Gc 1 1 1 0 NA 0 
AUS5 AUS5-Gd 1 1 0 1 0 0 
AUS5 AUS5-Gf 1 1 0 1 0 0 
AUS5 AUS5-Ge 1 1 0 1 0 0 
AUS5 AUS5-Sa 1 1 1 0 NA 0 
AUS5 AUS5-Sb 1 1 0 1 0 0 
AUS5 AUS5-Sc 1 1 1 0 NA 0 
AUS5 AUS5-Sm 1 1 1 0 NA 0 
AUS5 AUS5-Sd 1 1 0 1 0 0 
AUS5 AUS5-Sf 1 1 1 0 NA 0 
AUS6 AUS6-Ga 1 1 0 1 1 0 
AUS6 AUS6-Ga 1 1 0 1 1 0 
AUS7 AUS7-Ga 1 1 1 0 NA 1 
AUS7 AUS7-Gb 1 1 0 1 0 0 
AUS7 AUS7-Gc 1 1 0 1 0 0 
AUS7 AUS7-Gd 1 1 0 1 1 L 0 
AUS9 AUS9-Ga 1 1 0 1 0 0 
AUS9 AUS9-Gb 1 1 0 1 0 0 
AUS9 AUS9-Gc 1 1 0 1 0 0 
AUS9 AUS9-Gd 1 1 0 1 0 0 
AUS9 AUS9-Ge 1 1 0 1 0 0 
AUS9 AUS9-Gg 1 1 0 1 0 0 
AUS9 AUS9-GL 1 1 0 1 0 0 
AUS9 AUS9-Gk 1 1 0 1 0 0 
AUS9 AUS9-Go 1 1 0 1 0 0 
AUS9 AUS9-Gf 1 1 0 1 0 0 
 
1: PCR product was obtained. 0: no PCR product was obtained. 1L: large PCR product was obtained. NA: not applicable. 
Cam.: Campylobacter. Intestinal isolates are highlighted in blue. 
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Participant 
code 
Isolate 
code 
Cam. spp 
primers 
Pcisus 
primers 
CON1 
primers 
CON2 
primers 
VI 
primers 
ZoT 
primers 
AUS9 AUS9-Gm 1 1 0 1 0 0 
AUS9 AUS9-Gs 1 1 0 1 0 0 
AUS9 AUS9-Gt 1 1 0 1 0 0 
AUS9 AUS9-Gx 1 1 0 1 0 0 
AUS10 AUS10-Ga 1 1 0 1 1L 0 
AUS10 AUS10-Gb 1 1 0 1 0 0 
AUS10 AUS10-Gc 1 1 0 1 0 0 
AUS10 AUS10-Gd 1 1 0 1 0 0 
AUS10 AUS10-Ge 1 1 0 1 0 0 
AUS10 AUS10-Gf 1 1 0 1 0 0 
AUS10 AUS10-Gm 1 1 0 1 1L 0 
AUS10 AUS10-Gn 1 1 0 1 0 0 
AUS12 AUS12-Ga 1 1 1 0 NA 0 
AUS12 AUS12-Gb 1 1 1 0 NA 0 
AUS12 AUS12-Gc 1 1 1 0 NA 0 
AUS12 AUS12-Gd 1 1 1 0 NA 0 
AUS12 AUS12-Ge 1 1 1 0 NA 0 
AUS12 AUS12-Gf 1 1 0 1 0 0 
AUS13 AUS13-Ga 1 1 1 0 NA 0 
AUS13 AUS13-Gb 1 1 1 0 NA 0 
AUS13 AUS13-Gc 1 1 1 0 NA 0 
AUS13 AUS13-Gd 1 1 1 0 NA 0 
AUS13 AUS13-Gf 1 1 1 0 NA 0 
AUS13 AUS13-Gm 1 1 1 0 NA 0 
AUS13 AUS13-Gk 1 1 1 0 NA 0 
AUS13 AUS13-Gn 1 1 1 0 NA 0 
AUS13 AUS13-Ge 1 1 1 0 NA 0 
AUS14 AUS14-Ga 1 1 1 0 NA 0 
AUS14 AUS14-Gb 1 1 1 0 NA 0 
AUS14 AUS14-Gc 1 1 1 0 NA 0 
AUS14 AUS14-Gd 1 1 1 0 NA 0 
AUS15 AUS15-Ga 1 1 1 0 NA 0 
AUS15 AUS15-Ga1 1 1 1 0 NA 0 
AUS15 AUS15-Gb 1 1 1 0 NA 0 
AUS15 AUS15-Gc 1 1 1 0 NA 0 
AUS15 AUS15-Ge 1 1 1 0 NA 0 
AUS15 AUS15-Gd 1 1 1 0 NA 0 
AUS15 AUS15-Gm 1 1 1 0 NA 0 
AUS 15 AUS15-Ga 1 1 1 0 NA 0 
AUS15 AUS15-Gn 1 1 1 0 NA 0 
AUS15 AUS15-Gf 1 1 1 0 NA 0 
AUS15 AUS15-Gk 1 1 1 0 NA 0 
AUS15 AUS15-Go 1 1 1 0 NA 0 
AUS19 AUS19-GA 1 1 1 0 NA 0 
AUS19 AUS19-Gb 1 1 0 1 0 0 
AUS19 AUS19-Gc 1 1 0 1 0 0 
 
1: PCR product was obtained. 0: no PCR product was obtained. 1L: large PCR product was obtained. NA: not applicable. 
Cam.: Campylobacter. Intestinal isolates are highlighted in blue. 
 
221 
 
Participant 
code 
Isolate code Cam. spp 
primers 
Pcisus 
primers 
CON1 
primers 
CON2 
primers 
VI 
primers 
ZoT 
primers 
AUS19 AUS19-Gd 1 1 0 1 0 0 
AUS19 AUS19-Ge 1 1 0 1 0 0 
AUS19 AUS19-Gn 1 1 0 1 0 0 
AUS19 AUS19-Gm 1 1 0 1 0 0 
AUS19 AUS19-Gf 1 1 0 1 0 0 
AUS20 AUS20-Ga 1 1 1 0 NA 0 
AUS20 AUS20-Gb 1 1 0 1 0 0 
AUS20 AUS20-Gc 1 1 1 0 NA 0 
AUS20 AUS20-Gd 1 1 0 1 0 0 
AUS20 AUS20-Ge 1 1 1 0 NA 0 
AUS20 AUS20-Gf 1 1 0 1 0 0 
AUS21 AUS21-Ga 1 1 0 1 0 0 
AUS22 AUS22-Ga 1 1 0 1 0 0 
AUS22 AUS22-Gb 1 1 1 0 NA 0 
AUS22 AUS22-Gc 1 1 0 1 0 0 
AUS22 AUS22-Gd 1 1 0 1 0 0 
AUS22 AUS22-Ge 1 1 1 0 NA 0 
AUS22 AUS22-Gf 1 1 0 1 0 0 
AUS22 AUS22-Bd2 1 1 1 0 NA 0 
AUS23 AUS23-Ga 1 1 0 1 0 0 
AUS23 AUS23-Gb 1 1 0 1 1 0 
AUS23 AUS23-Gc 1 1 0 1 0 1 
AUS23 AUS23-Gd 1 1 1 0 NA 1 
AUS23 AUS23-Ge 1 1 1 0 NA 0 
AUS25 AUS25-Ga 1 1 0 1 0 0 
AUS25 AUS25-Gb 1 1 0 1 0 0 
AUS25 AUS25-Gc 1 1 0 1 0 0 
AUS25 AUS25-Gd 1 1 0 1 0 0 
AUS25 AUS25-Ge 1 1 0 1 0 0 
AUS25 AUS25-Gf 1 1 0 1 0 0 
AUS26 AUS26-Ga 1 1 0 1 1L 1 
AUS26 AUS26-Gb 1 1 0 1 1L 0 
AUS26 AUS26-Gd 1 1 0 1 1L? 0 
AUS27 AUS27-Ga 1 1 1 0 NA 0 
AUS27 AUS27-Gb 1 1 0 1 0 0 
AUS27 AUS27-Gc 1 1 1 0 NA 0 
AUS27 AUS27-Gd 1 1 0 1 0 0 
AUS27 AUS27-Ge 1 1 1 0 NA 0 
AUS28 AUS28-Ga 1 1 0 1 1 0 
AUS28 AUS28-Gb 1 1 0 1 1 0 
AUS28 AUS28-Gc 1 1 0 1 1 0 
AUS28 AUS28-Gd 1 1 0 1 1 0 
AUS28 AUS28-Ge 1 1 0 1 1 0 
AUS28 AUS28-Gf 1 1 0 1 1 0 
 
1: PCR product was obtained. 0: no PCR product was obtained. 1L: large PCR product was obtained. NA: not applicable. 
Cam.: Campylobacter. Intestinal isolates are highlighted in blue. 
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Participant 
code 
Isolate 
code 
Cam. spp 
primers 
Pcisus 
primers 
CON1 
primers 
CON2 
primers 
VI 
primers 
ZoT 
primers 
AUS28 AUS28-Gm 1 1 0 1 1 0 
AUS28 AUS28-Gn 1 1 0 1 0 0 
AUS29 AUS29-Ga 1 1 1 0 NA 0 
AUS29 AUS29-Gb 1 1 0 1 0 0 
AUS29 AUS29-Gc 1 1 0 1 0 0 
AUS29 AUS29-Gd 1 1 0 1 0 0 
AUS29 AUS29-Ge 1 1 0 1 0 0 
AUS30 AUS30-Gc 1 1 1 0 NA 0 
AUS30 AUS30-Gd 1 1 0 1 0 0 
AUS30 AUS30-Gf 1 1 0 1 0 0 
AUS31 AUS31-GA 1 1 1 0 NA 1 
AUS31 AUS31-GB 1 1 1 0 NA 1 
AUS32 AUS32-Ga 1 1 0 1 1 0 
AUS32 AUS32-Gb 1 1 0 1 1 0 
AUS32 AUS32-Gc 1 1 0 1 1 0 
AUS32 AUS32-Gd 1 1 0 1 1 0 
AUS32 AUS32-Ge 1 1 0 1 1 0 
AUS32 AUS32-Gf 1 1 0 1 1 0 
AUS33 AUS33-Ga 1 1 0 1 1 0 
AUS33 AUS33-Gb 1 1 0 1 1 0 
AUS33 AUS33-Gc 1 1 0 1 1 0 
AUS33 AUS33-Gd 1 1 0 1 1 0 
AUS33 AUS33-Ge 1 1 0 1 1 0 
AUS33 AUS33-Gf 1 1 0 1 1 0 
AUS33 AUS33-Gm 1 1 0 1 1 0 
AUS34 AUS34-Ga 1 1 1 0 NA 0 
AUS34 AUS34-Gb 1 1 1 0 NA 0 
AUS34 AUS34-Gc 1 1 1 0 NA 0 
AUS34 AUS34-Gd 1 1 1 0 NA 0 
AUS34 AUS34-Ge 1 1 1 0 NA 0 
AUS35 AUS35-Ga 1 1 1 0 NA 0 
AUS35 AUS35-Gb 1 1 1 0 NA 0 
AUS35 AUS35-Gc 1 1 1 0 NA 0 
AUS35 AUS35-Gd 1 1 1 0 NA 0 
AUS37 AUS37-Ga 1 1 1 0 NA 0 
AUS39 AUS39-Ga 1 1 0 1 0 0 
AUS39 AUS39-Gb 1 1 0 1 0 0 
AUS39 AUS39-Gc 1 1 0 1 0 0 
AUS39 AUS39-Gd 1 1 0 1 0 0 
AUS39 AUS39-Ge 1 1 0 1 0 0 
AUS39 AUS39-Gm 1 1 0 1 0 0 
AUS40 AUS40-Ga 1 1 1 0 NA 0 
AUS42 AUS42-Ga 1 1 0 1 0 0 
AUS42 AUS42-Gb 1 1 0 1 0 0 
 
1: PCR product was obtained. 0: no PCR product was obtained. 1L: large PCR product was obtained. NA: not applicable. 
Cam.: Campylobacter. Intestinal isolates are highlighted in blue. 
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Recruit 
code 
Isolate 
code 
Cam. spp 
primers 
Pcisus 
primers 
CON1 
primers 
CON2 
primers 
VI 
primers 
ZoT 
primers 
AUS43 AUS43-Ga 1 1 1 0 NA 0 
AUS43 AUS43-Gc 1 1 0 1 0 0 
AUS43 AUS43-Ge 1 1 1 0 NA 0 
AUS43 AUS43-Gm 1 1 1 0 NA 0 
AUS43 AUS43-Gn 1 1 1 0 NA 0 
AUS43 AUS43-Go 1 1 1 0 NA 0 
AUS43 AUS43-Gk 1 1 1 0 0 0 
AUS44 AUS44-Ga 1 1 0 1 1L 0 
AUS44 AUS44-Gb 1 1 0 1 1L 0 
AUS44 AUS44-Gc 1 1 0 1 1L 0 
AUS45 AUS45-Ga 1 1 0 1 1 0 
AUS45 AUS45-Gb 1 1 0 1 1 0 
AUS45 AUS45-Gc 1 1 0 1 1 0 
AUS45 AUS45-Gd 1 1 0 1 1 0 
AUS45 AUS45-Ge 1 1 0 1 1 0 
AUS45 AUS45-Gf 1 1 0 1 1 0 
AUS46 AUS46-Ga 1 1 1 0 NA 0 
AUS46 AUS46-Gb 1 1 1 0 NA 0 
AUS46 AUS46-Gc 1 1 1 0 NA 0 
AUS47 AUS47-Ga 1 1 1 0 NA 1 
AUS47 AUS47-Gb 1 1 1 0 NA 1 
AUS47 AUS47-Gc 1 1 0 1 1 0 
AUS47 AUS47-Sa 1 1 0 1 0 0 
AUS48 AUS48-Ga 1 1 0 1 0 0 
AUS48 AUS48-Gb 1 1 0 1 0 0 
AUS48 AUS48-Gd 1 1 0 1 0 0 
AUS48 AUS48-Ge 1 1 0 1 0 0 
AUS48 AUS48-Gf 1 1 0 1 0 0 
AUS48 AUS48-Ba 1 1 0 1 0 0 
AUS49 AUS49-Ga 1 1 0 1 1 0 
AUS49 AUS49-Gb 1 1 0 1 0 0 
AUS50 AUS50-Gb 1 1 1 0 NA 0 
AUS50 AUS50-Gc 1 1 1 0 NA 0 
AUS50 AUS50-Gd 1 1 0 1 0 0 
AUS50 AUS50-Ge 1 1 1 0 NA 0 
AUS50 AUS50-Gf 1 1 1 0 NA 0 
AUS51 AUS51-Ga 1 1 0 1 0 0 
AUS51 AUS51-Bd 1 1 0 1 1L 0 
AUS52 AUS52-Ga 1 1 0 1 0 0 
AUS52 AUS52-Gb 1 1 0 1 0 0 
AUS52 AUS52-Gc 1 1 0 1 0 0 
AUS52 AUS52-Gd 1 1 0 1 0 0 
AUS52 AUS52-Ge 1 1 0 1 0 0 
AUS52 AUS52-Gf 1 1 0 1 0 0 
 
1: PCR product was obtained. 0: no PCR product was obtained. 1L: large PCR product was obtained. NA: not applicable. 
Cam.: Campylobacter. Intestinal isolates are highlighted in blue. 
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Appendix XXII: Alignments of the zot gene sequences for C. concisus obtained from 
clinical isolates. 
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